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7PREFACE
I’ve found a beauty in seeing how complex and sophisticated, but logi-
cally these pathways have evolved. It’s a challenge to get to know every 
single little piece of that puzzle. Worth to mention the membrane, a 
structure of which once was believed it was just a barrier to shield off the 
cytosolic fraction of a cell. Yet today many questions are open to resolve 
its contribution to cell signal transduction. If only we could miniaturize 
and take a walk on the membrane to behold its actions and movements. 
One thing is for sure, in a cell and on a membrane nothing happens 
without a reason.
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SUMMARY
Pathogen inactivation technology (PIT) is 
developed to decrease transfusion transmit-
ted infections. The methods on the market 
today use ultraviolet light illumination with 
or without a photosensitizer. The impact of 
these treatments on products for transfusion 
is not clear and therefore we thoroughly 
investigated the quality of blood products 
following PIT treatment.
In the first chapter, three different PIT 
developed for treatment of plasma are 
compared. The activity and concentration 
of plasma proteins was studied with a focus 
on ADAMTS13 as a sentinel molecule for 
relevant plasma components. The different 
PIT methods all affected ADAMTS13, FVIII 
and fibrinogen albeit to different degrees. 
The pathogen inactivation method using 
riboflavin (RF-PRT) as a photosensitizer 
had the largest impact on plasma which was 
caused by reactive oxygen. Our data were the 
first to show that removal of dissolved oxygen 
protected plasma proteins during RF-PRT 
treatment.
In the following chapters, we examined the 
influence of PIT on platelet concentrates. 
For this, platelet function was assessed in mi-
crofluidic flow chamber experiments. These 
indicated a decreased platelet function 
for all PIT compared to untreated controls. 
Additional experiments showed that the 
underlying mechanisms of platelet damage 
were different for each PIT however resulting 
in similar decreased thrombus formation in 
flow chambers. 
In the last chapter, biochemical research 
on platelets treated with AS-PCT found a 
specific inhibition of the PI 3-kinase signal 
transduction pathway. This was caused 
by covalent binding of amotosalen to acyl 
chains of membrane phospholipids changing 
the overall membrane structure. This pheno-
type was also found in T lymphocytes follow-
ing extracellular photopheresis in a patient 
being treated for graft-versus-host disease. 
So research initiated from the observation 
that platelet function is decreased following 
AS-PCT has uncovered a fine-tuning role for 
phospholipid acyl chains in the regulation of 
PI 3-kinase signal transduction.
SAMENVATTING
Pathogeen inactivatie technologie (PIT) is 
ontwikkeld om de kans op een transfusie 
overdraagbare infectie te verlagen. De 
methodes die momenteel operationeel 
zijn, maken gebruik van belichting al dan 
niet in combinatie met een fotosensitizer. 
De impact van deze behandelingen op de 
kwaliteit van transfusieproducten is niet 
altijd duidelijk en daarom onderzochten 
wij de kwaliteit van bloedproducten die 
behandeld werden met PIT.
In het eerste luik vergeleken we drie PIT 
voor de behandeling van plasma. De 
activiteit en concentratie van plasma 
eiwitten werd bestudeerd met onder 
andere ADAMTS13 als referentie-eiwit voor 
relevante plasma componenten. Uit deze 
studie bleek dat zowel ADAMTS13, FVIII als 
fibrinogeen bij de drie methodes aangetast 
waren. De pathogeen inactivatie methode 
die gebruik maakt van riboflavine (RF-PRT) 
als fotosensitizer, vertoonde de grootste 
impact, veroorzaakt door oxidatieve stress. 
Onze data waren de eerste om aan te tonen 
dat de schade aan plasma eiwitten beperkt 
kon worden door de opgeloste zuurstof 
vóór de RF-PRT behandeling te verwijde-
ren.
Vervolgens onderzochten we de invloed 
van PIT op bloedplaatjesconcentraten. 
Eerst werd de functie van de bloedplaatjes 
met behulp van flow kamer experimenten 
bestudeerd. Deze toonden een daling in 
functionaliteit aan voor de drie methodes. 
Bijkomende functionele experimenten we-
zen echter op verschillende onderliggende 
mechanismen. 
In het laatste onderdeel werd voor de 
bloedplaatjes behandeld met AS-PCT een 
specifiek defect in de PI 3-kinase signaal 
transductie cascade gevonden. Dit werd 
veroorzaakt door een covalente binding 
tussen amotosalen en de vetzuurzijketens 
van membraan fosfolipiden, met een veran-
dering in de structuur van de celmembraan 
tot gevolg. Inhibitie van PI 3-kinase kon 
bovendien ook aangetoond worden in de 
T-lymfocyten van een graft-versus-host 
patiënt na behandeling met extracorporele 
fotoferese. 
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ADP Adenosine diphosphate
Akt Protein kinase B
AS Amotosalen
AS-PCT Amotosalon Photochemical Treatment (Intercept Blood System, Cerus Corp, Concord, CA)
Btk Bruton’s Tyrosine kinase 
CalDAG-GEF1 Calcium and DAG-regulated guanine nucleotide exchange factor
cAMP Cyclic adenosine monophosphate
CCI Corrected Count Increment
CMV Cytomegalovirus
COX-1 Cyclo-oxygenase 1
CPD Citrate Phosphate Dextrose Solution
DAG Diacylglycerol
ECP Extracorporeal photopheresis
FcR Fc receptor
GDP Guanosine disphosphate
GPCR G-protein coupled receptor
GTP Guanosine triphosphate
GvhD Graft-versus-host disease
HBV Hepatitis B-Virus
HCV Hepatitis C-Virus
HIV Human Immunodeficiency Virus
HLA Human Leukocyte Antigen
HPA Human Platelet Antigen
IP3 Inositol 1,4,5- trisphosphate
ITAM Immunoreceptor, tyrosine-based activation motif
LAT Linker for activation of T cells
MBT Methylene Blue Technology
NAT Nucleid Acid Testing
Orai1 Calcium release-activated calcium channel protein 1
PAR Protease-activated receptor
PAS Platelet Additive Solution
PC Phosphatidylcholine
PDK1 3-phosphoinositide-dependent protein kinase 1
PG Phosphatidylglycerol
PH Pleckstrin Homology
PI 3-kinase Phosphatidylinositol 3-kinase
PIT Pathogen inactivation technology
PKC Protein kinase C
PLC Phospholipase C
PI(3,4)P2 Phosphatidylinositol 3,4-bisphosphate
PI(3,4,5)P3 Phosphatidylinositol 3,4,5-trisphosphate
PI(4,5)P2 Phosphatidylinositol 4,5-bisphosphate
PTEN Phosphatase and tensin homolog
RBC Red Blood Cell
RF-PRT Riboflavin Pathogen Reduction Technology (Mirasol Pathogen Reduction  
Technology, TerumoBCT, Lakewood, CO)
RhD Rhesus D
ROS Reactive oxygen species
RTK Receptor tyrosine kinase
SARS Severe Acute Respiratory Syndrome
SFK Src family kinase
SH2 Src Homology 2
STIM1 Stromal interaction molecule 1
Syk Spleen tyrosine kinase
TP Thromboxane receptor
TTI Transfusion Transmitted Infection
TXA2 Thromboxane A2
UVA Ultraviolet A 
UVC Ultraviolet C
UV-C Ultraviolet C Pathogen Inactivation (Theraflex UV-platelets, Macopharma,  
Tourcoing, France)
VWF Von Willebrand factor
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1. THE PATHWAY OF BLOOD
1.1 COLLECTING BLOOD
1.1.1 DONOR RECRUITMENT AND SELECTION
The pathway of blood starts with the donor. In 2014 there were close to 185,000 donors that 
made it possible to collect 372,759 successful donations in Flanders. Bearing in mind that 
only 3% of the population donates blood while more than 70% will need blood in the course 
of their lives, donor recruitment is a very important aspect in the pathway of blood. Several 
awareness campaigns successfully recruited 41,339 new donors in 20141 (Figure 1).
Figure 1: Campaign banner.  
It is used to promote blood donation by the Red Cross-Flanders donor relation service.
In a first step, careful consideration of donor and patient health helps to minimize product 
wastage and to reduce risks inherent to transfusion. For this, a questionnaire is filled out by 
the candidate donor. The questionnaire is designed according to the medical donor selec-
tion guideline which follows European and Belgian legislation based on scientific evidence 
and recommendations of the Federal Agency for Medicines and Health Products, and the 
Superior Health Council. The filled in and signature confirmed questionnaire is analysed in a 
private consultation with a trained medical doctor who performs a basic medical anamnesis 
to assess donor well-being and risk behaviour carefully. This questionnaire and medical 
examination protects the donor by setting minimum thresholds of different criteria like 
haemoglobin levels and total blood volume by donor weight. On the other hand, these serve 
as first-line elimination tools to prevent transfusion transmittable disease2,3. The inquiry 
to risk behaviour like overseas travelling, ongoing or past medical treatments and specific 
sexual activities is intended to mitigate the risk for receiving patients. Furthermore, donor 
selection is important to minimize wastage of resources caused by collecting blood from 
unsuitable donors, exemplified by the 92 million worldwide donations and 13 million pro-
spective donor deferrals due to anaemia and other medical conditions4.
1.1.2 WHOLE BLOOD COLLECTION
Whole blood is the most common collection type, for which 87% of our donors are signing in. 
Before venepuncture, the phlebotomy site is disinfected to avoid contamination of the blood 
by skin bacteria5. The first 25mL is deviated to a sample bag and will be used for laboratory 
tests. Then, depending on the 
gender, weight and height of the 
donor, 470mL or 400mL blood is 
drawn into a specialized sealed 
and sterile bag containing Cit-
rate Phosphate Dextrose Solution 
(CPD)6 to prevent coagulation. 
The duration of the donation is 
9 minutes, on average. Donors 
are allowed four whole blood 
donations a year, with minimally 
60 days in between. After collec-
tion the unit is thermostatized 
to 20-22°C in specially designed 
klimacontainers (Figure 2). 
These are then transported to the 
manufacturing sites for blood com-
ponent preparation7.
PART.1
Figure 2: Klimacontainer.  
The klimacontainer is equipped with temperature sensors 
and keeps fresh whole blood at 20-22°C.
INTRODUCTION
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1.1.3 APHERESIS
Another way to collect blood products is by apheresis. It is a more expensive and time 
consuming technology but only the desired components (plasma and/or platelets and/
or red blood cells and/or granulocytes) are collected. It is less common than whole blood 
donation with about 11% of the donors signing in for plasmapheresis and roughly 2% for 
thrombopheresis8. Yet, these thrombopheresis products do account for 50% of the plate-
let concentrates produced in Flanders. A major advantage of apheresis is the increased 
flexibility towards the donor as (s)he can choose for only plasma or a combination of plasma 
and platelets. Because red blood cells are not collected with plasma- and thrombopheresis, 
the likelihood of developing post-donation anaemia, is very small allowing donation every 
two weeks. Apheresis allows to invite donors for targeted donation with specific human 
leukocyte antigen (HLA) and human platelet antigen (HPA) profiles for patients, refractory 
to certain phenotypes due to antibodies against HLA or HPA.
Depending on the donors height and weight, up to 650 mL plasma can be collected over 
45–60 minutes in a plasmapheresis procedure. During this procedure, blood is collected 
in 4% sodium citrate anticoagulant and plasma is separated from cells and pumped into a 
collection bag. The cellular fraction is returned to the donor with 500mL of saline solution 
to replace the donated volume. In the Red Cross-Flanders, 20% of the collected plasma is 
obtained by plasmapheresis.
During dual apheresis of platelets and plasma an average of 350mL plasma and 5.5 x 1011 
platelets is collected during a 60-100 minutes procedure. Like in plasmapheresis, the re-
mainder cellular components are returned to the donor with 500mL of saline.
1.2 TESTING BLOOD
To prevent transfusion transmitted infections (TTI), the donor questionnaire and laboratory 
screening tests fulfil complementary roles. Laboratory tests are performed on every donation 
using the deviated blood sample that is taken in a separate pouch prior to donation. The Cen-
tral Laboratory of the Belgian Red Cross-Flanders performs these tests which include serologi-
cal tests, nucleid acid tests (NAT) and complete blood counting. 
Serological tests are used to test the presence of hepatitis C-virus (HCV), hepatitis B-virus 
(HBV), human immunodeficiency virus (HIV) and Treponema pallidum (syphilis). Routine NAT is 
a multiplex-assay of a pooled sample of 6 donations to assess the presence of HIV-RNA, HCV-
RNA and HBV-DNA. When this combined sample is positive, discriminatory experiments are 
performed on each of the six samples included to differentiate what specific donation and what 
virus is involved. Depending upon the results of the medical questionnaire, additional tests for 
Trypanosoma cruzi, malaria or hepatitis B core antibodies are conducted. Additional laboratory 
work includes blood group determination, irregular blood group antibodies and whole blood 
cell counting to measure hemoglobine, red blood cell, white blood cell and platelet counts9. 
1.3 PROCESSING BLOOD
Following collection, transportation and temporary storage, the whole blood is separated into 
two (red blood cells and plasma) or three (red blood cells, plasma and platelets) components 
(Figure 3). This fate is linked to the type of container the blood was collected in. Blood is sepa-
rated by centrifugation exploiting the differences in size and density of the blood constituents. 
During a ‘hard spin’ centrifugation, the red cells condense at the bottom of the container. The 
white blood cells and platelets sediment on top of these red cells, leaving plasma as a superna-
tant. Using an automated separator, red blood cells and plasma are transferred through top and 
bottom tubings, respectively until only the buffy coat remains in the original collection bag. 
1.3.1 RED BLOOD CELLS
After centrifugation and separation, leukocytes are removed by filtration (targeting <1.0 x 106 
leukocytes per unit) and an additive solution, saline-adenine-glucose-mannitol (SAGM) is added 
which supports preservation of red blood cell concentrates during 42 days of storage at 2-6°C10. 
The tubing connected to the storage bag contains red blood cells and is sealed in segments of 
approximately 5 cm in length. These are used as samples in the immunohematology laboratory 
for typing and cross matching prior to transfusion. An additional production step is 25-50 Gray 
gamma irradiation to prevent lymphocyte proliferation in the host11. Following this manipulation, 
red blood cell concentrate shelf life is shortened to 28 days, but these units can be transfused to 
Figure 3: Blood processing. Schematic of blood component routes in Red Cross-Flanders.
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immunocompromised patients at risk of graft-versus-host disease (GvhD).
About 85 million red blood cell units are transfused worldwide12 for the treatment of clinically sig-
nificant anaemia. Anaemia occurs in a wide variety of diseases which can be acquired by malignan-
cies or infection, or they can be inherited like in sickle cell disease. Furthermore, blood loss during 
surgery or after trauma is a common indication for red blood cell transfusion13.
Some blood components are modified for specific indications and patient groups, like washed red 
blood cells for patients with recurrent severe allergic transfusion reactions or Cytomegalovirus 
(CMV) negative units for intrauterine red blood cell transfusions. Though, all transfusions should be 
ABO and Rhesus D (RhD) compatible and will raise the hemoglobin of an average size adult by 1g/
dL for each red blood cell concentrate, helping the oxygen-carrying capacity to restore14.
1.3.2 PLASMA
To maintain the quality, fresh plasma is frozen within 24 hours after collection. If not, labile clotting 
factors deteriorate and protein extraction is less productive. During the freezing process, a core 
temperature below -30°C must be reached within one hour from the time freezing starts. Fresh 
frozen plasma is then sold to a fractionation centre where coagulation factors, immunoglobulins 
and albumin solutions are prepared by extraction from a pool of several thousand blood donations. 
The products obtained by fractionation are used to treat different disorders. Coagulation factors 
are used for treatment and prophylaxis to prevent bleeding in patients with a clotting disorder, 
linked to a specific coagulation factor deficiency, like haemophilia A (Factor VIII) or B (Factor IX) 
or von Willebrand Disease (VWF-FVIII concentrate)15. The immunoglobulin fraction is used for 
protein replacement therapy for immune deficient patients who have decreased or abolished 
antibody production capabilities, for example patients with idiopathic thrombocytopenic purpura 
or Kawasaki disease16. The albumin fraction is used to treat conditions associated with pronounced 
hypoproteinemia like nephrotic syndrome or extensive and serious burns17.
Some of the collected plasma is not sold for fractionation, but is treated instead with a photo-
chemical pathogen inactivation method to obtain pathogen inactivated plasma. To this purpose, 
remainder cells and debris are removed by filtration prior to the Methylene Blue Technology 
treatment (MBT, Macopharma, Tourcoing, France or Baxter International Inc, Deerfield, IL). After 
the addition of methylene blue (final concentration 0.8 to 1.2µM), the units are illuminated with 
visible light (630nm). The photo-activated methylene blue then damages nucleic acids preventing 
proliferation of pathogens and donor derived leukocytes. Finally, methylene blue is removed by a 
second filtration step and the units are frozen and preserved at -30°C.
Methylene blue pathogen inactivated plasma contains all coagulation factors and additionally 
serum salts, sugars, fats, hormones and vitamins. This blood product is used for patients with 
a coagulopathy who are bleeding or at risk of bleeding, and where a specific therapy or factor 
concentrate is not appropriate or unavailable. For instance, to treat thrombotic thrombocytopenic 
purpura or when several labile plasma coagulation factors need to be replaced, i.e. during massive 
transfusion18,19.
1.3.3 PLATELETS
Platelet concentrates are prepared from apheresis or from pooling of buffy coats. The main 
difference between these products is the multitude of exposure to donor material by the host. 
To produce buffy coat pooled platelet concentrates, five to six buffy coats of the same ABO 
blood group are pooled and supplemented with platelet additive solution (PAS)(SSP+, Macoph-
arma). A ‘soft spin’ centrifugation step sediments the residual red and white blood cells while the 
platelets largely remain suspended in the plasma/PAS supernatant. This platelet rich superna-
tant is transferred to a platelet bag through automated separators. After pathogen inactivation, 
the platelets are stored at 22 ± 2°C under continuous, gentle agitation in a storage container 
composed of semipermeable plastic to allow exchange of metabolic gas. Some countries allow 
storage for 7 days while others for 4 days. Belgian legislation (2005) allowed extended storage 
to seven days in the case a validated system for bacterial growth was in place (which was the 
case in Flanders since 1998). However, the internal medical committee of our organisation 
questioned the quality of PAS stored platelets preserved for longer than five days and opted not 
to implement a seven day storage time. When pathogen inactivation was introduced in 2009 in 
the southern part of Belgium, a seven day shelf life was introduced for PI platelets. However in 
2009, following an advice of the Superior Health Council of Belgium concerning the therapeutic 
efficiency of pathogen inactivated platelet concentrates, the Federal Agency for Medicines and 
Health Products issued a recommendation to limit storage time to five days (and an minimal 
content of 3 x 1011 platelets per product) because of eight cases of cerebral hemorrhage (of 
which two were fatal) shortly after PIT implementation.
Worldwide, 4 million platelet concentrates are transfused each year. They can be used for 
therapeutic treatment of patients with bleeding due to functional abnormal platelets or se-
verely decreased platelet concentration. On the other hand, platelets can also be administered 
prophylactically to mitigate the risk of bleeding in patients with rapidly falling or low platelet 
counts secondary to cancer, chemotherapy, bone marrow failure or other primary conditions18,20.
1.3.4 PATHOGEN INACTIVATION OF BLOOD COMPONENTS
As mentioned before, the donor questionnaire and the prevailing exclusion criteria are the 
first instrument to avoid TTIs. In conjunction with laboratory screening of known pathogens, it 
reduces the risk of TTI dramatically and has rendered transfusion increasingly safe. Today the 
residual risk for viral TTIs is decreased to 1/1,467,000 for HIV, 1/1,149,000 for HCV21 and 1/282,000 
for HBV22. For bacterial TTIs however, it are mainly the platelet concentrates that are vulnera-
ble as their storage temperature is high enough for germ growth (22 ± 2°C), with an estimated 
risk of 1/2-3,000. These bacterial TTIs are the major cause of transfusion related morbidity and 
mortality because transfusion-related bacterial sepsis (1/20-50,000 ) can be fatal in 10% of 
cases23. Besides the known viral and bacterial TTIs, the emerging pathogens like Chagas disease, 
Dengue, Chikungunya-virus, West Nile virus and Severe Acute Respiratory Syndrome (SARS) are a 
weighty argument to consider implementation of pathogen inactivation of blood components24. 
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Solvent-detergent (SD) 
method
Methylene Blue  
technology UVC technology Riboflavin/UV technology
Amotosalen/UVA  
technology S-303 technology
Blood component Plasma Plasma Platelets Plasma / Platelets Plasma / Platelets Red blood cells
Technology Chemical Photochemical Photochemical Photochemical Photochemical Chemical
Active compound Trinitrobutyl phosphate 
and Triton X-100
Methylene Blue / Riboflavin Amotosalen (S-59) S-303
Wavelength / Visible light UVC Broad spectrum UVA /
Additional step Fitration Filtration / / Filtration Glutathione
Mechanism Membrane disruption Nucleic acids damage by 
reactive oxygen
Nucleic acids damage 
by pyrimidine dimer 
formation
Nucleic acids damage 
by reactive oxygen and 
cross-linking
Nucleic acids damage by 
cross-linking
Nucleic acids damage 
by cross-linking
Status
PLASMA Used in 32 countries 
FDA approved in 2013
Used in 15 countries / Used in 11 countries  
CE mark class IIb
Used in 13 countries 
CE mark class III 
FDA approved in 2014
/
PLATELETS / / Phase III clinical trial  
CE mark class IIb
Used in 18 countries  
CE mark class Iib
Used in 22 countries  
CE mark class III 
FDA approved in 2014
/
RED BLOOD CELLS / / / / / Phase III clinical trial 
Clinical trials
PLASMA No difference in clinical 
efficacy
Reduced effectivity: re-
quired more exchanges
/ Trials ongoing No difference: recovery, 
tolerance and efficacy OK
/
PLATELETS / / / Reduced CCI: primary end-
point not met*
Reduced CCI* /
RED BLOOD CELLS / / / / / Trials ongoing
* Cfr 1.3.4.2 for more 
details
Table 1: Overview 
of the available 
pathogen inactiva-
tion technologies 
for blood compo-
nents25,28-30
Emerging pathogens are in the spotlight, because tests are not routinely available and often very 
expensive. Besides, the large biological diversity of (opportunistic) pathogens infecting humans, 
makes implementation of tests for each of these unrealistic. Several pathogen inactivation 
technologies (PIT) are available for the treatment of blood components25. An overview is given in 
Table 1. For platelet concentrates and plasma three of these methods use ultraviolet light (UV) 
illumination in combination with an exogenously added photosensitizer to damage nucleic acids 
and one uses UV-C illumination alone26. These methods are not suitable to treat RBC contain-
ing blood products because the optical properties of densely packed hemoglobin requires very 
high doses of light. Some companies are developing a different approach suitable to treat RBC 
concentrates and whole blood27,28.
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1.3.4.1. PLASMA
Different bench-top technologies applicable to single units of plasma are available. The 
Mirasol Riboflavin (vitamin B2) pathogen reduction technology31 (RF-PRT, TerumoBCT, 
Lakewood, CO) with broad spectrum UV light, INTERCEPT amotosalen (S59) photochemical 
treatment32 (AS-PCT, Cerus Corp, Concord, CA, USA) with UVA, and THERAFLEX Methylene 
Blue Technology33 (MBT, Macopharma) with visible light are used to treat plasma products. 
The mechanisms of action described by these suppliers is that the chemical sensitizers 
intercalate in helical regions of RNA and DNA and form irreversible adducts and cross-links 
with pyrimidines following photoexcitation. Consequently, replication of cells/viruses is 
prevented. Although these treatments provide additional safety for fresh plasma products, 
they degrade product quality to some degree. This has been demonstrated by our group in 
an in vitro paired study comparing all three methods34.
1.3.4.2 PLATELETS
RF-PRT and AS-PCT were originally developed and are most widely known for the treatment 
of platelet concentrates. Besides these two, a third method (THERAFLEX UV-PLTs, UV-C, 
Macopharma) uses short-wavelength UVC light in the absence of exogenously added 
photosensitizer35. As with plasma, the product quality of platelet concentrates after treat-
ment is a subject of research and debate. In vitro assays have investigated the matter but 
conflicting reports require a critical read of available results36-41. For example, Apelseth T.O. 
et al concluded a generally reduced in vitro quality of platelets treated with AS-PCT36, while 
Hechler B et al state that they have similar functional, morphologic and proteomic charac-
teristics37. However, in the latter one, AS-PCT treated platelets were washed and resuspend-
ed in Tyrode’s buffer before testing.
As of April 2015 platelet concentrates prepared by our facilities are all treated with path-
ogen inactivation (AS-PCT) compliant to the Royal Decree of June 17th, 2013. Belgium was 
the first country to adopt legislation on pathogen inactivation for platelet concentrates, 
despite delays in implementation caused by a number of issues during the course of the 
past years. These events are summarized in Table 2 and were influenced by the outcomes of 
the clinical trials over time. Ten completed trials comparing pathogen inactivated platelets 
with standard platelets were analysed by a Cochrane review published in 201342. Nine trials 
assessed AS-PCT (1312 patients) and one RF-PRT (110 patients). Trials of multiple pathogen 
inactivated platelets showed a significant shorter transfusion interval and the participants 
required 7% more platelet transfusions. The corrected count increments at 1 and at 24 hours 
were significantly lower following pathogen inactivated platelet transfusions compared to 
standard platelets. Furthermore, the meta-analysis demonstrated no differences in mor-
tality, clinical significant bleeding or severe bleeding between treatment arms. Five trials, 
however, reported a significant increase in ‘any bleeding’ in the pathogen inactivated plate-
lets arm using a fixed-effect model (favouring standard platelets). The conflicting results of 
these two analysis makes it difficult to interpret. It shows the need for studies with reliable 
design, relevant endpoints and sufficient statistical power. 
The hemovigilance data of Belgium suggest that Intercept PIT reduces bacterial transfu-
sion-transmitted infections. More than 150 000 pathogen inactivated platelet concentrates 
have been transfused since 2009. None of them provoked bacterial transfusion-transmit-
ted infections. In the same time period, 4 bacterial transfusion-transmitted infections were 
reported in approximately 186 000 standard platelet transfusions.
1.3.4.3 RED BLOOD CELLS
For the red blood cell concentrates a different approach is needed. Their greater viscosity 
and the absorption spectrum of haemoglobin prohibits the use of illumination. The S-303 
pathogen and leukocyte inactivation system includes glutathione as a quencher for oxida-
tive side-effects27. The compound S-303 acts as a pathogen inactivator in the intracellular 
compartment where it targets and cross-links nucleic acids to prevent further replication. 
After this, a breakdown product S-300 is formed and rapidly degraded. The quenching 
glutathione is included to minimize extracellular reactions with common nucleophiles. 
Treatment solution and breakdown products are partially removed by centrifugation before 
storage. This method is under development by Cerus Corporation and phase III clinical 
trials are ongoing43.
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Date Authority Decision or recommendation Reason
2005/02/01 RD
Platelet concentrates can be stored 
for 7 days, provided bacterial 
screening or PIT 
2009/06/28 RD
National mandatory implemen-
tation of PIT on platelets starting 
July 2010 
SHC recommends national man-
datory implementation of PIT on 
platelets
2009/11/16 FAMHP/
SHC
Platelets treated with PIT should at 
least contain 3x1011 platelets and 
shelf-life limited to 5 days
Hemovigilance annals reports 8 
registered hemorrhage cases de-
spite transfusion of platelets treated 
with PIT (Int), including 2 deaths by 
cerebral hemorrhage. 
2010/06/13 RD
National mandatory implementa-
tion of PIT on platelets postponed 
until July 2011
Further advice on clinical efficacy of 
photochemical PIT required 
2010 FAMHP
Hemovigilance annals reports 4 reg-
istered hemorrhage cases despite of 
transfusion of PIT treated platelets 
(Int), including 1 death by cerebral 
hemorrhage. 
2011/07/29 BRC-F BE Cessation of PIT (Mir) implementa-
tion at BRC-F BE
Perforation of bags by breaking 
pen shatter: registered frequency of 
leakages in the final PRPC >1/500
2011/06/01 SHC
SHC recommends national man-
datory implementation of PIT on 
platelets, extensive hemovigilance 
analysis and repeats restrictions to 
product content and shelf-life
FAMHP seeked advice on clinical 
efficacy of photochemical methods 
2011/06/28 RD
National mandatory implemen-
tation of PIT on platelets is post-
poned until July 2013
2012/12/24 BRC-F BE
Premature abortion of validation for 
routine implementation of PIT on 
platelets
>50% of products (Mir) fail quality 
control during validation 
2013/06/17 RD
National mandatory implementa-
tion of PIT on platelets is postponed 
until July 2015
Table 2: Chronological series of decisive events during and following the mandatory implementation  
of PIT for platelets in Belgium (2009).
PIT=Pathogen inactivation technology; RD=Royal Decree; Federal Government decision; SHC=Superior Health 
Council; the scientific advisory body of the Federal Public Service of Health, Food Chain Safety and Environment; 
FAMHP=Federal Agency for Medicines and Health Products; the competent authority responsible for the quality, 
safety and efficacy of medicines and health products; BRC-F BE=Belgian Red Cross-Flanders Blood Service; Belgian 
Regional Blood Establishment; Int=Intercept Blood System; amotosalen and ultraviolet A light treatment ; Mir=Mira-
sol Pathogen Reduction Technology; riboflavin and broad spectrum ultraviolet light treatment.
2. PLASMA
2.1 PLASMA: THE LIQUID COMPONENT 
 OF OUR BLOOD
This pale yellow liquid part of anticoagulated blood, remains after separation from the cellu-
lar components as described above. It makes up about 55% of the body’s total blood volume. 
Beside water as its main constituent, plasma contains low molecular weight (glucose, the 
whole set of amino acids, nucleotides, vitamins, hormones, fatty acids, lipids, etc.) and high 
molecular weight components (peptides, proteins, saccharides, etc), dissolved gases and 
products of the metabolism. Furthermore, plasma contains ions which are essential for 
several biological processes and the maintenance of a constant pH. The plasma transports 
nutrients to the cells of various organs, and waste products to the kidneys, liver and lungs. 
It carries red blood cells, white blood cells and platelets, transporting oxygen, providing an 
immune response, and delivering clotting agents44,45, respectively. 
2.2 THE PLASMA PROTEOME
The thousands of proteins, which are dissolved in plasma are divided in different categories, 
each with its own properties and function46.
2.2.1 ALBUMIN
This multifunctional, non-glycosylated, negatively charged plasma protein comprises 50% 
of the total plasma protein content. With only 66kDa, it is a relative small protein compared 
to other plasma proteins47. Albumin is synthesized in the liver. It contains three homolo-
gous domains and each consists of two separate helical subdomains, connected by random 
coil48. Albumin possesses extraordinary ligand binding properties and thereby transports 
a diversity of molecules49. Because of its abundance, its carrier function is important in 
pharmacokinetics of many drugs, influencing efficacy and rate of delivery50. Furthermore, 
at high concentration and strong negative charge, albumin is responsible for around 70% of 
plasma oncotic pressure and therefore plays a pivotal role in modulating the distribution of 
fluid between compartments51. 
It has not been clearly determined whether there is a threshold concentration of albumin 
below which its oncotic function is compromised to a clinically relevant degree. There is, 
however, a consensus that oncotic activity remains physiologically adequate at values of 
albumin ≥ 2g/dL and total proteins ≥ 3.5g/dL. Hypoalbuminemia can occur in acute condi-
tions like hemorrhagic shock and major surgery or in chronic states, like liver cirrhosis and 
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nephrotic syndrome. It may have life-threatening effects as it results in extravascular fluid 
accumulation or increased concentrations of protein-bound drugs in the unbound form, 
leading to either adverse effects or rapid metabolism and decreased efficacy52.
Solution of albumin is prepared in the fractionation centre from the plasma of healthy 
donors. When volume deficiencies have been demonstrated and the use of a colloid is indi-
cated, albumin is infused in order to restore and maintain the blood circulation volumes 53.
2.2.2 GLOBULIN
Although globulins make up a smaller fraction (36%) of blood plasma protein and include 
protein carriers, enzymes, gamma globulin and immunoglobulins. Globulins are actually 
subdivided into four major categories: gamma globulin, alpha-1 globulin, alpha-2 globulin, 
and beta globulin. The former one contains immunoglobulins and is the specific group 
of plasma proteins that functions as antibodies providing protection against disease on 
a cellular level. The alpha and beta globulins primarily act as transporters for fat soluble 
vitamins, hormones and lipids45. 
Immunoglobulins prepared at the fractionation centre from the plasma of healthy donors, 
is used as an ‘immunomodulatory’ agent in an increasing number of immune and inflam-
matory disorders54. Intravenous globulin therapy is either a substitution therapy in the case 
of primary immunodeficiency syndroms or a immunomodulatory therapy in the case of 
allogeneic bone marrow transplant or Kawasaki disease55.
2.2.3 COAGULATION PROTEINS
The coagulation proteins are the core components of the coagulation system; the complex 
interplay of reactions resulting in the conversion of soluble fibrinogen to insoluble fibrin 
fibers56. Two key players relevant for transfusion are fibrinogen and factor VIII.
Fibrinogen is a 340kDa glycoprotein comprising 4% of the total plasma protein content 
at a concentration of 2g/L to 4g/L57. It consist of two disulfide-linked monomers, each 
containing three different polypeptide chains, Aαα, Bβ α and Cγα58. In the coagulation cascade, 
fibrinogen is converted to fibrin when thrombin cleaves off the peptides A and B from the 
amino-terminal segments of the fibrinogen Aαα-and Bαβ α-chains. Soluble fibrinogen is thus 
converted into fibrin monomers, which can form insoluble fibrin polymers and a network of 
fibrin fibers catalyzed by the action of (activated) FXIII. This cohesive network also provides 
a temporary support for wound healing59. In transfusion medicine, plasma-derived fibrino-
gen concentrate is the replacement therapy of choice in patients with afibrinogenemia. It 
is virally inactivated, a smaller infusion volume is needed and the risk of allergic reactions is 
lower compared to the use of cryoprecipitate or FFP60.
Factor VIII participates in the middle phase of the intrinsic pathway of blood coagulation 
where it functions as a cofactor in the factor IXa-mediated conversion of factor X to factor 
Xa. It is synthesized as a single polypeptide chain, but circulates in plasma as a two-chain 
molecule non-covalently linked to von Willebrand factor. Factor VIII circulates in plasma in 
an inactive form that is proteolytically cleaved by factor Xa and/or thrombin in the presence 
of calcium and negatively charged phospholipids, to yield factor VIIIa61. Mutations in the 
factor VIII gene can result in hemophilia A62, a mild to severe bleeding disorder. A replace-
ment therapy with intravenously delivered plasma-derived FVIII concentrates, aimed at 
correcting the coagulation factor deficiency in the case of, or in order to prevent, bleeding 
in patients with hemophilia A. As with the fibrinogen replacement therapy described above, 
this specific and viral-inactivated product is the source of choice over cryoprecipitate or 
FFP63.
2.2.4 REGULATORY PROTEINS
Other plasma proteins are regulatory proteins, such as enzymes, proenzymes and hor-
mones. One of those enzymes is ADAMTS13. It circulates as an active enzyme in plasma at a 
concentration of approximately 5nM64 and cleaves VWF multimers, decreasing their avidity 
for platelet GPIb-IX-V complex65. A deficiency in ADAMTS13 causes thrombotic thrombocy-
topenic purpura which is a rare systemic disorder where ultra-large VWF multimers cause 
accumulation of platelet microthrombi in the (micro)vasculature. These lead to thrombotic 
occlusion of small blood vessels and platelet consumption with severe thrombocytopenia. 
Disseminated multi-organ ischemia ultimately leads to death if untreated66. In transfusion 
medicine, this disease is treated by plasma exchange in order to replenish ADAMTS1367.
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3. PLATELETS
3.1 PLATELETS:  
 THE SMALLEST CELLS IN BLOOD
Circulating platelets have a life span of approximately 8 to 9 days and about 30% of plate-
lets are residing in spleen and liver, resulting in an average turnover of 1011 platelets each 
day in a healthy adult68. The platelet precursor cell, called the megakaryocyte, originates 
from the bone marrow and is differentiated out of hematopoietic stem cells. One megakar-
yocyte at 50-100µm in diameter, can produce 2000 to 5000 platelets of 2-5µm69. Plate-
lets are considered the smallest operating cells in circulating blood and adopt a discoid 
morphology while resting, but following activation they quickly change shape by extend-
ing filopodia and increasing their surface by more than 400%70 (Figure 4). Platelets are 
anucleate but contain distinct mitochondria, a dense tubular system, a highly specialized 
cytoskeleton and unique granules. Numerous proteins and biologically active molecules are 
stored in these granules that can be released during activation. The normal platelet count 
in human peripheral anticoagulated blood is 150,000 to 400,000 per microliter of blood71.
In response to vascular damage, platelets form a plug to stop bleeding. They adhere to 
subendothelial matrix proteins like collagen and VWF. Following binding, platelets activate 
through a complex series of (signal transduction) events caused by triggering receptors. 
This results in shape change, granule secretion, integrin activation, aggregation and sup-
port of coagulation72. Recently, researchers in the Brass group demonstrated that platelet 
activation is not uniform throughout the hemostatic plug. Local variations in environmental 
chemistry and different elements of the platelet-signalling network work in concert to pro-
duce marked differences in the platelet activation state thereby regulating a single tailored 
hemostatic response to injury73.
Figure 4: Platelet spreading. 
A differential interference con-
trast microscopic image series of 
a human platelet activating and 
spreading on a surface of immo-
bilized fibrinogen74.
3.2 SIGNAL TRANSDUCTION PATHWAYS 
 IN PLATELET PLUG FORMATION
3.2.1 PLATELET ADHESION TO THE INJURED VESSEL WALL
The formation of thrombi at sites of vascular damage is the result of a concerted action of 
diverse signal transduction pathways (Figure 5). This sequence initiates when the sub-
endothelial extracellular matrix is exposed to blood. The mechanism for initial tethering 
and platelet adhesion to the exposed subendothelial matrix is influenced by the localized 
rheological conditions and prevailing flow rates75. At high shear (>600s-1) encountered in 
(small) arteries, vascular VWF binds through the A1 and A3 domain to collagen fibres in the 
injured vessel wall, creating a landing strip for fast flowing platelets76,77. Circulating erythro-
cytes push platelets towards the vessel wall where a dynamic process of transient interac-
tions between the platelet GPIb/IX/V complex and immobilized VWF decelerates platelets, 
allowing firm binding to collagen with GPVI and integrin α 2αβ1, and to VWF with integrin 
α IIbαβ3. At low shear rates (<600s
-1) platelets can directly bind to damaged vessel wall proteins 
like collagen, fibronectin and laminin78.
3.2.2 PLATELET ACTIVATION AND AGGREGATION 
Following adhesion, co-ordinated signal transduction events occur downstream of multiple 
agonist receptors of which the most relevant are those responding to collagen, thrombin, 
adenosine diphosphate (ADP) and thromboxane A2 (TXA2).
3.2.2.1 A CASCADE OF EVENTS STARTS WITH COLLAGEN BINDING
When platelets adhere to collagen fibres, a signal transduction cascade starts from GPVI 
activation (Figure 6). This glycoprotein couples to a disulphide-linked Fc receptor (FcR) 
αγ-chain homodimer in the cytoplasmic membrane. When GPVI clusters are formed, Src 
family tyrosine kinases Fyn and Lyn phosphorylate the immunoreceptor, tyrosine-based 
activation motif (ITAM) of the FCR αγ-chain. This creates a docking site for the tandem Src 
Homology 2 (SH2) domains of Syk. The binding of this tyrosine kinase initiates a signal 
transduction cascade that leads to the formation of a linker for activation of T cell (LAT) 
signalosome and following activation of one of the major effector enzymes, phospholipase 
C (PLC) αγ279. Phospholipases hydrolyze phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) to 
form diacylglycerol (DAG) and inositol 1,4,5- trisphosphate (IP3). The latter diffuses through 
the cytosol and binds IP3 receptors in the dense tubular system (DTS) which results in Ca
2+ 
release into the cytosol. When the calcium pool in the DTS is depleted, a second rise of cyto-
solic Ca2+ is achieved by stromal interaction molecule 1 (STIM1) which triggers calcium entry 
from the extracellular compartment via calcium release-activated calcium channel protein 1 
(Orai1). The simultaneously generated glyceride DAG is a lipid signal transduction molecule 
essential for localization and activation of protein kinases C (PKC). These play pivotal roles 
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in cytoskeleton reorganization through phosphorylation of its major substrate, pleckstrin80, 
and in platelet granule secretion by elevating the inhibitory effect of cytohesin-281. Rap1 
calcium and DAG-regulated guanine nucleotide exchange factor 1 (CalDAG-GEF1) is anoth-
er effector downstream of DAG and calcium elevations important in integrin α IIbαβ3 activa-
tion82. This integrin makes a dramatic conformational change in its extracellular domain 
enabling the crucial interaction with fibrinogen to substantiate interplatelet binding83.
Another pathway following receptor tyrosine kinase (RTK) activation involves phosphati-
dylinositol 3-kinase (PI 3-kinase). The PI 3-kinase family all catalyse phosphorylation of 
(phospho)inositides on the 3’ position of the inositol ring. There are three classes, based on 
their structure and lipid substrate preferences. Class I is divided into 2 subclasses of which 
Class IA represents heterodimers of a catalytic (p110α α, p110β α or p110αδ) and regulatory sub-
unit (p85αα, P85β α, p55αα, p55γα or p50α ) and class IB consist of heterodimers built from one 
catalytic subunit (p110γα) associating with either of three regulatory subunits p101 or p84/87. 
Class II PI 3-kinases catalyse the production of PI3P and PI(3,4)P2. Finally, Class III PI 3-ki-
nases form PI3P out of PI84. The class IA is activated downstream of tyrosine kinases which 
results in the transient formation of phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) 
and phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2)
85. Cytosolic kinases with pleckstrin 
homology (PH) domains like Protein kinase B (Akt) and Bruton’s Tyrosine kinase (Btk) bind 
to these products and in turn are phosphorylated. The precise mechanisms of Akt, Btk or 
other PH-dependent kinases in regulating platelet activation are poorly understood86.
Figure 5: Overview of signal 
transduction during platelet  
plug formation87.
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3.2.2.2 EXPANDING ACTIVATION WHEN THROMBIN COMES ALONG
Thrombin activates platelets at concentrations below 0.1nM making it the most potent 
platelet agonist. Thrombin signals through protease-activated receptors (PAR), more spe-
cifically PAR1 and PAR4 on human platelets. Activation occurs when thrombin cleaves the 
extended PAR N-terminus, exposing a de novo N-terminus which functions as a tethered 
ligand for self-activation. PARs are G-protein-coupled receptors (GPCR), which are 7-trans-
membrane domain proteins transmitting signals through heterotrimeric G proteins. These 
consist of a guanine-nucleotide binding subunit α, which is non-covalently linked toα β and α 
γ subunits. In the resting state, G
α
 α is guanosine disphosphate (GDP) bound and associates 
withα β and γ α. Upon agonist engagement, GDP exchanges for guanosine trisphosphate 
(GTP) on G
α
 which causes dissociation from G
βγ 
αα. Downstream signal transduction specifici-
ties depend on the G protein subtype these receptors are coupled to88.
PAR1 and PAR4 are both activated by thrombin and there is considerable overlap in signal 
transduction through activation of Gq, Gi and G12/13 coupled isoforms. Yet, PAR1 and PAR4 
have different roles in platelet activation. PAR1 causes an acute and short-lived reaction in 
response to low thrombin concentrations, while PAR4 causes a slower but sustained platelet 
activation only in response to high thrombin concentrations89,90. 
The signal transduction pathway through Gq causes PLCβ α activation and consequent DAG 
and IP3 formation
91. The IP3 secondary messenger stimulates Ca
2+ mobilization. The subse-
quent increase in intracellular Ca2+ concentration activates or potentiates multiple proteins, 
including actin-myosin, calmodulin, NO synthases and calcium-dependent proteases. 
One of those is the exchange factor CalDAG-GEF1 which leads to integrin activation, TXA2 
synthesis and granule secretion92. Furthermore, the elevation of intracellular Ca2+ concen-
tration stimulates the phosphorylation of certain PKC isoforms by DAG93.
G12/13 signals through Rho guanine nucleotide exchange factors, activating Rho kinase 
which phosphorylates and inhibits myosin light chain phosphorylation and contraction of 
actin. This leads to platelet shape change and granule secretion94. 
Finally, the signalling molecules of the Gi family are important for cyclic adenosine 
monophosphate (cAMP) concentration decreases through inhibition of adenylyl cyclase. 
Decreasing cAMP concentration is one of the primary mechanisms supporting sustained 
platelet activation through the P2Y12 receptor. Furthermore, the PI 3-kinase-Akt axis is 
downstream of Gi activation and cooperates sustained platelet responses
95.
3.2.2.3 AUTOCRINE AND PARACRINE ACTIVITIES OF ADP AND TXA2
Compared to thrombin, platelet self-generated ADP and TXA2 are less potent agonists by 
themselves, but are nonetheless very important synergistic activators absolutely required 
for efficient recruitment of platelets to the site of injury. Stimulation of P2Y1 and P2Y12 
by ADP reinforces integrin αIIbαβ3 inside-out activation and consolidates its interplatelet 
binding function96. It thus stabilizes the hemostatic plug through synergy with other 
platelet agonists97. P2Y12 is Gi coupled and marginally present on the resting cytoplasmic 
membrane. But upon activation, an inducible pool of P2Y12 receptors is exposed98. Besides 
inhibition of adenylyl cyclase, P2Y12 plays a crucial role in PI 3-kinase signal transduction99. 
P2Y1 on the other hand, is mainly Gq-coupled, resulting in PLCα activation
100.
Like ADP, TXA2 is a weak agonist by itself, but amplifies initial stimuli. TXA2 is produced 
through the conversion of arachidonic acid by the cyclo-oxygenase 1 (COX-1) pathway and 
diffuses through the cytoplasmic membrane to bind thromboxane receptors (TP). TP is 
coupled to both Gq and G12/13
101. 
Figure 6: GPVI signal transduction pathway. Phosphorylation of the FcRγ-chain by Fyn/lyn kinases is 
followed by activation of Syk. This in turn phosphorylates the LAT signalosome resulting eventually 
in central PLCγ2 and PI 3-kinase activation, leading to increased concentrations of cytosolic ionized 
calcium and PI(3,4,5)P3 formation, respectively
102
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3.2.2.4 AGGREGATION AND THROMBUS STABILIZATION THROUGH 
 OUTSIDE-IN SIGNALLING
The above described agonist-dependent intracellular signal transduction pathways stim-
ulate the binding of key regulatory proteins to the cytoplasmatic tail of integrins, which for 
example induces the transformation of integrin α IIbαβ3 from a ‘resting’ state to an ‘activated’ 
state. A key requirement for this so-called inside-out signalling is the binding of talin and 
kindlin to the membrane proximal half of the ααβ3 cytoplasmic domain
103. The following un-
clasping of the transmembrane and cytoplasmic domains of αIIbα and αβ3 increases the affinity 
for subsequent ligands, like fibrinogen and VWF. When these multimeric ligands bind the 
receptor, avidity is increased through clustering of integrin αIIbαβ3 molecules
104 (Figure 7). 
This causes outside-in signal transduction because signalling complexes proximal to the 
cytoplasmic tails of integrin αIIbαβ3 are assembled. The Src kinases that are constitutively 
bound to the αβ3 cytoplasmic tail in the cytoplasm are activated, clustered, unclamped and 
phosphorylated, which eventually leads to additional recruitment and phosphorylation 
of signalling and scaffolding proteins like Src and Syk protein tyrosine kinases105, RhoA106, 
PLCαγ2107, PI 3-kinase108 and Rap1b109 amplifying platelet spreading, granule secretion, stabi-
lization and clot retraction106,110.
Figure 7: Inside-out and outside-in 
signal transduction of the platelet 
integrin receptor
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4. CELL MEMBRANE 
 AS SIGNAL ORGANIZER
4.1 CELL MEMBRANE COMPONENTS
The reigning fluid mosaic three-dimensional model of the cellular cytoplasmic membrane 
was devised in 1972 by Singer and Nicolson111. (Figure 8) In this model, the cell membrane is 
a discontinuous fluid bilayer of amphipathic phospholipids in which lipophilic proteins are 
(partially) embedded. Phospholipids spontaneously arrange back-to-back to thermody-
namically stabilize hydrophobic acyl chains by shielding these from the surrounding watery 
environment. This biochemical property enables cells to segregate internal constituents 
from the extracellular environment
Figure 8: Fluid mosaic model. Cell membranes share 
a common structural organization of phospholipid 
bilayer with associated proteins112.
Cell membrane constituting phospholipids are variable by their polar head groups which 
differ in size and electric charge. Common polar head groups are glycerol, ethanolamine, 
choline, inositol and serine. Eukaryotic cells typically bear 45-55% phosphatidylcholine, 
15-25% phosphatidylethanolamine, 10-15% phosphatidylinositol, 5-10% sphingomyelin, 
2-10% phosphatidylserine, 1-2% phosphatidylglycerol and 1-2% phosphatidic acid113. An 
important additional level of phospholipid variability is caused by the number of hydropho-
bic acyl chains (one, two or three), the acyl chain length and the number of double bonds or 
so-called unsaturations in the acyl chain114. Next to phospholipids, the cytoplasmic mem-
brane harbours proteins, carbohydrates and sterols (mainly cholesterol). Within the lipid 
bilayer, cholesterol lines up approximately parallel to the acyl chains of the lipids with its 
hydrophilic hydroxyl group situated near the polar interface and the short hydrocarbon tail 
towards the nonpolar centre. Local cholesterol concentration is important for mechanical 
stability and fluidity of the membrane115.
Proteins constitute between 25% to 75% of the dry mass of cell membranes and are there-
fore of major importance both to the membrane biophysical properties as well as to its rela-
tion with the intra- and extracellular biological environment. Membrane dwelling proteins 
are diverse in composition, function and in their interaction with the membrane which can 
be weak in peripheral proteins or strong in integral proteins116.
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4.2 CELL MEMBRANE ARCHITECTURE
The cell membrane is a site where important cellular processes are carried out ranging from 
controlled transmembrane trafficking and surveillance to mechanical sensing. By its ar-
chitecture, that is, the organization of constituents in space and time, it orchestrates these 
processes carefully. The membrane is separated in large and smaller compartments  
(Figure 9) depending on the actin cytoskeleton, protein complexes and lipid packing. 
The first one, the actin cytoskeleton, dynamically associates with the cell membrane 
through interactions with integral membrane proteins, phospholipids and bridging 
molecules, forming compartments of roughly 40 to 300nm in diameter117,118. The second 
type of cell membrane domain, dynamic protein complexes, are generally between 3 and 
10nm in diameter and can be subdivided in three types: oligomers of membrane-anchored 
proteins119, coat-protein-facilitated domains (endocytosis and exocytosis)120, and scaffold-
ing-protein-induced protein complex domains, assembling more than two molecules121. 
Finally, compartments of 2 to 20nm in diameter are formed by the organization of the 
(phospho)lipids. The formation of these microdomains (sometimes called ‘rafts’) is regulat-
ed by the size of the polar headgroup of phospholipids which is small (e.g. phosphatidylg-
lycerol) or large (e.g. phosphatidylinositol), and by the acyl side chains. Single double bonds 
in the hydrophobic core cause kinks in the chain because of their cis conformation, thereby 
physically pushing away vicinal molecules influencing hydrophobic core packing122. The two 
characteristics (head group and acyl chain), both determine the overall three dimensional 
shape of a phospholipid and the extent to which the membrane displays “imperfections” 
in the geometrical tightness, so-called lipid packing defects (LPD). For instance, tightly 
packed and highly ordered lipid microdomains are composed of phospho- and sphingolip-
ids containing mainly saturated acyl chains, with “cavities” that are filled with sterols123. Less 
tightly packed disordered microdomains exist of mono- and polyunsaturated acyl chains 
and less (chole)sterol. This suborganization restricts and permits access of specific proteins 
allowing spatiotemporal organization of membrane-dependent cellular processes124.
Modulation of signal transduction and associated lipid and protein interactions along the 
cell membrane surface is also influenced by the electrostatic environment. For example, the 
tetravalent acid PI(4,5)P2 can be attracted by cationic (membrane-associated) molecules, 
because of the negative charges on the inositol ring. On the other hand, acidic phospho- 
lipids will repulse molecules with negatively charged domains125. 
Figure 9: Membrane architecture. The microdomains (2) can vary from 2 to 20nm in diameter while 
the dynamic protein complexes (3) vary from 3 to 10nm. Both are accommodated in the mem-
brane-skeleton-induced compartments (1) which vary from 40 to 300nm in diameter. Depending 
on the interactions between lipids and proteins and their architectural behavior, molecules have 
different diffusion abilities in the cell membrane118.
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4.3 CELL MEMBRANE RELAYING SIGNAL 
TRANSDUCTION
The phosphorylated phosphatidylinositol molecules or phosphoinositides are present in 
the cell membrane in small amounts. For instance, PI(4,5)P2 comprises 0.5-1% of the total 
phospholipid content. Despite this, PI are of great importance as scaffolding molecules 
and nucleation centres in virtually all living eukaryotic species126. Following GPCR and RTK 
signal transduction there are two well described, known fates for PI(4,5)P2. (1) PLC enzymes 
hydrolyze this inositide to yield IP3 and DAG, and (2) PI 3-kinase phosphorylate the 3’ posi-
tion to yield PI(3,4,5)P3. The concentration of PI(3,4,5)P3 thus transiently rises, and functions 
as a nucleation centre for signalosomes to build on in a spatiotemporally restricted manner.
As described earlier, the PI 3-kinase family contains three classes. For this work, Class I 
enzymes are most relevant. These phosphorylate PI(4,5)P2 and PI(4)P to yield PI(3,4,5)P3 
and PI(3,4)P2 respectively. Both PI(3,4,5)P3 and PI(3,4)P2 are potent scaffolding molecules 
that regulate cell growth, replication, survival, proliferation and motility in a plethora of cell 
types throughout biology127. More specific, they coordinate the spatiotemporal function of 
effector proteins which bind via so-called PH domains. Abundantly expressed effector pro-
teins are Btk and Akt128. For instance, Akt translocates from the cytosol to where PI(3,4,5)P3 is 
formed at the inner leaflet of the cell membrane binding to the negatively charged pocket 
via the PH domain. Then the PH- containing enzyme 3-phosphoinositide-dependent pro-
tein kinase 1 (PDK1) phosphorylates Akt at T308129. Next, phosphorylated Akt in turn phos-
phorylates a diversity of substrates which can regulate energy metabolism, cell survival, cell 
cycle progression, or differentiation depending on the tissue and the signaling context130.
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PART.2
RESEARCH OBJECTIVES
Transfusion transmitted infections are a considerable threat to global blood supplies. The 
implementation of preventive measures like screening tests and donor questionnaires have 
decreased the risk substantially. However, emerging pathogens and bacterial contamina-
tion of platelets still remain a concern for blood safety. Pathogen inactivation technology 
adds a layer of safety to the latter. The efficacy of pathogen inactivation to prevent repli-
cation of viruses, bacteria and protozoa has been investigated extensively. However, many 
questions are still open concerning the consequences of pathogen inactivation technolo-
gies to blood product quality and function.
For plasma, the solvent/detergent treatment was developed in the early 1980s. Nowadays, 
several bench-top pathogen inactivation technologies are available. Coene et al1  previously 
compared the impact of Mirasol Riboflavin (vitamin B2) pathogen reduction technology, 
INTERCEPT amotosalen (S59) photochemical treatment and THERAFLEX Methylene Blue 
Technology on plasma units. A significant decrease in the activity of fibrinogen, FII, FV, 
FVIII, FIX and FXI was found. Following this work, we investigated the molecular mechanism 
causing decreased activity of protein in plasma treated by Mirasol in particular, because 
the decrease was the largest in that case. We focused on the proteolytic enzyme ADAMTS13 
which is important for the treatment of thrombotic thromobyctopenic purpura (RESULTS  
§ 1.1)
Next, we investigated the off-target effects on platelets caused by pathogen inactivation. In 
the past decade the behavior of pathogen inactivation treated platelets has been assessed 
using many in vitro assays like light transmission or impedance aggregometry, flow cytom-
etry, thromboelastography, cone-and-plate viscometry and blood gas analysis. However, it 
is not entirely clear what this implies for platelet behavior in general or the context of hemo-
stasis. We approached this question by setting up a comprehensive platelet function test 
with hydrodynamic shear and real-time analysis of platelet deposition onto immobilized 
collagen (RESULTS § 2.1) This microfluidic flow chamber model is then used together with 
traditional platelet function experiments to evaluate the impact of pathogen inactivation 
on platelet concentrates in a paired study in function of storage time. (RF-PRT and AS-PCT 
in RESULTS § 3.1; UV-C in RESULTS § 3.2) Finally, a critical analysis of AS-PCT is done to 
examine what biochemical defects impact platelet function. (RESULTS § 3.3)
1. Coene, J., et al. Paired analysis of plasma proteins and coagulant capacity after treatment 
with three methods of pathogen reduction. Transfusion 54, 1321-1331 (2014).
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PART.3
RESULTS
1. PATHOGEN INACTIVATION 
 OF PLASMA
1.1 OXYGEN REMOVAL DURING PATHOGEN  
INACTIVATION WITH RIBOFLAVIN AND UV 
LIGHT PRESERVES PROTEIN FUNCTION  
IN PLASMA FOR TRANSFUSION  
INTRODUCTION
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INTRODUCTION
Fresh frozen plasma (FFP) is used clinically to replenish isolated coagulation factors 
deficiencies, to reverse the effect the warfarin, and to treat the dilution coagulopathy that 
occurs with massive bleeding 1. Plasma exchange, requiring large quantities of donor plas-
ma, has become the treatment of choice in patients suffering from thrombotic thrombocy-
topenic purpura. Like other blood components for transfusion, FFP inherently carries a risk 
of pathogen transmission 2,3 which can be reduced by various treatment methods. Solvent/
detergent (S/D) treatment efficiently kills enveloped viruses and was licensed in Europe in 
1991 and recently in the United Sates. The process includes pooling of multiple donations 
increasing patient exposure to donor material4. In the last couple of decades bench-top 
alternatives have been developed allowing treatment of single donations and effectiveness 
against non-enveloped viruses. These methods are commonly based on light energy treat-
ment of individual component bags in the presence of a dissolved chemical photosensitizer. 
Photosensitizers are exogenously added molecules which interact with nucleic acids to 
various extents and react upon photoexcitation to induce strand breakage or cross-linking, 
thereby irreversibly preventing replication4. Methylene Blue5 (Macopharma, Tourcoing, 
France or Baxter International Inc, Deerfield, IL) treated plasma is used in some European 
countries but requires freezing or additional filtering to release or remove cytoplasm-borne 
pathogens, respectively. ‘Newer’ photosensitizers include amotosalen6,7 (or S-59, Cerus Cor-
poration, Concord, CA) which does not require a freezing step and riboflavin8 (or vitamin B2, 
Terumo BCT, Lakewood, CO) which is a naturally occurring vitamin and therefore does not 
require cumbersome removal from plasma products following treatment. Both amotosalen 
and riboflavin initially were described for inactivation of pathogens in platelet concentrates, 
but have since also been validated for treatment of single plasma units6,9. 
Pathogen inactivation treatment of plasma involves risks of losing valuable material 
through processing and/or affecting the constituents required for efficient transfusion10. 
There are few sufficiently powered studies that have evaluated clinical efficacy of pathogen 
reduced plasma11,12, therefore evaluation of plasma quality is principally based on in vitro 
analysis of (labile) coagulation factors. From our previous paired analysis on the effects of 
the three photosensitizer-based methods13, we concluded that coagulation factor loss is 
most pronounced in riboflavin treatment, though compensated to some extent by its low 
volume loss. Inversely, the methylene blue and amotosalen methods affect the constituent 
proteins less but are associated with larger volume losses. 
The present work reveals the mechanism underlying the protein loss in riboflavin-based 
pathogen inactivation showing a significant role for reactive oxygen species and suggest-
ing significant improvement by removal of dissolved oxygen prior to treatment. 
METHODS
PATHOGEN INACTIVATION METHODS
For comparison of methods, paired samples were used following a pool and split design 
which joined and mixed five single plasma units followed by an equal split per pathogen 
inactivation method13.
Plasma for methylene blue (MB) treatment14 (Macotronic, Macopharma) is passed over a 
0.65µm membrane filter and a dry MB tablet while being transferred to an illumination bag. 
The plasma containing approximately 1µM MB is exposed to a light dose of 180J/cm2 by illu-
mination for about 20 minutes with long wavelength light (mainly 590nm). Next, the treated 
plasma is led over an auxiliary filter to remove residual MB. 
Plasma for riboflavin (RF) treatment15 (Mirasol, Terumo BCT) is mixed with 35mL RF solution 
(final concentration approximately 50µM) and transferred to an illumination bag which is 
subsequently illuminated with a UV (265-370nm) light dose of 6.24J/mL. Finally, the treated 
plasma is transferred to the storage bag. 
Plasma for amotosalen (AS) treatment16 (Intercept, Cerus) is led through a pouch containing 
15mL AS solution (final concentration approximately 150µM). A UV (320-400nm) light dose 
of 3J/cm2 is delivered followed by an auxiliary adsorption step to reduce residual AS.
ADAMTS13 ACTIVITY AND ANTIGEN DETERMINATION
ADAMTS13 enzyme activity was measured using the fluorogenic substrate FRETS-VWF73 
(AnaSpec, Fremont, CA, USA)17 with modifications18. Normal human pooled plasma (NHP) 
(n=21) was used as a reference and EDTA at 10mM as a negative control. The final mixture 
contained 50mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, pH 
7.4 supplemented with 1mM CaCl2, 1µM ZnCl2, 4.2mM 4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride (Sigma-Aldrich) and 2µM FRETS-VWF73. Fluorescence intensity was 
measured every 150 seconds for 90 minutes at 25°C in a microplate reader (Infinite F200 
Pro, Tecan, Männedorf, Switzerland) equipped with a 340nm excitation and 448nm emission 
filter. Product formation rates were determined relative to NHP.
A sandwich enzyme-linked immunosorbent assay (ELISA) (Imubind, American Diagnostica, 
Greenwich, CT, USA) was used to measure ADAMTS13 antigen, following the instructions 
of the provider. Detection of bound antigen is through a goat anti-human IgG antibody 
labeled with a streptavidin-horseradish peroxidase (HRP) which reacts with the perbo-
rate-3,3’-5,5’-tetramethylbenzidine (TMB) substrate to generate a blue colored solution. 
After acid addition to stop colorimetric development, absorbance was measured at 450nm 
in a microplate reader. 
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ELECTROPHORESIS AND WESTERN BLOTTING
Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) was performed on 
stain-free precast TGX gel, 7.5% (Bio-rad, Hercules, CA, USA) in a 2-Amino-2-hydroxyme-
thyl-propane-1,3-diol Tris -glycine buffered system (25mM Tris, 192mM Glycine, 0.1% (w/v) 
SDS). Plasma samples were diluted twenty-fold in phosphate buffered saline (PBS) contain-
ing 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM KH2PO4, pH 7.4 and non-reducing sample 
buffer containing 60mM Tris-HCl, 10% (v/v) glycerol, 2% (v/v) SDS and 0.01% (w/v) bromo-
phenolblue. NHP was used as a negative control. As a positive control, NHP was incubated 
with 250U/mL urokinase-type plasminogen activator (Sigma-Aldrich, St Louis, MO, USA) 
overnight at 37°C, followed by addition of 100µM Amiloride hydrochloride hydrate (Sig-
ma-Aldrich, St Louis, MO, USA) to stop proteolysis. Transfer was on nitrocellulose blotting 
sandwiches for TurboTM (Bio-rad, Hercules, CA, USA). After incubation with anti-ADAMTS-13 
primary antibody19 (kind gift of Dr. JTB Crawley, Imperial College London), HRP-labeled goat 
anti-rabbit (Jackson ImmunoResearch, West Grove, PA, USA) and chemiluminiscence (Ther-
mo Fisher Scientific, Rockford, IL, USA) were used to detect bound antibody. Gel images 
were developed on a digital imager (ChemiDoc MP System, Bio-rad, Hercules, CA, USA) and 
analyzed by Image Lab (Bio-rad, Hercules, CA, USA).
SUPEROXIDE ANION MEASUREMENTS
As a reporter for oxidative stress20 170µM nitroblue tetrazolium (NBT) (Merck, Darmstadt, 
Germany) was mixed with 5µM riboflavin (RF) and 0.5mM ethylenediaminetetraacetic acid 
(EDTA) (both Acros Organics, Geel, Belgium) in phosphate buffered saline (PBS, pH 7.4) in a 
polyolefin platelet illumination and storage bag (Terumo BCT). In order to specifically scav-
enge O2-, superoxide dismutase (SOD) (Sigma-Aldrich, St Louis, MO) was added to 100U/mL. 
Following PIT according to standard operating protocols in a Mirasol illuminator (Terumo 
BCT), formazan formation was measured by absorbance at 550nm in a regular spectro-
photometer (UV-3100PC, VWR International, Radnor, PA). For dynamic range purposes, a 
lead-up experiment using a serial dilution of RF in the same assay conditions (Figure S1) 
indicated that 5µM of RF resides in the linear portion of the dose-response relationship. 
All samples, bags and equipment were kept shaded from ambient light at all times and air 
bubbles were removed manually by applying physical pressure. 
DEGASIFICATION PROCEDURE
Molecular oxygen gas dissolves in aqueous solutions according to Henry’s law depending 
on partial gas pressure and solubility. To remove dissolved oxygen from buffer solutions 
or plasma, a small tube carrying pressurized inert nitrogen gas (Air Liquide, Paris, France) 
at 40kPa was introduced in polyolefin storage bags and mixed for 20 minutes at room 
temperature in the dark. Following this procedure, oxygen concentrations were decreased 
to levels unable to oxidize resorufin (Figure S2) in the alkaline ‘blue bottle’ oxygen reporter 
system containing 0.5M KOH and 0.2M D-glucose (all Acros Organics). Measurements by 
micro-Clark electrode potentiometry (Lazar Laboratories, Los Angeles, CA) indicated that 
the residual oxygen pressure in the bags was 540±169Pa (mean±SEM, n=3) (Figure S3). 
FACTOR VIII AND FIBRINOGEN
FVIII activity (%) was measured in a one-stage activated partial thromboplastin time based 
clotting assay with factor deficient plasma. Fibrinogen activity was measured by the Clauss 
method and both analyses were performed in duplicate on a STA-R Evolution apparatus 
with tools and reagents from Diagnostica Stago (Asnières, France).
CARBONYLATION
Carbonyl content was determined by spectrophotometric analysis of dinitrophenylhydra-
zone as described by Dalle-Donne et al21. In brief, samples containing 2mg protein were sup-
plemented with 10mM 2,4-dinitrophenylhydrazine (DNPH) (Sigma-Aldrich) in 2M HCl (final 
concentrations) and incubated at room temperature with shaking for one hour in shaded 
vials. Parallel samples only contained vehicle (2M HCl) to determine background. Next, 
trichloroacetic acid (VWR International) in water was added to a final 10% (m/v) followed by 
gentle mixing and 10 minute incubation on ice. Precipitated proteins were centrifuged at 
2,000g for 10 minutes at 4°C followed by resuspension of the pelleted fraction in 6M gua-
nidine hydrochloride (GuHCl) in water. Excess unreacted DNPH was removed by desalting 
column chromatography over a 6M GuHCl pre-equilibrated spin column (ZebaTM, Thermo 
Fisher Scientific). Absorbance of dinitrophenylhydrazone in the flow-through fraction was 
determined by spectrophotometry at 370nm and values were corrected for background. An 
extinction coefficient of 22,000M-1cm-1 was used for determination of carbonyl quantity. 
Finally, the flow-through samples were analyzed for protein concentration by BCA assay to 
enable expression of carbonylation as mole per milligram protein.
STATISTICAL ANALYSIS
Statistical analysis used standard algorithms from Prism 5.04 software (GraphPad, La Jolla, 
CA) including one-way repeated measures ANOVA with Bonferroni or Dunn’s post-tests, 
t-test and Mann-Whitney U-tests for comparison of means. Estimation of Gaussian distri-
bution used Shapiro-Wilk or Kolgomorov-Smirnov tests. 
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RESULTS
ADAMTS13 IN PATHOGEN INACTIVATION
Plasma exchange or infusion is the standard treatment for thrombotic thrombocytopenic purpura 
(TTP)22, a thrombotic microangiopathy caused by severe ADAMTS13 deficiency. ADAMTS13 
content in plasma products is well studied, but the effects of pathogen inactivation were never 
compared in paired samples. Therefore, ADAMTS13 activity and antigen were measured in three 
photosensitizer-based pathogen inactivation methods as part of a prior comprehensive study by 
our group13. 
Figure 1 indicates the percentage recovery which relates final to initial ADAMTS13 values and is 
a measure for retention over the entire pathogen inactivation procedure. Recovery percentages 
hence take into account all procedural steps including volume loss which is prominent in MB but 
absent in the RF methodology. Yet, Figure 1 shows that RF treatment is not necessarily superior 
in retaining ADAMTS13 than MB or AS. This is explained by a significant decrease of ADAMTS13 
antigen and function (by activity) of 29% and 23%, respectively in RF (Figure 2). Taken together, 
significant ADAMTS13 (functional) enzyme is lost in both MB and RF, but volume loss accounts for 
decreases in the former while molecular changes contribute most to the latter. Recovery is most 
sustained by AS treatment. 
Figure 1: Percentage recovery of ADAMTS13 in three pathogen reduction methods.The percentage of AD-
AMTS13 activity (top) or antigen (bottom) retained in the final bag relative to the starting amount is depicted 
in function of each photochemical pathogen reduction method. It takes into account several procedural 
steps including molecular degradation as well as volume loss. Individual data are shown as dots, dataset 
mean as a horizontal line and standard deviation as whiskers. Statistics indicated on top were generated by 
repeated measures one-way ANOVA with Bonferroni multiple comparison testing (n=24). 
Figure 2: ADAMTS13 activity and antigen are affected most by RF-based pathogen reduction. ADAMTS13 
activity (top) and antigen (bottom) absolute concentrations were determined in plasma sampled from paired 
bags before (black boxes) and after (grey boxes) pathogen reduction treatment with either MB, RF or AS. 
Box edges represent standard deviations, median (horizontal line) and mean (+). Whiskers indicate data 
range (n=24). Statistical results of repeated measures one-way ANOVA with Bonferonni multiple comparison 
testing are indicated above each dataset. 
ADAMTS13 IS NOT CLEAVED NOR DIRECTLY INHIBITED BY RIBOFLAVIN
In order to explain the ADAMTS13 molecular changes in RF-based pathogen inactivation, 
we hypothesized that the plasma treatment causes collateral serine protease activation. It 
is known that ADAMTS13 is variably susceptible to proteolytic degradation and subsequent 
inactivation by serine proteases, including factor Xa, thrombin or plasmin19,23. However, de-
spite substantial loss of the intact full length ADAMTS13 molecule in western blot analysis 
(Figure 3), no increase in smaller immunoreactive fragments characteristic for proteolytic 
breakdown is seen. 
In addition, VWF73 proteolysis is not directly inhibited by RF at concentrations used in 
pathogen inactivation (Figure S4) indicating no direct binding of RF to ADAMTS13. 
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SUPEROXIDE ANIONS ARE GENERATED DURING PATHOGEN INACTIVATION 
WITH RIBOFLAVIN
Next, we hypothesized that the molecular changes in ADAMTS13 are caused by oxidation 
promoted by newly generated ROS. Oxidative stress during RF-based pathogen inactivation 
was directly measured by (colorless) NBT reduction to blue formazan. In buffer, significant 
formazan formation is seen upon illumination of 5µM RF in a Mirasol apparatus (Figure 4). 
To dissect the nature of the reactive species involved, the specific superoxide scavenging 
enzyme SOD was added. A significantly lower signal is seen in the presence of 100U/mL 
SOD indicating that a considerable portion of NBT reduction is caused by O2- which can be 
scavenged by SOD. Superoxide anion radicals are formed when dissolved molecular oxygen 
(O2,aq) accepts the excess energy from photochemically excited sensitizers. Indeed, when 
the O2,aq concentration is experimentally lowered by nitrogen gas sparging, the O2- related 
NBT reduction can no longer be diverted using SOD (Figure 4). Instead, NBT reduction 
is now established through non-oxygen and most probably direct electron transfer from 
excited photosensitizer molecules to the reporter. These data show that photosensitized RF 
transfers its excitation energy to O2,aq when present, generating O2- in the exact conditions 
used for pathogen inactivation of blood components.
Figure 3: ADAMTS13 is not proteolyzed but partially degraded. Plasma samples before (-) or after (+) patho-
gen reduction were analyzed in SDS PAGE with western blotting for ADAMTS13 protein. An equal amount of 
protein was loaded in each lane. As negative and positive controls for enzymatic proteolysis, untreated (NHP) 
or urokinase (NHP+u-PA) incubated paired plasma samples were loaded. The sample prior to thawing for 
pathogen reduction (pre) is also included. Molecular weight references are indicated to the left in kilodaltons.
Figure 4: Pathogen reduction conditions of RF and light generate O2- depending on O2,aq. The nitroblue 
tetrazolium redox indicator is converted to formazan which absorbs at 550nm upon reduction by superoxide 
or its derivatives. The absorbance in blood component storage bags before (open bars) and after (closed 
bars) pathogen reduction with 5µM RF in a Mirasol apparatus is shown. Addition of 100U/mL SOD indicates 
the specific presence of O2- molecules. These are generated in function of O2,aq availability as is shown when 
ambient partial pressures (‘nor’) of O2,aq are experimentally lowered (‘low’) by nitrogen gas sparging. Means 
(n=5) with standard error of the mean as error bars are depicted. 
OXIDATIVE DAMAGE CAN BE PREVENTED BY LOWERING DISSOLVED  
MOLECULAR OXYGEN
Superoxide anions and its derived radicals are highly reactive and not selective, therefore not 
restricting its effects to ADAMTS13. To assess disseminated oxidative damage on plasma proteins, 
total carbonylation levels were determined (Figure 5). Carbonyl groups (both aldehydes and 
ketones) are irreversibly added to protein by many different oxidative mechanisms24 including 
reactions with advanced glycation and lipid end-products as well as metal-catalyzed (Fenton-like 
chemistry) reactions. The data show that in the presence of normal O2,aq concentrations generic 
oxidation of proteins is prominent following RF-PRT. However, when O2,aq is experimentally low-
ered by inert gas sparging this damage is prevented (Figure 5). This shows a direct role of O2,aq in 
modification of proteins present in plasma.
Because some proteins in donorplasma are specifically relevant in the context of coagulopathies, 
these were investigated in more detail with respect to RF-PRT in the presence or absence of O2,aq. 
Figure 6 shows that ADAMTS13 activity, fibrinogen concentration and FVIII:C are significantly 
better retained when the donorplasmas are pretreated with nitrogen gas to reduce O2,aq. 
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Figure 5: Disseminated oxidative damage of plasma proteins. Carbonyl content of protein molecules is de-
termined by chromogenic derivatization on paired samples (n=7) taken from plasma bags before (black bars) 
and after (grey bars) pathogen reduction with RF without plasma pretreatment ([O2,aq]nor) or following oxygen 
reduction ([O2,aq]low) by inert gas purging. Data are expressed as mean molar carbonyl content per unit of 
mass protein and standard deviations are indicated by whiskers. Statistics compared means by repeated 
measures one-way ANOVA using Bonferonni multiple comparison post testing.
DISCUSSION
Photochemical treatment of biological material affects the (functional) integrity of the constitu-
ents to various degrees. This has been demonstrated for plasma with all three available methods 
for blood product processing and most specifically using intrinsically labile factors like FVIII10. 
However, the molecular basis for the observed effect is unclear and novel insights should allow 
optimization of current methods to deliver better blood products to patients.
From our experiments measuring ADAMTS13 in treated plasma it is clear that the largest biomo-
lecular damage is seen with RF-PRT when compared to MB and AS. These specific data corrobo-
rate well with the observed changes in other unrelated coagulation factors during PIT13. Although 
clinically not investigated to date, plasma products containing fewer active ADAMTS13 may in 
theory be less efficient to treat TTP. Remission might be achieved more slowly or only following 
administration of a larger volume which may in turn increase typical risks of plasma exchange or 
plasma infusion like fluid overload or citrate-induced hypocalcemia. Some might argue that the 
difference in ADAMTS13 concentration is not that relevant when taking into account the seem-
ingly low threshold of ADAMTS13 activity required for achieving remission of TTP25, but clinical 
studies are lacking to confirm either statement. 
Although adverse effects of photochemistry on coagulation factors have been reported before, 
there are no data describing the underlying phenomenon that damages plasma biomolecules. 
Using the ADAMTS13 susceptibility to RF-PRT as a readout, a series of experiments sought to 
identify the cause. First, direct riboflavin inhibition of ADAMTS13 function was investigated as a 
potential bias in the readout. Using the FRETS-VWF73 based ADAMTS13 activity assay, no direct 
effect of RF on the enzyme function could be detected. Next, random activation of zymogens 
was hypothesized relating the observed functional and effective decrease in ADAMTS13 to its 
previously reported susceptibility to serine proteases23. In a western blotting experiment known 
to be sensitive to proteolytic bands of ADAMTS1319, no increased breakdown could be detected 
following RF-PRT despite a significantly weaker intensity of the full length band of ADAMTS13. 
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Figure 6: Dissolved molecular oxygen underlies damage to ADAMTS13, fibrinogen and FVIII during path-
ogen reduction with riboflavin. ADAMTS13 activity, fibrinogen and FVIII levels were determined in paired 
samples taken from plasma bags before (black bars) and after (grey bars) pathogen reduction with RF with-
out plasma pretreatment ([O2,aq]nor) or with oxygen reduction ([O2,aq]low) by inert gas purging. Bars represent 
means and whiskers standard deviations (n=7). Statistics compared means by repeated measures one-way 
ANOVA using Bonferonni multiple comparison post testing
Next, the role of increased oxidative stress was investigated by using the redox reporter NBT20.  
Riboflavin and ultraviolet light have been used for decades in chemistry laboratories as an easy 
and inexpensive model system for the generation and investigation of superoxide anions and sin-
glet oxygen. However, in the specific context of pathogen inactivation it is unknown if and to what 
extent ROS are produced. To investigate this, blood product bags that would otherwise contain 
donor plasma were filled with buffered NBT redox reporter and treated with RF pathogen inactiva-
tion. An oxidative response in function of RF dose could be detected, indicating dose dependent 
increase of redox potential in the exact setting of bench-top plasma pathogen inactivation. By 
addition of the specific superoxide scavenger SOD, the reporter was significantly less reduced 
demonstrating that substantial amounts of superoxide anion were driving the NBT redox reaction 
during the process of RF pathogen inactivation. 
Since ROS react with multiple targets in an unspecific fashion, generic damage to the plasma 
content was investigated by measurement of carbonyl modifications to plasma protein. Carbon-
ylation is irreversible and can be detected and quantified by chemical derivatization in solution. 
Indeed, following RF mediated pathogen inactivation, a significant increase in protein carbonyl 
content is seen. This might also explain the observed decrease of anti-ADAMTS13 binding in west-
ern blot (Figure 3) as epitopes may be directly affected by these or other molecular modifications 
induced by ROS. 
Nonetheless, our data show that the damage to the product can be bypassed through performing 
the pathogen inactivation procedure in a hypoxic environment. First, when the NBT redox reporter 
experiment with and without SOD was repeated in hypoxic conditions we found that the RF-me-
diated NBT redox reaction was no longer driven by superoxide. This shows that in the absence of 
dissolved oxygen photo-excited RF intermediates are still able to reduce NBT and possibly other 
targets (like pathogen nucleic acids) but that the superoxide production is severely hampered. 
Secondly, in such hypoxic conditions the disseminated carbonylation of protein also was efficient-
ly rescued as shown in figure 5. Finally, the earlier reported specific damage to FVIII, fibrinogen 
and ADAMTS13 can be rescued eventually resulting in higher yields of these clinically significant 
factors. 
Taken together, our data show that UV light excitation of RF in the practical context of patho-
gen inactivation transfers energy to dissolved molecular oxygen, generating superoxide anion. 
This and other reactive species not only cause protein carbonylation but may potentially also 
induce fatty acid peroxidation chain reactions in lipids26, auxiliary modifications in proteins27 (eg 
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nitrosylation) and glycation of carbohydrates28. Therefore, superoxide and other ROS generated 
during pathogen inactivation likely contribute to the biostatic action of pathogen inactivation 
technologies by effectively damaging pathogen biomolecules29 as an indirect effect of RF excita-
tion. However, this is not the sole pathogen inactivation mechanism30 because direct damage of 
nucleic acids by excited RF is also likely to be involved since direct irreversible oxidative chemistry 
by photo-excited RF has been demonstrated31 as well as direct (non-covalent) binding of RF to 
nucleic acids32. Therefore performing the pathogen inactivation procedure in hypoxic conditions 
may still adequately affect pathogenic nucleic acids with the important advantage of avoiding 
random damage in the product caused by ROS. 
The same phenomenon may apply to platelet concentrates treated with Mirasol technology be-
cause recent work by the Australian Red Cross33 indicates that platelet lysates from concentrates 
treated with RF pathogen inactivation have increased carbonylation levels as well as a rise in the 
advanced lipid end product 4-hydroxy-2-nonenal. It is unclear if performing pathogen inactiva-
tion of platelets in the absence of dissolved molecular oxygen can rescue the observed biomo-
lecular damage without compromising the cell’s metabolic housekeeping. Anoxia causes meta-
bolic damage in platelets34 and therefore the beneficial effects of such pretreatment in the setting 
of pathogen inactivation may be balanced out. Despite this, the entire process of illumination only 
takes a couple of minutes which may allow to effectively remove and resupply oxygen without sig-
nificantly disturbing platelet metabolism and gas exchange. If feasible, this would prove a major 
technological step forward in safekeeping blood products during pathogen inactivation. 
Pathogen inactivation is an important step forward in the aim to reduce transmission of disease 
by transfusion of blood products. Our experimental work indicates that the delicate balance to 
conserve blood product integrity while ensuring a high safety level may benefit from working in 
hypoxic conditions, at least for plasma but maybe also for platelets. 
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SUPPLEMENTARY FIGURES
Figure S1: Reduction of nitrobluetetrazolium (NBT) by Mirasol illumination of various RF concentrations. 
Nitroblue tetrazolium reduction to formazan derivatives was measured by spectrophotometry following ( n ) 
illumination of storage bags in a Mirasol illuminator in the presence of varying concentrations of riboflavin 
(RF) in PBS with EDTA. Absorbance values of each paired sample before illumination (● ) is also shown. This 
experiment allows selection of an RF concentration in the linear part for dynamic range purposes.
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Figure S2: Nitrogen gas sparging effectively decreases dissolved oxygen in illumination bags. The classical 
‘blue bottle experiment’ used the resazurin-resorufin redox relationship to report the presence of dissolved 
molecular oxygen (pink) or not (transparent) in bags sparged with nitrogen gas (right) or not (left) during 
constant orbital agitation. Values below panels indicate sparging times in minutes. Following  
15 minutes of sparging, sufficient molecular oxygen was removed from the bag to prevent reporter oxidation
Figure S3: Partial pressure of dissolved oxygen in plasma decreases in function of N2 sparging time.
Plasma bags containing 250mL single donor plasma was sparged with 0.5bar of dry gaseous N2 under 
continuous mixing. A Clark-type oxygen sensing microelectrode was suspended in the bag content for 
continuous potentiometric recording. The data are depicted in kilopascal (kPa) and represent means with 
standard deviations of three independent experiments. 
Figure S4: ADAMTS13 is not directly inhibited by RF. ADAMTS13 activity was measured in paired plasma 
samples (n=9) in the presence (+RF) or absence (-RF) of 50µM riboflavin. Activity is expressed relative to an 
unrelated NHP. A paired two tailed t-test was used for comparison of means.
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2. POWERFUL RESEARCH TOOL 
TO INVESTIGATE THE  
FUNCTION OF PLATELETS
2.1 MICROFLUIDIC FLOW CHAMBERS USING 
RECONSTITUTED BLOOD TO MODEL  
HEMOSTASIS AND PLATELET TRANSFU-
SION IN VITRO
INTRODUCTION
Hemostasis requires the combined and regulated activity of cells, proteins, ions and tissues 
in a restricted spatiotemporal context1. Uncontrolled activity may lead to hemorrhage or 
thrombosis and morbidity or mortality in a spectrum of disorders related to blood coagulation. 
A microfluidic flow chamber experiment is a challenging technique that mimics hemostasis in 
vitro. This approach allows investigation of the complex interplay of processes that take part 
in hemostasis with a leading role for blood platelets. 
Following vascular injury, platelets adhere to the exposed subendothelial matrix (glyco)
proteins to prevent blood loss. Following adhesion, platelets activate and aggregate in 
response to auto- and paracrine signaling which finally leads to the formation of a platelet 
network, stabilized by fibrin and resulting in a firm, wound sealing thrombus2. Unlike most 
other platelet function tests, experiments with flow chambers take into account the physical 
parameter of blood flow and therefore the influence of rheology on the participating cells and 
biomolecules3,4.
Flow chamber experiments have generated landmark insights in hemostasis and thrombosis 
by varying key parameters that influence hemostatic (sub)processes including the adhesive 
matrix, rheology and flow profiles, cellular composition, presence of toxins or drugs, ionic 
strength and many more. In the past two decades, low throughput flow chamber experiments 
requiring large sample volumes (10-100mL) have evolved to microfluidic chambers often 
consisting of small parallel-plate chambers and including modern technology for perfusing 
whole blood at controlled wall shear conditions5. Microscaling has significantly increased 
assay throughput mostly because the hardware setup has simplified and less (blood) volume 
is required, rendering the experiment more accessible and versatile. For instance, blood 
from small laboratory animals can now be used without the need to sacrifice animals. Blood 
samples of genetically modified mice have thus aided in the identification of key molecules 
promoting or inhibiting hemostasis and in novel basic insights 6.
Specialized research laboratories often still use custom made flow chambers for instance 
from polydimethylsiloxane (PDMS)7 that polymerizes on lithographed molds which can be 
blueprinted by software. The resulting chamber is inexpensive, disposable and can be easily 
disassembled for post hoc analysis. Furthermore, basically any design of vessels, including 
bifurcations or sharp turns can be built on command. This advantage is also its downside 
since standardization was already the primary problem with flow chamber experiments, and 
PDMS custom made chambers have not aided this. On top of this particular issue, coating 
(conditions), fluorescent probes, anticoagulant, temperature and time between sampling and 
analysis are all poorly standardized8. Standardization of these variables is challenging, but 
nonetheless required to permit comparison of results between laboratories. This topic is the 
major subject of the International Society on Thrombosis and Haemostasis in Scientific and 
Standardization subcommittee on Biorheology9,10. 
Platelet concentrates (PC) are transfused in patients suffering from various diseases that 
cause thrombocytopenia and/or bleeding. But platelets in PC are known to desensitize, es-
pecially in function of storage time11, a deterioration process linked to ageing and commonly 
referred to as platelet storage lesion. It is sometimes claimed that such platelets restore in 
circulation once transfused12, but evidence for this is scarce. Furthermore, the functionality 
of platelets making up a PC is not routinely tested because the relationship between such 
assays and therapeutic or prophylactic efficacy is unclear13. Microfluidic flow chambers offer a 
means to investigate platelet function in PC to optimize the chain of manipulations between 
collection and issuing. It is a powerful research tool for direct (paired) comparisons of PC as 
we have previously published14,15 and is described here. 
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PROTOCOL
This protocol follows the institutional ethical guidelines for research on human samples and 
informed consent was obtained from all donors involved. Approval for the experiments described 
here was obtained from the institutional review board of the Antwerp University Hospital.
Note: Temperature indications are always room temperature, unless specified.
1. PREPARATION FLOW CHAMBER SET UP
1.1 PREPARING LANES, TUBING AND PINS
1.1.1 Vortex the collagen suspension vigorously and dilute 1/20 in the isotonic 
glucose solution supplied by the provider to a final concentration of 50µg/mL.
 Note:  We use equine tendon collagen, mainly made up of type I fibrils. The equine collagen type 
I is often referred to as “Horm” collagen and is the golden standard for this type of assay9 for both 
historical as well as biological reasons. Human type III collagen can also be used, but the fibrils 
coat less well and the platelet response is not as strong. Other coating surfaces can also be used, 
for example von Willebrand Factor (VWF), fibrinogen, fibronectin, laminin, vitronectin, thrombos-
pondin-1 or combinations of these16. 
1.1.2 Take a new disposable biochip from the provider’s container. The dimen-
sions of the biochips used here are 0.4W X 0.1H X 20L in mm.
1.1.3 Pipet 0.8µL into the lane(s) of the microfluidic biochip on one end of the 
chip and mark as outlet. Make sure that the lane is filled 5/6th with the collagen 
containing coating solution prepared in 1.1.1. Ensure that there are no air bub-
bles.
 Note:  Channels are partially coated to avoid accumulation of collagen fibers at the entrance of 
the channel (see discussion).
1.1.4 Incubate at 4°C for 4h or overnight in a humidified and closed container.
1.1.5 Block the coated channels by pipetting blocking buffer (1.0% (w/v) bovine 
serum albumin and 0.1% (w/v) glucose in 10mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES) buffered saline (HBS; 0.9% (w/v) NaCl, pH 7.4) 
at the other end and mark as inlet. Make sure that the lane is completely filled 
with the blocking buffer avoiding air bubbles.
1.1.6 Cut tubing at equal length (12cm). Use one per lane and connect each 
tubing with a pin. For example, an experiment comparing two conditions, run in 
duplicate will require four tubing stretches and four pins to be prepared. 
1.1.7 Rinse the tubing with distilled water using a syringe and a 26G needle or the 
accompanying connectors.
1.1.8 Saturate the tubing with blocking buffer. Store in a closed and humidified 
container for a minimum of 1h.
1.2 PREPARING PUMP AND MANIFOLD
1.2.1 Rinse the pump and manifold with distilled water, remove air bubbles.
1.2.2 Aspirate the blocking buffer out of the biochip lane(s) using the fixed 10µL 
tip at the outlet. Clean the surface of the biochip with a precision dust free wipe 
and denaturated alcohol to remove prints and dust.
1.2.3.Fix the biochip on an automated microscope stage. If more than one lane is 
used simultaneously in one run, connect the eight-lane manifold splitter to the 
biochip outlet.
 Note:  The eight-lane manifold splitter is a piece of hardware (Figure S1) connected to the pump 
and the biochip. It allows operation of all available (eight) lanes on a biochip or a combination of 
lanes which can be operator-defined in the accompanying software. 
1.2.4.Use the pins in the tubing to fix them in the biochip inlet. Place the other 
end of the tubing (without pin) in a 1.5mL conical test tube filled with HBS. Rinse 
all tubing and their connected lanes with 1mL HBS using the pump, so as to 
remove remainder blocking buffer and poorly adhering collagen.
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2. PREPARATION OF BLOOD SAMPLES
2.1 COLLECTION AND SEPARATION OF FRESH WHOLE BLOOD FROM A 
HEALTHY VOLUNTEER.17 
2.1.1 Collect the first milliliters of blood in an evacuated tube containing Ethyl-
enediaminetetraacetic acid (EDTA) as an anticoagulant and exclusively use this 
sample for complete blood count (CBC) with an automated hematology analyzer.
2.1.2 Collect a volume of blood in a suitable anticoagulant using evacuated 
tubes.  Standard anticoagulants for flow chamber experiments are heparin or 
hirudin when fibrin formation is not part of the study protocol and sodium citrate 
when it is.
 Note:  Heparin was used as an anticoagulant for all the experiments described in the results.
 Note:  The amount of blood depends on the number of experiments to be performed. Approxi-
mately 1 tube (7mL) for 3 lanes.
2.1.3 Place the tubes on a rotator pending blood reconstitution. 
 Note:  The assay should be completed within 3 hours of phlebotomy.
2.1.4 Centrifuge for 15 minutes at 250g to prepare platelet rich plasma (PRP). Do 
not use the centrifuge break to prevent disturbance of the loosely packed pellet. 
2.1.4.1 When more than one tube was collected, pool the blood in a single conical 
centrifugation tube.
 Note:  Centrifugation can be done more slowly or less long, depending on the PRP yield and 
differential cell “contamination” preferred.
2.1.5 Remove and discard the PRP and buffy coat yielding packed red blood cells 
with few platelets.
 Note:  The platelet count in the packed red cell fraction is 13±5x103 per µL (mean±SD, n=12) on 
average in our hands.
2.2. BLOOD RECONSTITUTION
2.2.1 Thaw blood group AB (Rhesus D negative) plasma at 37°C for 5 minutes and 
20 seconds per 4mL. 
2.2.2 Determine the hematocrit of the packed red blood cells prepared in 2.1.5 
using an automated hematology analyzer. 
2.2.3 Determine the platelet concentration in the blood bank prepared platelet 
concentrate that will be used to reconstitute the red cell fraction above. 
2.2.4 Calculate the volume of packed red blood cells and platelet concentrate 
that will yield 40% hematocrit and 250x10³ platelets/µL in a 1mL sample. 
 Note:  Other target titers of cells can be set arbitrarily, depending on the study protocol. 
2.2.5 Transfer packed red blood cells and plasma into a fresh tube using a 
clipped pipet tip and add platelet concentrate until a sample volume of 1mL is 
reached.
 Note:  Depending on the variables studied, the plasma fraction should be equal in all reconstitut-
ed samples because plasma has a significant influence on thrombus formation rate. For instance, 
repeated freeze-thawing or plasma taken from different donors or on different anticoagulants 
may influence the result. 
2.2.6 Mix the reconstituted blood gently by inverting and perform a CBC.
2.2.7 Prepare a “blank” control sample in which the volume of platelet fraction is 
replaced by the same volume of 0.9% (m/v) sodium chloride in water to deter-
mine the concentration of endogenous platelets (i.e. non-blood bank platelets) in 
the reconstituted blood using a CBC. 
2.3 LABELING 
2.3.1 Pipet 1mL reconstituted blood in a test tube containing 1µL 5mM Calcein 
AM (5µM final concentration).
 Note:  Other cell dyes can be used14.
2.3.2 Mix gently by inverting.
2.3.3 Incubate for 5min at 37°C prior to use.
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3. PERFUSION ASSAY
3.1 Focus the objective on the collagen fibers adhered at the bottom of the 
lanes. Ideally, use phase-contrast or differential interference contrast (DIC) set-
tings for this focusing strategy. Select ‘Set current Z for selected tile regions’ in 
the experiment software to digitally fix the selected Z-positions.
3.2 Select a region of interest (ROI) in the lane (xy) in the experiment soft-
ware of the microscope that will be recorded during the experiment.
Note: The ROI can be any surface area arbitrarily chosen within a perfusion lane. It is advisable 
not to analyze thrombus formation close to the in- and outlet of a lane so to avoid side effects 
of the variable flow profile in that region, even though this is relatively small. The ROI surface 
area should contain a significant number of platelets or thrombi to allow leveling of the signal. In 
this protocol the ROI is a digitally stitched aggregate of three equally sized side-by-side images 
resulting in 0.62mm2 in the middle of the 2cm long lane.
3.3 Mix the samples gently by inverting and position these next to the biochip 
on the automated stage.
3.4 Place the tubing that is connected with the inlet of the biochip in the test 
tubes containing the reconstituted blood samples.
3.5 Launch the pump at 50dyne/cm2 (or other shear stresses as desired) for 
those channels linked to test tubes containing the reconstituted blood samples 
using the software of the pump.
 Note:  Other shear stresses can be used.
3.6 Record images every 15 seconds for 5 minutes in real-time using the 
acquisition and experiment software of the microscope.
 Note:  Other time series can be used depending on the experimental set-up.
 Note:  We generally use a 100X magnification (10X objective and 10X lenses), but higher (or lower) 
magnification can easily be used as an alternative.
4. WASH OUT
4.1 Wash out all tubing attached to the outlet and connected to the multichannel 
manifold or pump using distilled water, followed by sodium hypochlorite (bleach) 
0.5% (v/v) and finally 0.1M NaOH in water. Discard the tubing pinned to the bio-
chip inlet as hazardous waste. 
5. DATA ANALYSIS
5.1 DETERMINE THROMBUS GROWTH KINETICS WITH THE IMAGE ANALYSIS 
SOFTWARE. THE FOLLOWING COMMANDS ARE SPECIFIC FOR ZEN2012.
5.1.1 Open the plugin Image Analysis to determine the surface coverage of the 
platelets.
5.1.2 Set the fluorescence threshold in the Analyze Interactive tab to define the 
pixel intensity that correlates with a positive signal, i.e. an adhered platelet or 
adhering platelets. 
5.1.3 Use Create Tables to automatically generate a spreadsheet that will contain 
the separate surface areas (in µm2) of those “objects” containing pixels with a 
signal between the selected thresholds. This is performed for each time point. 
 Note:  Once fluorescence thresholds have been chose, the analysis software automatically 
detects ‘objects’ in the view field that fulfill the criteria. These objects are thrombi, small platelet 
aggregates or single platelets and cover a number of pixels. Every object is listed in the spread-
sheet separately. 
5.1.4 Save these spreadsheets in xml format and open them in a spreadsheet 
program for further calculations.
5.1.5 Total the surface areas of the selected objects by summation and divide the 
result by the total area of the measurement field (µm2). This will yield the relative 
surface coverage (%). Do so for every time point. 
5.1.6 Plot these surface coverages in function of the perfusion time and calcu-
late the slope by linear regression, yielding the thrombus growth kinetic of that 
particular condition.
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RESULTS
To demonstrate intra-assay variation, three identical reconstituted whole blood samples were 
perfused simultaneously over collagen coated surfaces (figure 1). This resulted in a coefficient 
of variation of 8.7%. This statistic suggests acceptable intra-assay and intralaboratory variation 
permitting reliable comparison between related samples.
The inlet of the commercial flow chamber we describe here is perpendicular to the measurement 
chamber and this can cause slightly turbulent instead of laminar flow at that point. Especially in 
experiments without anticoagulation this may cause clogging because of the increased con-
tact time between the blood and the immobilized agonist. The clogged inlet can confound the 
readout downstream in the chamber. Therefore, the setup was optimized by partially coating the 
flow chamber (figure 2) leaving the inlets devoid of platelet agonist, thereby avoiding untimely 
activation of primary and secondary hemostasis. Partial coating of adhesive surfaces is moreover 
successfully used by other research groups in the field16. In addition, this straightforward practical 
trick is an asset to study the “transition” zone where blood flowing over the non-reactive (uncoa- 
Figure 1: Intra-assay variation in microfluidic flow chamber experiments. Microfluidic flow chamber ex-
periments were performed on immobilized collagen at 50dynes/cm². All three identical reconstituted whole 
blood samples were perfused in parallel and at the same time. The results are shown as range (whiskers) for 
surface coverage in function of perfusion time.
Figure 2: Partially coated channel. (A) Collagen fibers visualized by phase contrast microscopy were found 
only in the coated region. (B) A snapshot after 5 minutes of perfusion with a Calcein AM labeled reconstituted 
whole blood sample pumped at 50dynes/cm2 is shown. Both images were taken at a 100X magnification. 
ted) surface continues over the reactive (coated) portion. 
Transfusion was simulated by reconstituting blood with the deficient component. To this purpose, 
anticoagulated whole blood from a healthy donor was rendered thrombocytopenic by differential 
centrifugation and PC platelets were added to increase platelet counts. An important question 
here was what platelet count to aim for? In most cases, real-life transfusions do not result in 
normalization of platelet counts in the thrombocytopenic patient. Rather a value above a certain 
threshold is aimed for, although the exact target value is ill-defined18. To understand the influence 
of varying platelet counts on microfluidic flow chambers outcomes in the context of blood recon-
stitution, several reconstitutions were performed with decreasing platelet concentrations  
(figure 3). As expected, lower platelet counts resulted in less adhesion in function of perfusion 
time. Therefore, within a given study, platelet counts should be standardized to permit compari-
son between sample conditions19. The mere fact that there is fewer adhesion when platelet counts 
are low does however not imply that the assay cannot be used to measure platelet deposition in 
thrombocytopenic samples because microscopy and camera settings can be adapted to increase 
sensitivity. Finally, in most cases, the thrombocytopenic sample used for reconstitution contains 
remainder autologous platelets which resembles the situation in most transfusion demanding 
patients18. It is currently unclear if and what the role of autologous platelets is in the context of 
transfusion with allogeneic platelets but is an interesting question for future research. 
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Figure 3: Thrombus growth kinetics depend on platelet counts in reconstituted blood. (A) Blood was recon-
stituted using a blood bank platelet concentrate yielding different platelet concentrations: 245x10³/µL (●γ), 
42x10³/µL (γ n ) and 12x10³/µL (γ▲). Microfluidic flow chamber experiments with collagen coated channels 
were performed simultaneously for all three samples at a shear stress of 50dynes/cm². (B) The slopes calcu-
lated by linear regression of the raw data in panel A are depicted.
Following collection of blood from healthy voluntary donors, whole blood is often cooled to and 
kept at constant room temperature prior to component preparation. Platelets are however sen-
sitive to temperature changes. Figure 4 shows the effect of decreased temperatures after blood 
collection and during perfusion. Thrombi were found to build more slowly when the blood was 
cooled to room temperature (figure 4A) compared to an identical (paired) sample kept at 37°C 
throughout the study (figure 4B).
In circulation, platelets bind to vessel injury sites in conditions of elevated wall shear stress. Vary-
ing shear rates in microfluidic flow chambers coated with VWF/fibrinogen resulted in differences 
for total platelet adhesion at end point (figure 5A) and for thrombus growth kinetics (figure 5B). 
Figure 4: Temperature and microfluidic flow chambers. Whole blood collected in heparin vacutainers was 
preserved for 15 minutes in a water bath at room temperature (A) or at 37 °C (B). Microfluidic perfusion on 
immobilized collagen at a shear stress of 50dynes/cm2 was performed. Snap shots at end point (5 minutes 
perfusion) are depicted. 
Finally, to demonstrate how microfluidic flow chambers can be used to investigate PC used for 
transfusion, thrombus growth kinetics in function of PC storage was investigated. All variables 
in sample preparation and experimental set-up were standardized throughout the study period. 
Hence, the sole variable parameter was PC storage time. Figure 6 indicates decreasing thrombus 
growth in function of storage time demonstrating the effect of platelet storage lesion on hemo-
stasis in vitro.
DISCUSSION
Microfluidic flow chamber experiments are an excellent tool to investigate platelet function in 
flowing blood and are used to evaluate hemostasis in vitro in varying experimental contexts. 
Despite poor interlaboratory standardization9, we demonstrate that within our laboratory the 
experimental variation is acceptable. This allows to reliably compare (paired) samples within a 
given study. This was validated using the well documented phenomenon of platelet storage lesion, 
which is a detrimental consequence of platelet storage in blood bank conditions11. Furthermore, 
we recently published the impact of three available pathogen inactivation technologies on PC 
platelet function in microfluidic flow chambers following reconstitution of blood14,15. 
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Figure 5: Role of shear stress on platelet adhesion to immobilized VWF/fibrinogen. (A) Four identical, 
calcein AM labeled, reconstituted whole blood samples were perfused over a VWF/fibrinogen coated surface 
with variable shear stress: 4.5dynes/cm² (γ●), 50dynes/cm² ( nγ ), 90dynes/cm² (●γ) and 225dynes/cm² (♦). 
After 3 minutes of perfusion, a snap shot was taken of all four channels. (B) Surface coverages in function of 
time of the samples described in (A) are shown illustrating differences in thrombus growth kinetics.
Figure 6: Thrombus formation of platelet concentrates in function of storage time. All microfluidic flow 
chamber experiments were performed under standardized conditions on collagen coated surfaces at a 
shear rate of 50dynes/cm2. Blood was reconstituted with platelet samples of the same concentrate tested in 
duplicate on day three (●γ), seven ( n γ) and ten (γ▲) post donation. Surface coverages in function of perfusion 
time are depicted.
Platelets respond differently when biophysical and –chemical parameters are varied19. Therefore, 
shear stress, cell number and cellular composition, temperature, coating, anticoagulant and 
many more factors can be modified within this protocol depending on the research question. This 
protocol uses only commercially available hard- and software tools, allowing other laboratories to 
perform a similar assay. For basic research purposes this can be a disadvantage especially because 
the available hardware is less versatile than custom-made setups. The assay in itself is robust but 
reproducibility suffers from biological and temporal variation. Therefore, assay samples need to be 
paired as much as possible and study sizes should be sufficiently large. Samples also need to be 
paired in time, because reconstituted blood can only be stored for a short time. 
Although microfluidic flow chambers for platelet function studies have boosted the research field, 
caution should be taken to overinterpret the platelet dependence on blood rheology. First, the 
rectangular shape of the flow chamber is not physiologic, but the best we have to allow optical 
focusing on growing thrombi. Second, blood vessels are not made of plastic and the influence of 
blood vessel elasticity on platelet function can therefore not be studied in this protocol. Third, the 
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heart causes pulsatile flow, while syringe pumps are more linear (although also slightly pulsatile). 
Finally, fibrillar type I collagen is the standard material used for platelet studies under flow, which 
is of animal origin. Of note however, fibrillar type I collagen and clinical results for platelet function 
correlate well in many cases as shown by decades of experience in (light transmission) aggregom-
etry20,21. 
There are many assays to study platelet function22. Most of these address one or a couple of 
platelet features while putting platelets to work in (models of) hemostasis. Real time imaging of 
thrombus formation as demonstrated here is the most inclusive, to date. This means most aspects 
of the platelet’s response to vessel injury are included. Unique advantages are the inclusion of 
blood flow and the presence of all blood cells. The assay is sensitive to the currently used drugs for 
antiplatelet therapy23 as well as to genetic changes resulting in aberrant platelet function24. This 
demonstrates its value as a relevant indicator of platelet function. The comprehensive nature of 
this assay nonetheless also implies that it is less analytical than those assays measuring specific 
features of the platelet’s response. Effects of blood banking manipulations on platelet concen-
trates can therefore by picked up by flow chamber assays, but to interpret what causes them, addi-
tional analysis is required. For instance, our data indicate that temperature significantly influences 
platelet adhesion in microfluidic flow chambers. But additional detailed analysis has shown that 
refrigerated platelets change shape and cluster GPIbαα receptors25.
The versatility of the adhesive surface permits to study different reactive platelet substrates or 
combinations thereof. Recent work by De Witt et al16 demonstrated the relevance of substrate 
definition to platelet systems biology. Moreover, the combination of varying shear rates in func-
tion of the substrate is important because binding of platelets to immobilized VWF will require 
high shear rates, while this is less important for binding to collagen. Therefore, depending on the 
research question, choices can be made on what substrates and their respective flow rates are to 
be included. 
In conclusion, we present a protocol for microfluidic flow chamber experiments to study platelet 
function in the context of blood banking and transfusion medicine. Standardization efforts are 
ongoing9,10,26-28 and most of these recommendations are included in the protocol presented. The 
reconstitution of blood is a model for transfusion but additional validation work should indicate 
the relevance to clinical outcomes. 
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Figure S1: Microfluidic flow chamber hardware setup. (A) A Vena 8 Fluoro+ biochip is mounted on the auto-
mated stage of the microscope and is connected via flexible tubing to a syringe pump with manifold to split 
the pumping function into eight separate channels. (B) Reconstituted blood flows through the disposable 
tubing on the right side into the selected channels of the biochip (inlet). The disposable tubing is fixed in the 
inlet through a stainless steel disposable pin supplied with the setup. Blood flow in (B) is from right to left and 
is collected in long flexible tubings.
SUPPLEMENTARY FIGURE
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3. PATHOGEN INACTIVATION  
OF PLATELETS
3.1 RIBOFLAVIN AND AMOTOSALEN PHOTO-
CHEMICAL TREATMENTS OF PLATELET 
CONCENTRATES REDUCE THROMBUS  
FORMATION KINETICS IN VITRO
INTRODUCTION
Transfusion transmitted infections are a considerable threat to global blood supplies. 
Because the optimal conditions for safeguarding platelet integrity include storage at room 
temperature, platelet concentrates are in addition particularly vulnerable to bacterial con-
tamination. Photochemical treatment1 (PCT) efficiently tackles this problem by chemically 
damaging bacteria, viruses and protozoans. Three pathogen inactivation methods have been 
developed for platelet concentrates, one that uses exclusively ultraviolet (UV) C light2 and two 
employing an exogenously added photosensitizer with ultraviolet light illumination; ribofla-
vin (vitamin B2) pathogen reduction technology (RF-PRT, TerumoBCT, Lakewood, CO) uses 
broad spectrum UV light3 and amotosalen (S59) photochemical treatment (AS-PCT, Cerus 
Corp, Concord, CA) uses UVA4. 
Damage to nucleic acids is a major driver of pathogen kill following photoexcitation of many 
chemical sensitizers used for blood applications. Psoralens like amotosalen intercalate in 
helical regions of RNA and DNA and irreversibly form adducts and cross-links with pyrimi-
dines following photoexcitation. For RF-PRT, the pathogen reduction mechanism may be 
less confined to the sensitizer (dark) binding site5 but also includes nucleic acid damage6. 
Biostatic methodologies that specifically harm nucleic acids will evidently prevent targeted 
cells/viruses from replicating but this process by definition cannot be affected in cells with-
out the intrinsic potential to replicate at all, like platelets. Importantly though, this principally 
theoretical concept drives the notion that both PCTs are highly specific for damaging solely 
pathogens, which is not necessarily true. For instance, platelets do contain helical nucleic 
acid in the form of mitochondrial DNA and remnant RNA from their megakaryocytic precursor. 
Furthermore, all photosensitizers produce reactive oxygen species (ROS) and these are by no 
means specific in their chemistry with the surrounding milieu. Moreover, photosensitizers not 
only partition to nucleic acids7, but also to other biomolecules where reaction can occur.
For both PCTs the past decade has produced extensive in vitro data on platelet storage lesion 
(PSL) markers like pH and glycolytic metabolites, platelet receptor expression and/or hypo-
tonic shock response. However, less attention has gone to functional assays like platelet ag-
gregation8-11 or (even less) thrombus formation in microfluidic flow chambers under controlled 
conditions12. Notwithstanding this void, the latter is important since it is the most comprehen-
sive functional test with high sensitivity to perturbations in all steps of hemostasis13. 
A recent effort of the Biorheology subgroup of the Scientific and Standardization Committee 
of the International Society on Thrombosis Haemostasis has demonstrated the importance 
of comprehensive platelet function testing in systems with well known hydrodynamic shear 
profiles supplemented with real-time analysis of platelet deposition14. The technique is used 
for screening patients in (pre)clinical settings15 and has been proven valuable in drug devel-
opment as well, e.g. to assess platelet functional inhibition16,17. We have set up such an in vitro 
model of hemostasis with reconstituted blood perfused through microfluidic chambers com-
bined with real-time measurement of thrombus formation on immobilized collagen and von 
Willebrand factor (VWF). Our data show that in vitro thrombus formation kinetics are affected 
immediately following both RF-PRT and AS-PCT, but that their main causative biomolecular 
alterations are different. 
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MATERIALS AND METHODS
STUDY DESIGN
The two studies for RF-PRT and AS-PCT have been conducted separately, but with compa-
rable design. Within each study the samples were paired, but not between studies. For both 
RF-PRT and AS-PCT leukocyte-depleted platelet concentrates were prepared by pooling of 
five and six buffy coats, respectively. In all cases the buffy coats were derived from voluntary 
non-remunerated whole blood donations after giving written informed consent. 
For RF-PRT, three platelet concentrates in additive solution (SSP+, Macopharma, Tourcoing, 
FR) were pooled, gently mixed and then split in three equivalent products (n=6). One prod-
uct remained untreated (control), another was RF-PRT treated following a one hour resting 
period and the last one was treated with 25-50 Gray of gamma irradiation. In this particular 
study, gamma treated concentrates were included alongside untreated controls to include 
products that follow the current routine production. For RF-PRT, 35mL of riboflavin (RF) 
(500µM in saline) was added followed by expelling air bubbles and illumination with a dose 
of ultraviolet light (265nm-370nm) optimized by the provider for treating products in addi-
tive solution8. The RF-PRT concentrates were protected from ambient light and all concen-
trates were kept in the same type of storage container (TerumoBCT).
For AS-PCT, two platelet concentrates in additive solution (SSP+) were pooled, gently mixed 
and split in two equivalent products (n=6). One product remained untreated (control) and 
the other was treated with AS-PCT according to the guidelines of the manufacturer. In brief, 
the product was transferred to an illumination bag while 17.5mL amotosalen (final ~150µM) 
was added, followed by expelling excess air bubbles and UVA illumination (320-400nm). 
Following overnight incubation (<16 hours) with the compound adsorption device (CAD), it 
was transferred to a storage bag. Both concentrates were kept in the same type of storage 
container (Cerus Corp).
All concentrates were kept under standard blood bank conditions. Low volume samples 
were aseptically removed through sterile connections under a laminar flow hood to allow 
experiments before (day 1) and after (day 2, 5 and 7) treatment. The day of phlebotomy is 
considered day 0.
BLOOD RECONSTITUTION
An ABO-matched blood sample from healthy non-medicated volunteers was collected in 
heparin vacutainers (REF368480, BD Diagnostics, Franklin Lakes, NJ) with measures for 
preserving platelet quiescence18. The blood was centrifuged at 250g to prepare platelet rich 
plasma (PRP) and red blood cells (RBC). The PRP and buffy coat were transferred to a new 
tube and centrifuged at 4500g to yield platelet-poor plasma. The cell pellet was discarded. 
To obtain reconstituted blood, packed RBC and plasma from this fresh blood were mixed 
with platelets from the respective research conditions aiming at 40 percent hematocrit and 
250,000 platelets/µL. In the reconstituted blood a mean (±SD) platelet concentration of 
236±21 x103platelets/µL and a hematocrit of 40.4±1.1% was become for RF-PRT and 248±16 
x103platelets/µL and a hematocrit of 40.5±1.3% was become for AS-PCT (both n=6). 
PLATELET FUNCTION DURING BLOOD PERFUSION  
IN MICROFLUIDIC CONDITIONS
Perfusion experiments were performed using Vena8 Fluoro+TM biochips (Cellix Ltd, Dublin, 
Ireland). The microfluidic channels were incubated with 50µg/mL type I collagen (Takeda, 
Osaka, Japan) or 5IU/mL VWF (Wilfactin, CAF-DCF, Brussels, Belgium) at 4°C overnight 
and next blocked with 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer, pH 7.4 with 0.9% NaCl (HBS) containing 1.0% (w/v) bovine albumin and 0.1% (w/v) 
D-glucose at room temperature for 30 minutes. Blocking buffer and remainder collagen 
solution were rinsed with 1mL HBS buffer, pH 7.4 at 200dynes/cm2. The reconstituted blood 
in the RF-PRT study was labeled with 1µM 3,3’-dihexyloxacarbocyanine iodide (DiOC6) (Sig-
ma-Aldrich, Saint Louis, MO) for 10 minutes at 37°C. The reconstituted blood samples in the 
AS-PCT were labeled with calcein-AM (5µM final) (Life technologies, Carlsbad, CA) or where 
indicated with DiOC6 as mentioned above.
Paired samples (control vs treated) were perfused simultaneously and in duplicate using an 
automated microscope stage and a channel splitting manifold. Perfusion was performed at 
50dynes/cm2 (1,100s-1 flow rate) over collagen and at 135dynes/cm2 (3000s-1 flow rate) over 
VWF using a Mirus Evo microfluidic pump (Cellix). Where indicated 50ng/mL of tirofiban 
(aggrastat, Sigma-Aldrich) was added to block integrin α IIbβ α3 binding. Every 20 seconds, 
three side-by-side images were snapped in real-time in each lane during five minutes using 
an inverted fluorescent microscope at 100X magnification equipped with a Colibri-LED flu-
orescent light source (488nm) and high resolution CCD camera (all Carl Zeiss, Oberkochen, 
Germany). One single image per time point was generated by digitally stitching the three 
side-by-side images (ZEN2012 software (Carl Zeiss)). Surface coverage increased linearly in 
function of time for at least five minutes (Figure S1). Pixels were positive for platelet deposi-
tion using a fixed threshold of 400-4096 arbitrary fluorescence units. Slopes were deter-
mined by linear regression (Prism, GraphPad Software Inc, La Jolla, CA) and are a measure 
for the rate at which thrombi deposit on collagen. Blood reconstituted with RF-PRT platelets 
maximally contained 12.5µM RF which did not interfere with the readout (data not shown). 
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BLOOD GASES AND PLATELET COUNT
Glucose, lactic acid and pH were measured immediately after sampling by a point-of-care 
instrument (Siemens Rapidpoint 500, Munich, Germany). Whole blood counts and mean 
platelet volume (MPV) were determined using an automated hematology analyzer (pocH-
100iTM, Sysmex, Kobe, Japan).
FLOW CYTOMETRY
Expression of glycoprotein Ibα (anti-CD42b~fluorescein, Life technologies, Carlsbad, CA), 
activated integrin αIIbβ α3 (PAC-1~fluorescein, BD Biosciences, Erembodegem, Belgium), P- 
selectine (anti-CD62P~phycoerythrin, BD Biosciences) and Annexin V (Annexin V~Peridinin 
chlorophyll-Cy5.5; BD Biosciences) was determined using an acoustic focusing Attune flow 
cytometer (Life Technologies). Platelets were incubated with labeled antibodies or ligand 
for 10 minutes at room temperature in HBS, supplemented with 1mM MgSO4, pH 7.4 and di-
luted thousand fold immediately before readout as described in established methods19. For 
Annexin V measurements, buffers were supplemented with 2mM CaCl2. For measurements 
of integrin α IIbβ α3 activation on stimulated platelets, the PAR1 agonist thrombin related 
activating peptide SFLLRN (PAR1AP, Sigma-Aldrich) was added at 30µM. The signals of the 
isotype antibody controls were used to set threshold gates including 0.5% of 10,000 nega-
tive events. Mean or median fluorescence intensities and percentage positive events were 
determined of 10,000 cells staining positive for the platelet marker CD61 (anti-CD61~alloph-
ycocyanin, Life Technologies). 
AGGREGATION
Platelet aggregation was determined by light transmission in a dual-channel lumiag-
gregometer (Chrono-log, Helena Laboratories, Haverton, PA) using three different platelet 
agonists, each at two concentrations. A saturating concentration to boost aggregation and 
a threshold (i.e. halfmaximal or EC50) concentration to investigate platelet sensitivity. Both 
concentrations were determined in separate serial dilution experiments (data not shown) 
using the same assay conditions as below. For collagen (American Biochemical & Pharma-
ceuticals, Epsom, United Kingdom) 25µg/mL and 10µg/mL was used, PAR1AP at 10µM and 
6µM and ristocetin (American Biochemical & Pharmaceuticals) at 1.5mg/mL and 0.6mg/mL. 
Aggregation cuvettes contained platelets diluted to 250,000 platelets/µL with the corre-
sponding autologous platelet free plasma with additive solution. The latter was prepared by 
centrifugation at 4500g for 20 minutes to pellet the platelet fraction. The readout compris-
es maximal aggregation (amplitude (%)), rate (slope), and total aggregation potential (area 
under curve). In all cases maximal aggregation is shown, but the corresponding auxiliary 
parameters were comparable. 
VWF BINDING TO GLYCOCALICIN
Binding of VWF to GPIbα was determined with the VWF:RCo enzyme-linked immunosorbant 
assay (ELISA) as previously published20. In brief, the anti-GPIbα  monoclonal antibody 24B3 
is coated and following a blocking step, the binding sites are saturated with glycocalicin 
derived from a normal human plasma pool (n=38). Next, the suspending media of the platelet 
concentrates are incubated in the presence of 1mg/mL ristocetin to allow binding of VWF to 
the immobilized glycocalicin. After washing excess medium, bound VWF is detected by horse 
radish peroxidase labeled anti-VWF polyclonal antibody (Dako, Glostrup, Denmark).
STATISTICAL ANALYSIS
Comparison of mean values of the study arms in function of time was with repeated measures 
two-way ANOVA with Tukey’s or Sidak’s correction for multiple comparisons testing and a 
0.05 significance level. Analyses were performed with Prism software version 6.01 (GraphPad 
Software Inc).
RESULTS
PHOTOCHEMICAL TREATMENT DECREASES THE RATE OF THROMBUS FORMA-
TION IN MICROFLUIDIC FLOW CHAMBERS
The supplementary video files show that thrombus growth was faster from day two onwards 
for control conditions compaired to photochemical treated arms in both the RF-PRT and 
AS-PCT study. Figure 1 shows platelet deposition (surface coverage) in function of perfu-
sion time and confirms significant decreases for both inactivation methods. This result was 
independent of the fluorescent label used to visualize growing thrombi (Figure S2). Platelet 
concentrates treated with gamma irradiation in the context of the RF-PRT study were not 
significantly different from controls. We conclude that in reconstituted heterologous blood, 
in vitro hemostatic function of photochemically treated platelets is affected from the day 
after treatment with no signs of functional recovery during storage for both methods. 
RF-PRT AFFECTS PLATELET AGGREGATION 
An important step in hemostasis is interplatelet cross-linking which was measured by light trans-
mission aggregometry using different agonists. The thrombin-mimetic PAR1 activating peptide 
SFLLRN (PAR1AP) acts through the G protein-coupled receptor PAR1 while collagen activates 
platelets via GPVI-FcγRIIa and ristocetin modulates VWF to initiate agglutination through GPIbα . 
Figure 2 shows that RF-PRT affects platelet aggregation when compared to control and gamma 
irradiation at both agonist concentrations. However, the decrement is smaller at high (Figure 
2B, D and F) than at low-dose agonist concentrations (Figure 2A, C and E), which may indicate 
decreased amplification21. Gamma irradiation had no measurable effect compared to controls. 
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Figure 1: Photochemical treatment decreases the rate of thrombus formation, in vitro. Blood was recon-
stituted with platelets from control (closed bars), gamma (shaded bars) and photochemically treated (open 
bars) concentrates and perfused in microfluidic flow chambers at a shear stress of 50dyne/cm2. Data are 
shown for RF-PRT (A,C and E) and AS-PCT (B,D and F) studies. Real-time video microscopy measured 
surface coverage in function of time (%SC/Time). Results are shown for days 2 (A-B), 5 (C-D) and 7 (E-F) post 
phlebotomy as indicated. The statistical results of two-way ANOVA is shown on top of the panels (ns=not 
significant;**P<.01;***P<.001;****P<.0001).
Figure 2: RF-PRT affects platelet aggregation. Light transmission aggregometry was performed with three 
agonists, each in a low (A,C and E) and high (B,D and F) concentration. Maximal aggregation is depicted 
as means with standard deviation (n=6). Control ( � ), gamma (▲ γ) and RF-PRT (●) platelets were analyzed 
before (day 1) and after (day 2, 5 and 7) treatment. The statistical results of two-way ANOVA is shown on top 
of the panels (ns=not significant;*P<.05;***P<.001;****P<.0001). 
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AS-PCT SPECIFICALLY TARGETS RISTOCETIN INDUCED AGGLUTINATION
Differences in aggregometry between untreated control and AS-PCT treated platelets  
(Figure 3) were noticeably smaller or non appearant compared to results for RF-PRT  
(Figure 2). Of note, platelet storage profoundly decreased the aggregation response of 
both untreated control and AS-PCT platelets unlike the RF-PRT study. This may be caused 
by differences in storage container or in the number of composing buffy coats between 
AS-PCT and RF-PRT studies. Anyway, this phenomenon reduced the dynamic range of the 
assay thereby masking potential differences in aggregometry between AS-PCT and control 
platelets after storage. Nonetheless, AS-PCT induced decreased aggregation in response 
to collagen on day two (Figure 3A and B) and aggregation responses to PAR1AP were not 
different throughout the study period (Figure 3C and D). However, complete abolition of 
ristocetin induced agglutination was found but only at low-dose agonist concentrations 
(Figure 3E). High concentrations of ristocetin elicited normal agglutination of AS-PCT, 
together indicating altered affinity or avidity of the interacting biomolecules (Figure 3F). 
RF-PRT AND AS-PCT AFFECT INTEGRIN αIIBβ3 ACTIVATION IN A DIFFERENT WAY
The monoclonal antibody PAC1 binds to the activated conformation of the fibrinogen 
receptor integrin α IIbβ α3 and is a surrogate marker for platelet activation which can be meas-
ured in flow cytometry. RF-PRT induced spontaneous and irreversible activation of this 
integrin (Figure 4A) which may be caused by the UVB spectrum during illumination22. In a 
subsequent experiment, PAR1AP was added prior to PAC1 flow cytometry to investigate the 
platelet activation response. RF-PRT platelets did not react very different than untreated 
or gamma treated platelets on day two, but were less sensitive to this stimulation following 
storage (Figure 4C). AS-PCT platelets reacted differently because no spontaneous integrin 
α IIbβ α3 activation (Figure 4B) could be observed in ‘resting’ platelets while PAR1AP induced 
platelet activation was significantly and irreversibly affected on day two (Figure 4D).  
No differences for gamma irradiated platelets were noted.
Figure 3: AS-PCT affects low-dose ristocetin agglutination. Light transmission aggregometry was 
performed with three agonists, each in a low (A,C and E) and high (B,D and F) concentration. Maximal aggre-
gation is shown as means with standard deviation (n=6). Control ( � ) and AS-PCT (◆) platelets were analyzed 
before (day 1) and after (day 2, 5 and 7) treatment. The statistical results of two-way ANOVA is shown on top 
of the panels (ns=not significant;*P<.05;**P<.01;****P<.0001).
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Figure 4: RF-PRT spontaneously activates integrin α IIbβα3 while AS-PCT inhibits agonist stimulated integrin 
αIIbβα3 activation. PAC1 binding is specific for the activated integrin γIIbγ3 and was measured by flow cytometry 
without agonist (resting conditions; A,B) or following activation (30µM PAR1AP; C,D). The median fluores-
cence intensity (MFI) is shown for control ( � ), gamma (γ▲), RF-PRT ( ● ) and AS-PCT (◆) conditions.  
The statistical results of two-way ANOVA is shown on top of the panels (ns=not significant;*P<.05;**P 
<.01;****P<.0001)
RF-PRT MAINLY ACCELERATES PLATELET STORAGE LESION
Next, markers of the storage lesion were measured in flow cytometry with slight but signifi-
cant decreases in GPIbαα expression (Figure 5A and B) for both AS-PCT and RF-PRT follow-
ing storage. The fraction of platelets that had degranulated in response to RF-PRT signifi-
cantly increased (Figure 5C) from day two onwards until the end of the study as measured 
by expression of the α-granule marker P-selectin. Storage of RF-PRT platelets moreover 
increased the PSL apoptosis marker for phosphatidylserine/-ethanolamine exposure, an-
nexin V (Figure 5E). Furthermore, there was an increased rate of lactic acid production and 
glucose consumption in RF-PRT platelets (Figure S3). This caused a decreasing trend in pH 
(Figure S4) which nonetheless remained above 6.4 in all RF-PRT units at the end of storage. 
P-selectin also increased over controls during storage of AS-PCT treated platelets (Figure 
5D), but the difference with controls was much smaller than for RF-PRT. Furthermore, there 
was no marked annexin V binding (Figure 5F) nor anaerobic glycolytic increase (Figure 
S3-S4). 
AS-PCT MAINLY AFFECTS PLATELET ACTIVATION
Because low-dose ristocetin agglutination was defective in AS-PCT (Figure 3E), flow cham-
ber experiments were performed onto immobilized VWF and total platelet deposition was 
measured at two minutes perfusion (Figure 6 and supplementary video file). Like on colla-
gen, AS-PCT platelets formed fewer thrombi on VWF under these conditions of high shear 
stress (Figure 6A). To discriminate between GPIbα binding to VWF and integrin αIIbβ α3 inter-
actions with fibrinogen and VWF, the experiment was repeated in the presence of 50ng/mL 
tirofiban, a potent integrin α IIbβ α3 inhibitor. In this case, platelets do not form thrombi on the 
matrix but instead individually bind. In the presence of tirofiban, no difference between AS-
PCT and untreated platelet binding was seen (Figure 6B) indicating no relevant defect in 
the GPIb-VWF interaction. Endogenous VWF molecules present in the platelet concentrate 
were not affected by AS-PCT treatment as shown by ristocetin induced binding to immobi-
lized exogenous glycocalicin (Figure 6C). Additionally, activation with the strong platelet 
activator convulxin via the GPVI-FcγRIIa pathway also resulted in a significant reduction 
in integrin α IIbβ α3 activation (Figure 6D). Together with the PAR1AP activation data, these 
findings collectively indicate that activatory signals via PAR1, GPIb/IX/V complex and GP-
VI-FcγRIIa are not fully translated to integrin α IIbβ α3 in the case of AS-PCT platelets.
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Figure 5: RF-PRT increases the rate of storage lesion. (A,B) The expression level by mean fluorescence in-
tensity (MFI) of GPIbαγ measured by flow cytometry. (C-F) The percentage of platelets expressing P-selectin 
and negatively charged phospholipids. In all cases 10,000 platelets were counted for control ( � ), gamma  
(▲ γ), RF-PRT (●) and AS-PCT (◆) conditions before (day 1) and after treatment (day 2, 5 and 7). The statisti-
cal results of two-way ANOVA is shown on top of the panels (ns=not significant; *P<.05; **P<.01; ***P<.001; 
****P<.0001).
PHOTOSENSITIZATION IS SUFFICIENT TO DECREASE  
ACTIVATION RESPONSES TO TRAP
In order to find out what manipulation of the three main AS-PCT processing steps has the 
largest impact on platelet integrin α IIbβ α3 activation, the individual steps or their combi-
nations were analyzed using PAC1 binding following PAR1 stimulation. This experiment 
showed that there was a minor effect of illumination, amotosalen addition or CAD incu-
bation each by itself (Figure S5A). Combinations of two procedural manipulations on the 
contrary showed that mere photochemistry (without CAD incubation) had a similar impact 
as the complete AS-PCT procedure indicating a negligible role of additional CAD incuba-
tion. From this follows that CAD incubation is not necessary to study the damage caused by 
AS-PCT. Indeed, aggregation responses immediately after photosensitization (without CAD 
incubation) to both collagen and PAR1AP were much more affected than on day two (with 
CAD) (Figure S5B-E), indicating some recovery. It is currently not clear whether the CAD 
contributes to this recovery or whether mere overnight storage suffices. 
DISCUSSION
The blood storage lesion is the progressive loss of function during storage of live cells 
isolated from circulation. It is a combination of natural cellular senescence and accumulat-
ing artifacts instigated by the procedural steps required for proper isolation and storage. 
Photochemical treatment of platelet concentrates increases manipulation and procedural 
steps that attract attention because of conflicting reports11,12,23,24 on their contribution to PSL 
as well as decreased transfusion count increments25. 
Our work on RF-PRT is in line with Zeddies et al23 who showed fewer platelet spreading on 
immobilized collagen following RF-PRT. However, other experiments with RF-PRT platelets 
recirculating over rabbit aorta26 or in a viscometer27 do not corroborate. Different technical 
approaches probably underlie this, the latter methods continuously recirculate the cell 
suspension, allowing multiple passages over the activated surface making it more depend-
ent on secondary released paracrine amplificatory mediators while a single unidirectional 
perfusion is performed in our setup. Furthermore, following recirculation, the cited methods 
rinse the deposited thrombi with buffer or tap water, chemically fix/stain the sample and 
then perform a single readout, while our method continuously measures platelet depo-
sition in real-time. Terada et al24 used an affinity chromatography model to demonstrate 
that RF-PRT platelets are retained twice as well as untreated platelets on collagen coated 
beads. This model is difficult to compare to because it is independent of platelet aggrega-
tion, secretion and integrin interactions with RGD-containing motifs28 unlike hemostasis in 
vivo29 and in flow chambers30. Importantly, the above mentioned studies all used apheresis 
derived platelets and illuminated in autologous plasma which may also contribute to the 
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Figure 6: AS-PCT decreases platelet activatability. Platelet adhesion to immobilized VWF under hydro-
dynamic conditions is shown. (A) Adhesion of AS-PCT treated platelet was significantly less than paired 
untreated controls as shown by representative images (left) taken at two minutes perfusion and by the per-
centage of platelets covering the surface (right) (n=6,**P<.01). (B) Decreased AS-PCT platelet adhesion was 
caused by decreased integrin αIIbβγ3 ligand engagement, because the defect was rescued in the presence of 
the integrin inhibitor tirofiban (50ng/mL). (n=3, not significant). (C) The VWF molecules present in the plate-
let concentrate bound normally to glycocalicin. (n=10, not significant). (D) Integrin αIIbβγ3 is less activated by 
30ng/mL convulxin following treatment with AS-PCT on day two. (n=3, *P<.05). All comparisons of means 
were with paired t-tests. 
observed differences because plasma proteins may act as scavengers of oxygen radicals5. 
There are few studies using hydrodynamic shear flow with AS-PCT platelets. Hechler et 
al used a comparable experimental setup to ours measuring accumulation of platelets in 
real-time but found no major differences between controls and AS-PCT treated platelets. 
The major difference here was that the platelets were washed with buffer prior to analysis12. 
These authors speculate that washing reshapes platelets as would happen upon transfu-
sion. They contemplate that conditioned storage media inhibit platelet function, however 
in paired samples like ours it seems unlikely that AS-PCT media would inhibit more than 
control given the relatively low volumes added to fresh blood in our reconstitution experi-
ment and the reported integrity of the remaining plasma fraction31. 
The observed decreased response of RF-PRT platelets to agonists in aggregation and flow 
chambers may be explained by untimely platelet activation. There are several experimental 
arguments that support this notion; first, RF-PRT caused premature integrin α IIbβ α3 activa-
tion. This has been described by other groups 22,24 and was not seen in paired untreated nor 
gamma treated controls. Integrin α IIbβ α3 activation may also be responsible for the sponta-
neous aggregation observed previously23. Second, (premature) platelet activation causes 
degranulation demonstrated by increased P-selectin8,32. This receptor normally resides in 
α-granules which are indispensible for normal hemostasis because their deficiency causes 
the gray platelet syndrome bleeding disorder33. Furthermore, dense granules precede secre-
tion of α -granules34 so this cargo of amplificatory molecules (including ADP) may also be no 
longer fully available to feed amplification. Third, the gradual increase in annexin V binding 
indicates phosphatidylserine/-ethanolamine exposure, which is a marker of apoptosis as 
well as platelet activation35. Fourth, there was a clear increase in anaerobic glycolysis fol-
lowing RF-PRT32,36. Lactic acid buildup in RF-PRT concentrates has been studied previous-
ly37 to demonstrate that damage to mitochondria underlies the shift to anaerobic glycolysis. 
However, no immediate effect on the mitochondrial membrane potential could be detect-
ed. Therefore, an attractive alternative explanation is increased platelet activation and 
(subsequent) secretion of granules. These processes increase energy demands38, and in the 
specific case of ‘low-dose’ stimulation primarily anaerobic glycolysis39. Whether premature 
platelet activation indeed underlies the metabolic change in RF-PRT treated platelets will 
however require further research. Taken together, these observations suggest that RF-PRT 
‘primes’ platelets so that the seminal resources that are required for full platelet activation/
participation in hemostasis are partially dissipated and no longer entirely available to ac-
complish normal thrombus formation or aggregation, in vitro. This hypothesis moreover fits 
with the observation that in the specific context where granule secretion and inter-platelet 
aggregation are not required, RF-PRT platelets bind better to collagen24. 
Unlike the changes found in platelets treated with RF-PRT, the ones caused by AS-PCT do 
not involve premature platelet activation. Indeed, platelet anaerobic glycolysis following 
AS-PCT was either small or unexisting as shown by others4,10,11,40. Moreover, premature acti-
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vation should increase the exposure of negatively charged phospholipids which was not ob-
served here nor elsewhere10. Furthermore, PAC1 bound similarly to resting AS-PCT platelets 
as to untreated controls. Finally, increased P-selectin expression rates4,10,11 do not support 
premature activation since differences with untreated platelets were not significant shortly 
following treatment. 
Nonetheless, our experiments still indicate that thrombus formation on both collagen 
and VWF were significantly and irreversibly affected by AS-PCT. Because VWF adhesion 
precedes collagen binding21, the reduced thrombus formation onto VWF in flow chambers 
contributes to the decreases seen on collagen. From our flow cytometry data and the flow 
chamber experiment with tirofiban it is however clear that not GPIbαα receptor abundance 
nor its interaction with VWF underlies this, but rather defective subsequent interactions 
of integrin α IIbβ α3 posterior to GPIbα engagement. From this it seems that signal transduc-
tion from GPIb/IX/V to the fibrinogen receptor are decreased. Indeed, our data show that 
AS-PCT platelets respond less to agonist stimulation, in vitro. For instance, integrin αIIbβ α3 
activation was decreased by stimulation with convulxin and PAR1AP as reported11,41. Despite 
this observation in flow cytometry, differences in aggregation in response to both collagen 
and PAR1AP were small or absent. We speculate that amplification signals21 from secondary 
messengers including ADP and thromboxane A2, but also outside-in signals from (limit-
ed) integrin α IIbβ α3-fibrinogen engegament, are more prominent in bulk experiments like 
aggregation or recirculating flow, in part compensating for the initial weak response to the 
agonist. This may also explain why double agonist stimulation with thrombin and convulx-
in shows normal integrin αIIbβ α3 activation of AS-PCT platelets
12. Secondary activators and 
fibrinogen are much more diluted in flow cytometry experiments which may explain the 
apparent ambiguity between both readouts. Consequently, despite decreased integrin 
activation, the amplification machinery required for normal in vitro aggregation is least af-
fected by AS-PCT. Nevertheless, three other studies with comparable design have included 
aggregation experiments10,40,41 and significant decreases by AS-PCT. Taken together, we 
speculate that decreases in signal transduction from PAR1, GPVI-FcγRIIa and/or GPIb/IX/V 
underlie the reduced platelet deposition in microfluidic flow chambers on collagen. 
Our AS-PCT data furthermore demonstrate that the photochemistry as such, without CAD 
incubation, is responsible for the decline in activatability. Because the photochemistry by 
itself had the same impact as full AS-PCT treatment, platelet aggregation immediately 
following photosensitization could be investigated showing that the responses to col-
lagen, but now also PAR1AP were significantly decreased. This raises the question what 
biochemical mechanism(s) is/are affected as a consequence of photochemistry alone and 
what parameters contribute to the (partial) reversibility of aggregation, given that the most 
comprehensive platelet functional assay (flow chambers) did not indicate any functional 
recovery during storage.
Finally, it is challenging and beyond this in vitro work to speculate on clinical consequences 
based on our findings. The multifactorial context of the typically severely ill recipients of 
platelet transfusion adds to this. In a search for analogous platelet behavior in flow cham-
bers, research into (cardio)vascular disease has found similar reduced thrombus formation 
following treatment with commonly prescribed oral antiplatelet agents16,17. These com-
pounds do affect platelet function, but do not overtly tilt the hemostatic balance towards 
bleeding. Pathogen inactivation methods have been the subject of a number of clinical 
trials recently summarized in a meta-analytical review concluding that additional studies 
are required to provide sufficient evidence of non-inferiority to classical products42. A num-
ber of trials have been completed for AS-PCT and additional ones are on the way for RF-PRT 
including the PREPAReS (Dutch trial registration NTR2106) and IPTAS (United States NIH 
trial registration NCT01642563) trials. Currently, these have enrolled around half of patients 
and no major issues have been identified by the data safety monitoring board (personal 
communication Terumo BCT). 
In conclusion, microfluidic flow chamber experiments show that both photochemical inac-
tivation methods with riboflavin and amotosalen induce a decrease in thrombus formation 
rate in vitro but by different biochemical mechanisms. RF-PRT causes premature platelet 
activation with subsequent loss of amplificatory potential while AS-PCT platelets are less 
responsive to several agonists. Deeper research into the origins of certain cellular defects 
inherently caused by pathogen inactivation and the correlation to clinical outcomes could 
help to develop and refine methods so as to prevent or attenuate damage whilst retaining 
pathogen killing potential.
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Figure S1: Platelet deposition in function of time as measured by surface coverage (%) in a single repre-
sentative microfluidic flow experiment. Platelet deposition in microfluidic flow chamber experiments is 
determined by real-time video microscopy and subsequent image analysis of the platelet surface coverage 
(%) in function of time. This relationship is linear for at least five minutes and regression analysis allows for 
determination of the slope to deduce kinetics of hemostasis. Conditions in this case were untreated control 
(�), gamma treated (▲γ) and photochemically RF-PRT treated platelets (●). 
Figure S2: Thrombus formation differences on immobilized collagen are independent of the fluorescent 
label used. Analogous to the data in Figure 1 biologically paired reconstituted blood samples, containing 
either control (closed bar) or AS-PCT (open bar) platelets were perfused at 50dynes/cm² over immobilized 
collagen on day two. Thrombus formation kinetics were determined from the linear relationship of surface 
coverage (%SC) in function of perfusion time by regression analysis (Figure S1). In this case however, the 
cell suspension was labeled with DiOC6 instead of calcein that was used to generate the data for AS-PCT in 
Figure 1. Data are depicted as mean with standard deviation as whiskers (n=3). 
SUPPLEMENTARY FIGURES
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Figure S3: Glucose consumption and lactic acid production rates are significantly increased by RF-PRT 
but not AS-PCT. (A and B) Glucose consumption and (C and D) lactic acid production in function of storage 
time (in hours) is depicted for untreated control (�), gamma treated (▲), RF-PRT (●γ) and AS-PCT (◆γ) treated 
concentrates. (E and F) The glucose consumption (filled bars) and lactic acid production rates (open bars) 
are derived from the data in A and B by linear regression analysis. Data are shown as means with standard 
deviation (n=6). 
Figure S4: The pH of RF-PRT platelet concentrates gradually declines. The pH at ambient temperature 
of control (�), gamma treated (▲γ), RF-PRT treated (●) and AS-PCT treated (◆) platelet concentrates (n=6) 
was determined in function of storage time. The means were statistically analyzed by two-way ANOVA and 
Tukey’s or Sidak’s multiple comparisons algorithm and the results are shown on top of each panel (ns = not 
significant; ****P<.0001). 
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Figure S5: Photochemistry on itself has the largest impact on platelet activation. (A) Integrin αIIbβγ3  ac-
tivation to 30µM PAR1AP was measured by labeled PAC1 binding in flow cytometry. Platelet concentrates 
were treated with all possible combinations of the three principal AS-PCT steps (addition of photosensitizer 
(AS), illumination (UV) and adsorption (CAD)). Negative controls (closed bar) were not treated and positive 
controls (open bars) were treated according to the standard AS-PCT protocol. The other conditions (shaded 
bars) were either treated by UV, AS and CAD alone or by a combination of UV+CAD, AS+CAD and AS+UV. The 
median fluorescent PAC1 signal (MFI) of a minimum of two (AS, UV, AS+CAD, UV+CAD) or three (both control 
conditions, CAD and AS+UV) repeat experiments is shown. (B-E) Aggregation by light transmission was 
performed with collagen (B and C) and PAR1AP (D and E) each in a threshold (B and D) and high (C and E) 
concentration (n=4). The maximal amplitude is depicted relative to the result of untreated control platelets 
on day one. Data of paired samples were collected immediately following photosensitization without incu-
bation on CAD on day 1 (D1) and following overnight (16h) incubation on CAD (D2). Two-way ANOVA with 
SIDAK’s multiple comparisons test was used to detect significant differences (*P<.05; **P<.01; ***P<.001). All 
data are shown as mean values with standard deviations
SUPPLEMENTARY VIDEOS
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3.2 ULTRAVIOLET C LIGHT PATHOGEN  
INACTIVATION TREATMENT OF PLATELET 
CONCENTRATES PRESERVES INTEGRIN 
ACTIVATION BUT AFFECTS THROMBUS FOR-
MATION KINETICS ON COLLAGEN IN VITRO
INTRODUCTION
The increased risk for bacterial growth caused by room temperature storage of platelet con-
centrates and for (emerging) transfusion transmissible diseases including virus strains with 
long window periods are genuine reasons for introducing broad spectrum pathogen inacti-
vation1. There are currently three different standardized methods to inactivate pathogens 
in platelet concentrates. Two marketed systems use ultraviolet (UV) light combined with an 
exogenously added photoactive reagent, either the psoralen derivative amotosalen with 320-
400nm UV-A light2 (AS-PCT) called the Intercept Blood System (Cerus Corporation, Concord, 
CA) or riboflavin with 265-370nm broad spectrum UV-light3 (RF-PRT) called Mirasol Patho-
gen Reduction Technology System (TerumoBCT, Lakewood, CO). More recently, a third inac-
tivation method has been developed that uses the microbiocidal and virucidal characteristics 
inherent to short wavelength (254nm) UV-C light4 without exogenously added photosensitiz-
er (UV-C) called THERAFLEX UV-Platelets (Macopharma, Tourcoing, France). This particular 
technology mitigates concerns about toxicological effects of added photochemicals and/or 
photoproducts generated during illumination. 
The biochemical mechanism involved in UV-C treatment has not been demonstrated as such 
but is claimed5 to be similar to the general chemistry6 underlying UV-C induced damage of 
nucleic acids. If true, then photochemical formation of cyclobutane pyrimidine dimers, py-
rimidine 6-4 pyrimidone dimers as well as abasic sites, strand breaks and oxidative products 
prevent elongation of nucleic acid transcripts7 if not repaired by cellular machinery. A major 
practical hurdle is to obtain sufficient penetrance of the incident light because proteins as 
well as particles (including platelets) will respectively absorb and scatter incoming photons 
thereby dissipating the energy required for inactivation. Therefore conditions have been 
optimized to assure efficient delivery of UV-C light including reducing the plasma content to 
30-40% with additive solution, exposing both sides of the bag to the light sources, increasing 
the surface area, and agitating vigorously during illumination5,8,9. This way, in vitro pathogen 
inactivation of several transfusion transmitted pathogens has been demonstrated8,9.
Functional and biochemical studies of UV-C pathogen inactivated platelets showed an ac-
celeration of the storage lesion with decreased pH and hypotonic shock response, increased 
glucose consumption and lactic acid production. In addition, increased values for degranula-
tion (P-selectin expression), phosphatidylserine expression (annexin V binding) and integrin 
αIIbβ α3 activation (PAC1 binding) indicate moderate activation of platelets following UV-C 
treatment8-12. There is a low impact on the platelet proteome9 and neoantigen formation could 
not be detected in a dog model13. Furthermore, the results of a phase I study with autologous 
transfusions in healthy volunteers met the primary safety and tolerance criteria14 and Bashir 
et al demonstrated platelet recovery and survival rates within acceptance criteria following 
autologous transfusions in healthy volunteers12. 
There are few studies that investigate the influence of pathogen inactivation on integrated 
platelet function, for example in aggregometry or microcapillary flow chambers. The latter is 
a comprehensive functional in vitro test with high sensitivity to perturbations in all steps of 
hemostasis; adhesion, activation and aggregation15. Furthermore, in vivo studies of thrombus 
formation in mice have demonstrated that many of the regulatory processes determining 
arterial thrombosis can well be assessed with these in vitro flow experiments16. 
In the current study we have compared UV-C treated and untreated paired platelet concen-
trates using quality markers like pH, metabolic rate and receptor expression as well as the 
more comprehensive platelet function assays of light transmission aggregation and microflu-
idic flow chamber experiments. 
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MATERIALS AND METHODS
STUDY DESIGN
Whole blood donations from voluntary non-remunerated donors fulfilling Belgian eligibility 
criteria were used to prepare leukocyte depleted platelet concentrates from five buffy coats 
with a plasma content of approximately 35% and the remainder platelet additive solution (SSP+, 
Macopharma) following standard operating procedures of the blood service of the Belgian Red 
Cross Flanders. Three blood group matched platelet concentrates were pooled and split again 
to deliver three equivalent platelet concentrates of which one was left untreated to serve as 
control, one was treated with 25-50 Gray gamma irradiation and one was UV-C treated. 
UV-C treatment was according to the THERAFLEX UV-platelets standard operation proto-
col only with products fulfilling the inclusion criteria as set by the provider. In brief, the bag 
content was transferred to an UV-C-permeable ethyl vinyl acetate illumination container 
which was placed in the Macotronic UV illuminator (Macopharma). A total dose of 0.2J/cm2 
of 254nm UV light was delivered under continual agitation in a timespan not exceeding one 
minute. Next, the treated platelet concentrate was transferred to the n-butyryl tri n-hexyl 
citrate plasticised polyvinyl chloride storage bag included in the THERAFLEX UV-C bag 
combination. The paired control and gamma irradiated products were stored in the same bag 
type to ascertain similar storage conditions for all study arms. All products were kept under 
standard blood bank conditions at 20-24°C on a flatbed agitator. The experiments described 
below were performed on small volumes taken aseptically from the concentrates before (day 
1) and after (day 2, 5 and 7) treatment. The design included a total of six independent repeat 
experiments (n=6) unless where indicated differently.
BLOOD GASES AND PLATELET COUNT
Lactic acid, glucose and pH were determined immediately after sampling using a point-of-
care blood gas analyzer (Siemens Rapidpoint 500, Munich, Germany). Whole blood counts 
were performed with an automated hematology analyzer (PocH-100i, Sysmex, Kobe, Japan). 
BLOOD RECONSTITUTION
Whole blood was taken from healthy non-medicated donors in heparin vacutainers (REF 
368480, BD Diagnostics, Franklin Lakes, NJ) taking measures for preserving platelet quies-
cence17. A first soft centrifugation (12 minutes at 250g) divided the whole blood samples in 
platelet rich plasma (PRP) and concentrated red blood cells. Platelets of the PRP were then 
spun down by hard centrifugation (20 minutes at 4500g) to yield platelet poor plasma (PPP). 
Reconstitution was by mixing appropriate volumes of these packed red blood cells, PPP and 
either of the three subject platelet concentrates (control, gamma or UV-C) achieving 40 per-
cent hematocrit and 250,000 platelets/µL on average.
MICROFLUIDIC FLOW CHAMBER EXPERIMENTS
Reconstituted blood samples were perfused through microfluidic channels of dimensions 
400µmx100µmx28mm (Vena8 Fluoro+ Biochips) at a shear stress of 50dynes/cm2 (flow rate 
of 1,100s-1) using a Mirus Evo microfluidic pump (All Cellix Ltd, Dublin, Ireland). The channels 
were coated overnight at 4°C with 50µg/mL Horm collagen type I (Takeda, Osaka, Japan). 
Next, the channels were blocked with 1.0% (w/v) bovine serum albumin and 0.1% (w/v) glucose 
in 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline (HBS; 
0.9% (w/v) NaCl, pH 7.4) at room temperature for 30 minutes. The channels were then rinsed 
with 1mL plain HBS to remove remainder blocking buffer and unbound collagen. Platelets in 
the reconstituted blood samples were labeled with 1µM (final) of the fluorescent dyes 3,3’-di-
hexyloxacarbocyanine iodide (DiOC6) (Sigma-Aldrich, Saint Louis, MO) or 5µM calcein-AM 
(Life technologies, Carlsbad, CA) where indicated. 
Samples were perfused in duplicate at the same time using a channel splitting manifold and 
an automated x-y stage allowing up to eight simultaneous runs in one experiments. The 
biochip is mounted on a Z.1 Observer fluorescent microscope equipped with a Colibri-LED 
fluorescent light source (488nm) and high resolution CCD camera (all Carl Zeiss, Oberkochen, 
Germany). A simultaneous recording of three side-by-side images per microcapillary channel 
was performed in real-time during five minutes at 100X magnification. The three side-by-side 
images were digitally stitched to deliver one single compound image per time point. A fixed 
threshold of 400-4096 arbitrary fluorescence units was used to define platelet adherence 
allowing to determine the percentage of pixels covered by platelets in the measurement field 
(i.e. surface coverage) in function of time (ZEN2012 software, Carl Zeiss). The slopes of these 
relationships were determined by linear regression (Prism, GraphPad Software Inc, La Jolla, 
CA) and are a measure for thrombi growth kinetics.
FLOW CYTOMETRY
Expression of glycoprotein Ibα (fluorescein labeled anti-CD42b, Life technologies), activated 
integrin α IIbβ α3 (fluorescein labeled PAC1, BD Biosciences, Erembodegem, Belgium), P-selec-
tin (phycoerythrin anti-CD62P, BD Biosciences) and Annexin V (Peridinin chlorophyll-Cy5.5 
labeled Annexin V, BD Biosciences) of either platelet concentrate was analyzed with an 
acoustic focusing Attune flow cytometer (Life Technologies). Platelets were incubated with 
labeled antibodies or ligand for 10 minutes at room temperature in HBS, supplemented with 
1mM MgSO4 and diluted thousand fold immediately before readout according to previous 
published work18. For Annexin V measurements, buffers were supplemented with 2mM CaCl2. 
For measurements of integrin α IIbβ α3 activation on stimulated platelets, the PAR-1 agonist 
thrombin related activating hexapeptide SFLLRN (PAR1AP; Sigma-Aldrich) at 30µM or the 
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GPVI-FcγRIIa agonist convulxin (Santa Cruz Biotechnology Inc, Dallas, TX) at 6ng/mL were 
used. The signals of the respective isotype antibody controls were used to set threshold 
gates including 0.5% of 10,000 negative events. Mean or median fluorescence intensities and 
percentage positive events were determined for 10,000 cells staining positive for the platelet 
marker CD61 (allophycocyanin labeled anti-CD61, Life Technologies).
PLATELET AGGREGATION
Platelet aggregation was with a light transmission aggregometer (Chrono-Log, Helena Lab-
oratories, Haverton, PA). Three different platelet agonists were used, each at two concentra-
tions. A high agonist concentration to saturate signal transduction and a low concentration 
to investigate platelet sensitivity. For collagen (American Biochemical & Pharmaceuticals, 
Epsom, United Kingdom) 10µg/mL and 4.5µg/mL was used, PAR1AP at 10µM and 5µM and 
ristocetin (American Biochemical & Pharmaceuticals) at 1.5mg/mL and 0.6mg/mL. These 
agonist concentrations were determined in separate serial dilution experiments (data not 
shown). Aggregation cuvettes contained platelets diluted to 250,000 platelets/µL with the 
corresponding autologous platelet free plasma with additive solution prepared by centrifuga-
tion. Maximal aggregation (amplitude (%)) is reported here, the other parameters (slope and 
area under the curve) were comparable.
PARTIAL PRESSURE REDUCTION OF MOLECULAR OXYGEN BY DEGASIFICATION 
An independent series (n=5) of pool and split was performed for this experiment. Again, three 
blood group matched platelet concentrates were pooled and split; one platelet concentrate 
was left untreated to serve as a control, one was immediately processed with UV-C and one 
was treated to reduce the dissolved molecular oxygen partial pressure as described else-
where19 before processing with UV-C pathogen inactivation. To reduce molecular oxygen 
partial pressures inert nitrogen gas (Air Liquide, Paris, France) was blown into the illumination 
bag (not bubbled) under continuous gentle agitation to allow reequilibration of dissolved 
gases following Henry’s law. After seven minutes the residual molecular oxygen partial pres-
sure in the platelet concentrate suspension was 1.8±0.5kPa compared to 7.5±1.4kPa in controls 
as measured by a submerged Clark electrode in real time. Flow cytometric analysis and micro-
fluidic flow chamber experiments of these concentrates were performed as described above.
STATISTICAL ANALYSIS
Results are reported as mean values with standard deviation and analyzed with two-way 
ANOVA with Tukey’s multiple comparisons algorithm with Prism software version 6.01 (Graph-
Pad Software Inc.) to determine significance (P≤0.05) between the three subject groups.
RESULTS
UV-C TREATED PLATELETS SHOW IMPAIRED THROMBUS FORMATION KINET-
ICS FOLLOWING STORAGE
UV-C treated platelets were compared with gamma irradiated and untreated controls by 
measuring thrombus formation kinetics onto collagen coated microcapillaries. Figure 1 and 
the supplementary video files show a mean decreased surface coverage in function of time 
onto collagen coated microcapillary. This was found from day two on, but only statistically 
significant following storage on day five and seven. 
Figure 1: Platelet thrombus formation kinetics are affected by UV-C treatment following storage. Microflu-
idic flow chamber experiments with collagen coated microcapillaries were performed in duplicate on day two 
(A), five (B) and seven (C). Thrombus formation kinetics was followed in real-time using video microscopy 
and software measuring platelet surface coverage. The results are depicted as surface coverage in function 
of perfusion time (%SC/Time) for control (closed bars), gamma irradiated (open bars) and UV-C treated 
(shaded bars) platelets in reconstituted blood. The data are shown as means with standard deviation (n=8). 
Results from the statistical analysis are depicted on top of each panel. (ns=not significant; *P<.05; **P<.01; 
****P<.0001).
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INTEGRIN αIIBβ3 CONFORMATIONAL CHANGES AFTER UV-C TREATMENT
During thrombus formation, platelet integrin α IIbβ α3 becomes activated in a calcium-depend-
ent manner to expose the fibrinogen binding site and promote platelet cross linking. The 
PAC1 monoclonal antibody binds a neo-epitope on this receptor and so is a surrogate marker 
for integrin activation. Figure 2A shows that UV-C treatment caused increased PAC1 binding 
compared to both control and gamma irradiated platelets in the absence of any additional 
agonist. This “activated” receptor state persisted during subsequent seven day storage. We 
hypothesized that this premature receptor activation would compromise further activation of 
platelets by exogenous agonists. However, this was not the case as integrin αIIbβ α3 activation 
by both PAR1AP and convulxin was not significantly decreased for UV-C treated platelets  
(Figure 2B-C). Instead, a distinct increase was seen in the UV-C treated group following 
PAR1AP stimulation which may be attributed to the subpopulation of receptors that got 
‘pre-activated’ by UV-C treatment. The overall potency of convulxin to induce and sustain 
inside-out integrin activation is larger than for PAR1AP and therefore this particular ‘additive’ 
effect may be masked in this case. 
PLATELET AGGREGATION IS MOSTLY UNAFFECTED
Unlike PAC1 measurements in highly diluted flow cytometry conditions, aggregation is more 
inclusive taking into account effects of platelet shape change and amplification by vesicle 
release. The above mentioned ‘additive’ effect of integrin α IIbβ α3 activation was also noticed 
during low-dose collagen aggregations, where UV-C treated platelet displayed a slightly 
increased response on day two (Figure 3A). However, this observation could not be gener-
alized to the other conditions (Figure 3B-F), in particular to low dose PAR1AP and low dose 
ristocetin stimulation where a slightly decreased response was found on day two and follow-
ing storage, respectively. Overall however, few differences with gamma irradiated or untreated 
control platelets were found. 
Figure 2: UV-C treatment induces integrin αIIbβα3 conformational changes that does not affect further acti-
vation through PAR1 or GPVI. Integrin αIIbβγ3 activation was measured by binding of fluorescein labeled PAC1 
to 10,000 CD61 positive events in flow cytometry. Samples were analyzed in resting conditions (A) or fol-
lowing stimulation with 30µM PAR1AP (B) or 6ng/mL convulxin (CVX) (C) before (day 1) and after treatment 
(day 2, 5 and 7). Data of UV-C (●), gamma irradiated (▲γ) and untreated control (� ; dotted line) are shown as 
mean values with standard deviation. Results from the statistical analysis are depicted on top of each panel. 
(ns=not significant; ***P<.001; ****P<.0001).
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Figure 3: Light transmission aggregation is not substantially different. Plate-let light transmission ag-
gregometry was performed at 250,000 platelet per µL. Three different agonists were used each in a low (A, C 
and E) and high (B, D and F) concentration as indi-cated on the y-axis. Maximal aggregation (or amplitude 
%) is shown as means with standard deviation. Untreated control (� ; dotted line), gamma irradiated (▲) and 
UV-C (●) are shown before (day 1) and after treatment (day 2, 5 and 7) . Results from the statistical analysis 
are depicted on top of each panel. (ns=not significant; *P<.05; ****P<.0001).
UV-C TREATMENT CAUSED α-DEGRANULATION  
AND PHOSPHATIDYLSERINE EXPOSURE
Platelets contain a number of distinguishable storage α-granules including α granules, lyso-
somes and dense granules. During activation, platelet degranulation occurs thereby releasing 
proteins and small molecules that act as modulators of hemostasis by para- and autocrine 
signaling. P-selectin is a marker of α-granule secretion and showed a significant increase 
following UV-C treatment indicating increased spontaneous degranulation (Figure 4A-B). 
Furthermore, the expression of phosphatidylserine/-ethanolamine is measured by annexin 
V binding. Just like P-selectin there was an increased exposure after UV-C treatment (Figure 
4C). GPIbα expression was only marginally affected by UV-C treatment (Figure 4D). 
UV-C TREATMENT SLIGHTLY INCREASES PLATELET METABOLISM
A significantly higher glucose consumption and lactic acid production was seen for UV-C 
treated platelets (Figure 5A-C) resulting in a different pH trend (Figure 5D) with respect to 
the control conditions. These data indicate a slightly higher metabolic activity, but pH never 
dropped below 7.2.
DECREASED MOLECULAR OXYGEN LEVEL CANNOT RESCUE PLATELET THROM-
BUS FORMATION KINETICS 
Previous work from our group showed that experimentally decreased partial pressures of mo-
lecular oxygen rescues coagulation factor decreases in RF-PRT treated plasma by preventing 
oxidative damage20. We hypothesized that the variability in thrombus formation kinetics 
observed on day two (Figure 1A) was caused by variable molecular oxygen partial pressures in 
the primary product thus resulting in variable oxidative damage. In order to reduce oxidative 
damage during UV-C treatment, the partial pressure of molecular oxygen was lowered in the 
platelet concentrate before UV-C treatment by nitrogen gas equilibration. However, figure 6 
shows that such treatment did not alter the decreased thrombus formation kinetics onto col-
lagen on day two. Of note, this experiment independently replicated the results from figure 1 
confirming no statistically significant difference on day two for an additional five repeats. As a 
matter of control for the impact of nitrogen gas equilibration, glycoprotein Ibα, P-selectin, an-
nexin V and activated integrin α IIbβ α3 expression were measured but found not to be different 
between these conditions (Figure S1). 
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Figure 4: Platelet α degranulation and expression of negatively charged phospholipids is increased  
following UV-C treatment. Degranulation was measured by binding of a labeled P-selectin antibody and the 
percentage above isotype control (A) and median fluorescence intensities (B) are depicted. Externalization of 
phosphatidylserine/-ethanolamine was measured by binding of labeled annexin V (C) and percentage above 
control is shown. GPIbγ receptor expression is shown as mean fluorescence intensities (D). Untreated control 
(� ; dotted line), gamma irradiated (▲) and UV-C (●) are shown before (day 1) and after treatment (day 2, 5 
and 7). Results from the statistical analysis are depicted on top of each panel. (ns=not significant; *P<.05; 
**P<.01; ***P<.001; ****P<.0001).
Figure 5: Increased metabolic rate following UV-C treatment. The lactic acid production (A) and glucose 
consumption (B) per 1012 platelets of untreated control (� ; dotted line), gamma irradiated (▲) and UV-C 
treated (●) platelet concentrates was measured using a point-of-care blood gas analyzer. Linear regression 
was performed on the lactic acid production and glucose consumption in function of time to model the 
kinetics of respectively lactic acid (open bars) and glucose metabolism (shaded bars) (C). One-way ANOVA of 
the mean values indicated a significant difference between the lactic acid production (P<.0001) and glucose 
consumption (P<.003) of UV-C and both control and gamma irradiated platelet concentrates. Platelet  
concentrate pH (D) was determined before (day 1) and after treatment (day 2, 5 and 7). Untreated control  
(� ; dotted line), gamma irradiated (▲) and UV-C (●γ) are shown before (day 1) and after treatment (day 2, 5 
and 7). (ns=not significant; *P<.05; ****P<.0001).
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DISCUSSION
Three pathogen inactivation methods for platelet concentrates have been developed aiming 
to minimize chances of bacterial growth and/or transmission of virus. The UV-C procedure 
under study here is operationally straightforward and takes approximately eight minutes per 
product. There is no additional work load compared with methods that involve supplementa-
tion with a photoactive compound and especially to AS-PCT where an additional photosen-
sitizer removal step is required. On the other hand, criticisms on the UV-C method include its 
limited inactivation of certain viruses11 including HIV1 and its restrictive inclusion criteria5. 
Figure 6: Lowering the partial pressure of dissolved molecular oxygen does not alter reduced thrombus 
formation kinetics. Platelet surface coverage in function of perfusion time (%SC/Time) is measured in 
microfluidic flow chambers coated with collagen on day 2 according to figure 1. Paired reconstituted blood 
samples containing untreated control (closed bar), UV-C treated normoxic (open bar) and UV-C treated hy-
poxic (UV-C-O2) (shaded bar) platelets analyzed in duplicate at a shear stress of 50dynes/cm
2. Mean values 
with standard deviation as whiskers (n=5) are shown. Results from the statistical analysis are depicted on top 
of each panel. (ns = not significant).
There are substantial data on the in vitro quality of platelet concentrates generated by AS-
PCT and RF-PRT, generally indicating increased rates of storage lesion with a variable range 
of magnitude21-25. Published data on residual quality of platelets treated with UV-C are less 
abundant but also indicate a slightly increased anaerobic metabolic rate causing significant 
differences in lactic acid concentrations and pH. However, this is mostly near or beyond expi-
ration dates8-10,12 which is in line with our findings. Small but significant increases in degran-
ulation (P-selectin)9,10 and phosphatidylserine/-ethanolamine exposure12 also support our 
data and may collectively indicate basal platelet activation or increased apoptosis. Of note, in 
terms of lesion kinetics our data indicate a small but sudden increase in both degranulation 
and annexin V binding (Figure 4) with a subsequent normal rate of additional storage lesion 
when compared to gamma irradiated or untreated controls. 
Platelet functional assays have been used less frequently to evaluate residual platelet quality 
following pathogen inactivation, also for the other two commercial photochemical methods. 
We recently published data indicating that both AS-PCT and RF-PRT significantly and irre-
versibly affected thrombus formation kinetics onto immobilized collagen25. The same exper-
imental setup was applied to UV-C here and also showed an irreversible decrease although 
the impact on day two was variable but not statistically significant. We hypothesized that this 
is caused by the inherent variability in the partial pressures of dissolved molecular oxygen 
in the primary products based on our experience with RF-PRT where secondary superoxide 
anion formation causes biomolecular damage20. Therefore, we experimentally lowered the 
molecular oxygen partial pressures but this could not reverse variability nor the impact on 
thrombus formation kinetics (Figure 6). 
The increased binding of PAC1 to integrin α IIbβ α3 following UV-C treatment confirms the 
findings published in the landmark study by Verhaar et al26. They showed that short wave-
length light reduces disulfide bonds to free thiols in the fibrinogen receptor core structure. 
It is plausible that this disulfide reshuffling which is a fundamental biochemical aspect of 
integrin activation27,28 alters the conformation promoting untimely fibrinogen binding. Even 
though the overall physical conditions of the Verhaar study differ (they used a lower UVC 
dose of 0.15J/cm2, delivered to a different primary product with lower plasma content and 
a fixed penetration depth) from the routine procedure of pathogen inactivation by UV-C, it 
is unlikely that unrelated biochemical mechanisms cause the same observation5. In theory, 
enforced fibrinogen binding should lead to (some) activation of affected platelets through 
outside-in signal transduction29 which then subsequently explains the slightly increased 
metabolic rate30, phosphatidylserine exposure and degranulation. This is the case for RF-PRT, 
where the observed premature activation actually desensitizes subsequent platelet activa-
tion25. The latter was however not observed for UV-C where the platelet’s subsequent reaction 
to external stimuli acting through G-protein coupled receptors (PAR1AP) or receptor tyrosine 
kinases (CVX) was not abnormal in light transmission aggregation nor in flow cytometry. 
It is therefore tempting to ascribe this difference between the methods to the well known 
differential effects of UV-B versus UV-C illumination on platelet function; the former acting 
through direct activation of signal transduction cascades via protein kinases C31 and oxidative 
stress while the latter does not26. Furthermore, proteomic analysis has indicated changes in 
the protein disulfide isomerase ERp72 for UV-C and not UV-B treated platelets9 which adds to 
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the data from Verhaar et al26 a role for redox regulation of integrin α IIbβ α3 in the context of UV-C 
illumination induced biochemical alterations. 
We argue that the hemostatic sequence of platelet adhesion, activation, aggregation and 
retraction/stability as measured comprehensively in perfusion chambers is affected by 
all three pathogen inactivation methods albeit not equally in manner and/or magnitude. 
RF-PRT treatment prematurely activates platelets22,32 while AS-PCT does not. However, the 
latter method does specifically affect integrin αIIbβ α3 receptor activation following stimulation 
with agonists25. It is less clear from the current study what aspect of UV-C contributes to its 
reduced flow chamber thrombus formation, but the redox induced changes in integrin αIIbβ α3 
conformation are a likely culprit. We performed two separate but similar experimental series 
in the flow chambers (Figure 1 and 6) and confirmed that despite an average decrease in 
surface coverage kinetics, statistical difference between UV-C and gamma or untreated con-
trol was not reached on day two. Bashir et al12 previously demonstrated that UV-C pathogen 
inactivation reduces the post-transfusion recovery of platelets following storage. Whether 
the effect of storage of UV-C treated platelets on both post-transfusion recovery and on in 
vitro flow chambers reflect a related phenomenon is worth addressing. 
In our hands, all pathogen inactivation techniques have more or less of an impact on platelet 
thrombus formation rates under hydrodynamic flow. Despite the absence of serious adverse 
(bleeding) events in the published clinical studies33 for RF-PRT and AS-PCT, our findings do 
raise questions about the exact contribution of pathogen inactivated transfusion platelets in 
arterial hemostasis.
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Figure S1: Lowering molecular oxygen partial pressures has no effect on platelets. (A) P-selectin, (B) phos-
phatidylserine/-ethanolamine by annexin V binding, (C) GPIbα and (D) integrin αIIbβγ3 activation was not 
different in normoxic (open bars) versus hypoxic (shaded bars) conditions. (E) Integrin activation in response 
to 30µM PAR1AP or (F) 6ng/mL convulxin was also not different. The differences with untreated controls 
(closed bars) were consequently comparable. The results from statistical analyses are indicated on top of 
each panel (n=5). ns=not significant; *P<.05; **P<.01; ***P<.001.
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INTRODUCTION
Psoralens are linear furanocoumarins. The heterocyclic aromatic core reversibly intercalates 
nucleic acids in cells and cell nuclei1. Absorption of ultraviolet A (UVA) light excites psoralens, 
supplying energy for covalent bond formation. When binding to nucleic acids, the reaction is 
primarily with pyrimidine moieties2. This chemical addition is irreversible and prevents nor-
mal replication of DNA3, explaining why severe phytophotodermatitis occurs in sun exposed 
skin that has been in contact with psoralen producing plants. This biostatic photochemistry is 
utilized in a pathogen inactivation technology (Intercept Blood System, Cerus Corp, Con-
cord, CA) for plasma and platelet concentrates in transfusion medicine4 where it is intended 
to prevent replication of potentially infectious pathogens transmitted from the donor to the 
blood product. In the field of dermatology, PUVA technology is used to treat psoriasis, certain 
dermatoses and cutaneous T-cell lymphoma (CTCL)5. In these cases the psoralen is admin-
istered topically or systemically, followed by local or whole body UVA illumination. Treatment 
modalities are diverse and may differ by psoralen derivative and/or by doses of UVA light6. 
Furthermore, PUVA is under clinical investigation for the treatment of multiple other diseases, 
mostly involving uncontrolled cell proliferation7. But although broadly applied in medicine, 
the biochemical mechanism of PUVA is poorly understood.
Of note, psoralens are not therapeutic without UVA illumination and despite its well doc-
umented photoreaction with DNA, PUVA photochemistry is not specific for this particular 
biologic target alone. In theory, photoexcited psoralens can react with many other common 
biomolecules. Consequently, the net effect of PUVA in a cellular milieu is unlikely to be 
restricted to consequences of its chemistry with solely DNA as was acknowledged already in 
the late seventies8. This seemingly random reaction with multiple biomolecules explains why 
the quest for insights into PUVA and optimized therapies has been exceptionally challenging. 
For example, the systemic PUVA treatment modality called extracorporeal photopheresis 
(ECP) is used to treat CTCL and although clinically succesful9, the mechanism of action has 
remained elusive ever since its first application. Researchers speculate that induction of 
apoptosis through DNA damage causes priming of the immune system. However, apoptosis 
induction alone is insufficient for the typical immomodulation caused by PUVA10,11. Despite 
this indistinctness, ECP is used “off-label” for (auto)immune diseases including graft-versus-
host disease (GvhD), bronchiolitis after stem cell transplantation and Crohn’s disease12,13. But 
without understanding of definite biochemical mechanisms, both protocol uniformity and 
outcome variability remain problematic.
Adduct formation of photoexcited psoralens with targets other than DNA11,14 is primarily with 
membrane components15,16. Psoralens efficiently partition into lipid bilayers17,18 where reaction 
chemistry occurs with double bonds in unsaturated acyl chains19,20. As a consequence, rational 
hypotheses on the cell biological consequences of these modifications have been postulat-
ed21,22, but mechanisms explaining how membrane modifications exactly impact downstream 
cell signal transduction are underinvestigated. 
We chose platelets as a model cell to study these DNA-unrelated effects of PUVA because 
platelets have no nucleus, are easily isolated from whole blood and contain a complex signal 
transduction machinery exemplary of key signaling processes in eukaryotic cells. Further-
more, recent work has shown that PUVA significantly affects platelet function in an in vitro 
model of hemostasis23. Our data now show that PUVA can inhibit signal transduction of the 
PI 3-kinase pathway by preventing efficient plasma membrane binding of important small 
effector kinases such as Akt (alternative name protein kinase B) and Bruton’s tyrosine kinase 
(Btk). Our findings are not restricted to platelets, because T lymphocytes in patient samples 
treated with ECP displayed attenuation of Akt phosphorylation as well. 
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MATERIAL AND METHODS
MATERIALS
Ticagrelor dissolved at 30mM in DMSO (Cayman Chemical, Ann Arbor, MI); D-phenylala-
nyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) dissolved at 40mM in distilled water 
(Enzo Life Sciences, Farmingdale, NY); wortmannin dissolved at 2mM in DMSO, anti-P-Akt 
(clone D25E6), anti-total (pan) Akt (40D4), anti-phospho-PKC Substrate Motif [(R/KXpSX-
(R/K)] MultiMab corresponding secondary peroxidase labeled antibodies, anti-total-Btk 
(C82B8) (Cell Signaling Technologies, Danvers, MA); apyrase dissolved at 200U/mL in distilled 
water, SFLLRN hexapeptide dissolved at 1mg/mL in distilled water with 0.1% trifluoroacetic 
acid, indomethacin dissolved at 35mM in ethanol, pluronic F-127, calcium ionophore A23187 
dissolved at 5mM in DMSO, 4-chloro-7-nitrobenzofurazan (NBD) chloride, tris(2-carboxyeth-
yl)phosphine (TCEP), RPMI-1640 medium without phenol red, L-glutamine, 8-methoxyp-
soralen (8-MOP) dissolved at 15mM in DMSO, Interleukin-2 (IL2) (Sigma-Aldrich, St Louis, 
MO); thrombopoietin dissolved at 200µg/mL in distilled water with 4mM hydrogen chloride 
and 0,1% human serum albumin, anti-P-Btk (clone 797837) (R&D systems, Minneapolis, MN); 
AYPGKF hexapeptide (Anaspec, Waddinxveen, The Netherlands) dissolved at 5mM in distilled 
water; CRP-XL (University of Cambridge, Cambridge, United Kingdom) dissolved at 5mg/
mL in 0.01M acetic acid; Halt Protease & Phosphatase inhibitor cocktail (Thermo Scientific, 
Waltham, MA); 2-(Methylthio)adenosine 5-diphosphate (Santa Cruz Biotechnology, Dallas, 
TX) dissolved at 37mM in distilled water; anti-pleckstrin antibody (ab17020), human wild type 
α-synuclein (ab51188) (Abcam, Cambridge, UK). Oregon Green 488nm 1,2-bis(o-aminofenoxy)
ethane-N,N,N’,N’-tetra acetic acid-(acetoxymethyl) ester (BAPTA-AM), NBD iodoacetamide 
(IANBD), Dynabeads Human T-activator CD3/C28 (Life Technologies, Carlsbad, CA); All phos-
pholipids were purchased dissolved in chloroform (Avanti Polar Lipids, Alabaster, AL); ALPS 
peptide was custom made (Proteogenix, Schiltigheim, France) and based on the first 38 amino 
acids of the GMAP210 protein24 except for the N-terminal methionine which was changed to 
cysteine to allow targeted labeling; Ficoll-Paque Premium (d=1.077g/mL at 20°C) (GE Health-
care, Little Chalfont, United Kingdom). Anticoagulated AB RhD- serum was provided by the 
blood bank. 
PUVA TREATMENT
PUVA treatment of platelets was with the Intercept pathogen inactivation method devel-
oped by Cerus Corporation (Concord, CA) using amotosalen (AS) as the active photosen-
sitizing psoralen and ultraviolet A light (320-400nm) in a calibrated illumination device25. 
Platelet concentrates for transfusion (PC) which each fulfill the acceptance criteria set by 
Cerus Corporation were used in accordance to the instructions of the manufacturer26. PC 
were prepared by the buffy coat method27 which is by pooling of six buffy coats and resus-
pension in additive solution (SSP+, Macopharma, Tourcoing, France) as described23. To gen-
erate paired samples, two PCs were pooled, mixed and split again in two equivalent volumes. 
One volume remained untreated (control) and the other was PUVA treated. The latter PC 
was thereto transferred to an illumination bag while 17.5mL amotosalen (final ~150µM) was 
added, followed by expelling excess air bubbles and UVA illumination at a dose of 3.9J/cm2. 
Following overnight incubation on an orbital shaker at room temperature with a compound 
adsorption device to remove amotosalen and its photoproducts, treated PCs were trans-
ferred to a storage bag. Storage was under standard blood bank conditions. Experiments on 
platelets were performed 16-24 hours after PUVA by sampling low volumes through sterile 
connections under a laminar flow hood. 
SIGNAL TRANSDUCTION ANALYSIS 
Platelet samples from PC were washed in Tyrode’s buffer (5mM 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES) pH 7.4 with 136.5mM NaCl, 2.7mM KCl, 11.9mM NaHCO3, 
0.4mM NaH2PO4, 1mM MgCl2 and 0.1% (m/v) D-glucose), as previously described
28. Washed 
platelets were rested for maximally half an hour at 37°C prior to activation with the indicat-
ed agonists and incubation times. Activated platelets were lysed in ice-cold buffer (50mM 
Tris(hydroxymethyl)aminomethane (Tris) pH 8.0 with 100mM NaCl, 1.0% (v/v) octyl-phe-
noxypolyethoxyethanol (Igepal-CA630), 0.1% (m/v) sodium dodecyldisulphate (SDS), 10mM 
activated Na3VO4, and Halt protease cocktail) and mixed. Platelet lysates were loaded on 
4-15% polyacrylamine Tris-Glycine TGX gels (Bio-Rad, Hercules, CA) in reducing Laemmli 
sample buffer for SDS PAGE western blotting. Primary and secondary antibodies to blotted 
targets were prepared in tris buffered saline (TBS pH7.4, 25mM Tris with 150mM NaCl and 
2mM KCl) with 5% (m/v) skimmed milk. Where required, membranes were reprobed follow-
ing incubation for 30min at 60°C submerged in western reprobe buffer (50mM Tris pH 7.0, 
2.0% (m/v) SDS and 100mM β-mercaptoethanol). Images of bound antibody were developed 
with enhanced chemiluminescence and an imaging system (ChemiDoc MP) equipped with 
a CCD camera and analysis software (ImageLab v4.0.1) for densitometry (Bio-Rad). 
LIPID EXTRACTION AND LIPID SAMPLE PREPARATION
The solvents used for the lipid extraction and LC-MS separation were HPLC-grade chlo-
roform, ULC-MS grade water and ULC-MS grade methanol (Biosolve, Valkenswaard, The 
Netherlands). HPLC grade ammonium formate, HCl and HPLC grade methyl-tert-butyl-
ether were purchased from Sigma-Aldrich. Phosphoinositides from platelet lipid extracts 
were derivatized and analyzed as described29 with minor modifications. In brief, three 
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volumes of chloroform/methanol (1:2, v/v) were added to one volume of platelet suspension 
for extraction of neutral lipids. The samples were vortex-mixed, followed by centrifugation 
at 13,000g for two minutes. The supernatant was transferred to an LC-MS vial and used as 
such for analysis of phospholipids and phospholipids in complex with amotosalen. Inter-
nal standards PI(4,5)P2(17:0/20:4) and PI(3,4,5)P3(17:0/20:4) were added at 5µg/mL to the 
remaining pellet. A volume of 1365µL methyl-tert-butyl-ether/methanol/2M HCl (200:60:13; 
v/v/v) was used to re-suspend the fraction followed by incubation for 15 minutes at room 
temperature with intermittent mixing. Next, 250µL of 0.1M HCl was added, vortexed and 
centrifuged at 6,500g for 2 minutes. The upper organic phase was transferred to a new tube 
and 500µL of pre-derivatization wash solution (lower phase of methyl-tert-butyl-ether/
methanol/0.01M HCl 100:30:25 (v/v/v)) was added. The samples were again centrifuged at 
6,500g for 2 minutes and the upper phase was transferred for derivatization. Hereto, 50µL 
of 2M trimethylsilyl-diazomethane in hexane was added and mixed for 10 min at room 
temperature followed by addition of 6µL of glacial acetic acid (all Sigma-Aldrich) to stop 
the methylation reaction. Next, 500µL of post-derivatization wash solution (upper phase 
of chloroform/methanol/water 120:60:45 (v/v/v)) was added, vortex-mixed and centrifuged 
for 5 minutes at 1,500g. The upper phase was transferred to a high recovery glass vial and 
dried down in a centrifugal vacuum evaporator (MiVac duoconcentrator, Genevac, Ipswich, 
United Kingdom) at 37°C. The dried sample was reconstituted in 50µL of chloroform/meth-
anol (1:2, (v/v)) before injection. 
ANALYSIS OF (PHOSPHO)LIPIDS
The lipid analysis is based on high-resolution liquid chromatography coupled to high-res-
olution quadruple time-of-flight mass spectrometry30,31. For lipidomics analyses, a 1290 In-
finity LC system (Agilent Technologies, Waldbronn, Germany) was used. Lipid extracts were 
analyzed on an Acquity UPLC BEH Shield RP18 column (2.1 x 100mm; 1.7µm; Waters, Milford, 
MA, USA) placed in a Polaratherm 9000 series oven (Selerity Technologies, Salt Lake City, 
UT, USA) at 80°C. Elution was carried out with a multistep gradient of (A) 20mM ammonium 
formate pH 5 and (B) methanol, starting from 50% B to 70% B in 5 minutes, followed by a 
slow gradient of 70–90% B in 30 minutes. Mobile phase B subsequently reached 100% in 
0.1 minutes where it was maintained for an additional 5 minutes. The flow rate was 0.5mL/
minute and the injection volume 10µL for both positive and negative electron spray ioni-
zation (ESI) measurements. The whole system was allowed to re-equilibrate under starting 
conditions for 15 minutes. For measurement of derivatized phosphoinositides, elution was 
optimized using the same mobile phases at a flow rate of 1.0mL/minutes: starting from 50% 
B to 85% B in 5 min, followed by a very slow gradient of 85–90% B in 15 min. At the end of the 
analysis, mobile phase B reached 100% in 2 minutes where it was maintained for an addi-
tional 3 minutes. High-resolution accurate mass measurements were obtained on an Agi-
lent 6550 Q-TOF mass spectrometer (Agilent Technologies) equipped with a dual Jetstream 
ESI source. The instrument was operated in both positive and negative ESI mode. Needle 
voltage was optimized to +/- 3.5kV, the drying and sheath gas temperatures were set to 
290°C and 400°C, and the drying and sheath gas flow rates were set to 13 and 12L/minute, 
respectively. Data were collected in centroid mode from m/z 100–3,200 at an acquisition 
rate of 2 spectra/second in the extended dynamic range mode (2GHz), offering an in-spec-
trum dynamic range of 105 and a resolution of ± 20,000 FWHM in the lipid m/z range. MS/
MS experiments were performed in targeted MS/MS mode. The quadrupole was operated at 
medium resolution and the collision energy was fixed at either 20eV or 35eV. Study samples 
were analyzed in randomized order. Samples were kept at 4°C in the autosampler tray while 
waiting for injection. 
Abundances (area under the curve or AUC) of lipid species were extracted by the Find by 
Ion extraction algorithm in MassHunter Qualitative Analysis 7.0 software package (Agilent 
Technologies) using predefined mass (10ppm) and retention time extraction windows 
(15 seconds). The Agile integrator was used, with an absolute peak height cut-off of 1000 
counts.
Molecular formulas, based on accurate mass, isotopic abundance, and spacing both in 
positive and negative ionization modes, are complemented with accurate mass database 
searching in an in-house build database (populated with LIPID MAPS and HMDB entries 
and theoretical lipid structures) and MS/MS measurement in both modes. Lipid fragmenta-
tion mechanisms and spectra in both positive and negative ionization modes were equal to 
those reported in literature31. Each lipid class displays characteristic fragment ions in posi-
tive and/or negative ESI mode. Other parameters such as lipid elution behavior and adduct 
formation interpretation further assisted in the identification. Regarding phosphoinos-
itides, LC-MS cannot discriminate between bisphosphorylated phosphatidylinositol (PIP2) 
isomers differing in the position of phosphates on the inositol ring. For trisphosphorylated 
PIP3, the only known isomer is PI(3,4,5)P3.
FLOW CYTOMETRY
Expression of activated integrin αIIbβ3 (fluorescein labeled PAC1, BD Biosciences, Erem-
bodegem, Belgium) was analyzed with an acoustic focusing Attune flow cytometer (Life 
Technologies, Carlsbad, CA). Platelets were incubated with labeled antibodies with agonists 
or the respective vehicle buffer for 10min at room temperature in HEPES buffered saline pH 
7.4 with 1.0mM MgSO4 and diluted thousand fold immediately before readout according 
to previously published work32. Signals of the isotype antibody controls were used to set 
threshold gates including 0.5% of 10,000 negative events. Median fluorescence intensities 
and percentage positive events were determined for 10,000 cells staining positive for the 
platelet marker CD61 (allophycocyanin labeled anti-CD61, Life Technologies).
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CALCIUM SIGNALING
Kinetics of calcium release from internal stores was measured by fluorescence of Oregon Green 
BAPTA-AM loaded platelets. Washed platelets were incubated for 45min with 5mM Oregon 
Green BAPTA-AM in the presence of 0.05% pluronic F-127. The platelet suspension was cen-
trifuged and redissolved in Tyrode’s buffer with 3.5mg/mL human serum albumin and 250µM 
ethylene glycol tetraacetic acid (EGTA) to chelate trace extracellular calcium. A microplate read-
er equipped with a pipetting robot and thermostat (Tecan, Männedorf, Switzerland) was used to 
deliver Oregon Green loaded platelets in all white 96-well plates (100µL per second) containing 
agonists and/or antagonists followed by immediate readout at 550nm (excitation 488nm) in 
function of time for 4min. Cytosolic calcium concentrations were determined by extrapolation 
of signals using maximal fluorescence as determined by short incubation of loaded platelets 
with 5µM of calcium-ionophore A23187 in the presence of 2mM CaCl2 and minimal fluorescence 
as determined by addition of 0.5% (v/v) Triton-X-100 and 8mM EGTA.
 
LIPID PACKING ANALYSIS IN LIPOSOMES
Binding experiments of lipid packing sensors were based on pioneering work by Vanni et al33 and 
Pranke et al34. First, the lipid packing sensing peptide ALPS was covalently labeled with NBD to 
their N-termini. The ALPS peptide contained just one cysteine (at the N-terminus) and was kept 
in a reducing environment (10-fold molar excess of TCEP). Labeling was to that free N-terminal 
thiol using IANBD at a molar ratio of IANBD to ALPS of 10:1 in HK buffer (50mM HEPES pH7.2 
with 120mM potassium acetate) for 2 hours at room temperature in the dark. The reaction 
mixture was dialyzed (membrane molecular weight cut-off 2,000) to 4L of HK buffer during 24 
hours at 4°C. The degree of labeling for both peptides was determined by optical absorbance at 
wavelengths for peptides, bound and free label. 
Surface partition constants for ALPS-NBD binding to PUVA treated or control liposomes were 
determined by serial dilution of the phospholipid fraction as liposomes. Liposome preparation 
was with sonication as described above. Liposome composition is given in Figure 4. PUVA 
treatment was with amotosalen at 150µM. A serial dilution of liposomes (PUVA treated or not) 
was prepared in HKAc buffer (50mM HEPES pH7.2 with 120mM potassium acetate, 1mM MgCl2, 
1mM dithiothreitol) and supplemented with 0.17µM ALPS-NBD or unlabeled ALPS (for back-
ground correction). Fluorescence (emission 535nm) was measured at 37°C (excitation 485nm). 
The Surface partition constant (Kp) was calculated as described for NBD labeled peptides to lipid 
bilayers35. In brief, data were modeled by linear regression (Prism 6 v6.01, GraphPad Software, 
San Diego, CA) to equation (1), where Xb* is the corrected molar ratio of bound peptide to lipid. 
The correction factor is a constant and finds its origin in the fact that only the outer leaflet 
of the bilayer is accessible for the binding partner. Cf is the equilibrium concentration of free 
peptide in solution.
X*b = KpxCf eq. 1
T-CELL ACTIVATION 
PBMC were prepared by Ficoll gradient centrifugation of buffy coats prepared by centrif-
ugation of whole blood donations from healthy non-renumerated donors. Isolated PBMC 
preparations were washed three times in sterile phosphate buffered saline (PBS, pH 7.4) by 
soft centrifugation to remove contaminating platelets. Finally, the cells were resuspend-
ed in phenol red-free RPMI-1640 medium with 2mM L-glutamine, 10mM HEPES and 10% 
(v/v) AB (RhD-) human serum and rested for 2 hours at room temperature. The rested cells 
were resuspended to 40,000 leukocytes per µL in Tyrode’s buffer and mixed with 8MOP or 
amotosalen in a final amount of 60X106 leukocytes. Illumination of the suspension with 
UVA light was in a quartz cuvette. Following PUVA, T-cells were activated in Tyrode’s buffer 
with 2.5X106 CD3/CD28 human T-activator Dynabeads per 106 leukocytes in the presence 
of 10ng/mL of IL2 for 30min at 37°C on a rotator. Cells were lysed with ice-cold buffer and 
centrifuged at 20,000g for 3min. Supernatant was analyzed by SDS PAGE western blotting 
in reducing sample buffer. 
EXTRACORPOREAL PHOTOPHERESIS SAMPLES
A patient enrolled in a clinical trial not related to this study at the Hospital Network Antwerp 
(Belgium) for the treatment of chronic GvhD with off-line ECP gave informed consent for 
sampling of cells from the buffy coat suspension before and after PUVA. The study was 
approved by the hospital’s ethical committee (approval number 4591). The ECP procedure 
involved a leukapheresis (Spectra Optia, Terumo BCT, Lakewood, CO) yielding a buffy  
coat cell suspension that was diluted with saline in an illumination bag to a final 300g by 
mass. The psoralen 8MOP was added to a final 0.9µM followed by illumination in a Ma-
cogenic G2 UVA illumination device (Macopharma) which delivered 2J/cm2 or 2.5J/cm2 
depending on the suspension’s hematocrit of <2% or ≥2%, respectively. Before and after 
illumination, 2mL samples were taken aseptically from the bag. PBMC were prepared from 
these samples followed by activation of T-cells as described above. A total of three ECP 
procedures were performed on the patient. For each procedure PBMC isolation and T-cell 
activation were performed in triplicate to control for variation in SDS PAGE western blotting 
and densitometry.
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RESULTS
PLATELET INTEGRIN ACTIVATION IS DECREASED BY PUVA
Platelet activation involves a series of complex signaling cascades culminating in a number 
of pivotal functions that drive hemostasis. One of these is platelet aggregation which is 
mediated by crosslinking of soluble trimeric fibrinogen to multiple platelet integrin αIIbβ3 
receptors. This abundant but platelet specific integrin adopts a non-binding “closed” con-
formation during circulation in healthy vessels. A dramatic conformational change “opens” 
up the receptor caused by inside-out activatory signals initiated by extracellular agonists 
released at sites of vessel injury. The molecular change in integrin αIIbβ3 can be measured 
by a monoclonal antibody (PAC1) that recognizes this activated form only36. In flow cytom-
etry this particular readout was used to test how PUVA affects the platelet’s response to 
specific agonists. PUVA decreased platelet integrin activation by half in a dose increasing 
experiment of the peptide SFLLRN which activates the high affinity thrombin receptor PAR1 
(Figure 1a). PAR1 is a G-protein coupled receptor (GPCR), but the defect was not specific 
for this class of receptors because dose-dependent integrin activation via the unrelated 
collagen receptor couple GPVI-FcγR using cross-linked collagen related peptides (CRP-XL) 
was decreased eightfold (Figure 1b). Moreover, the respons of low affinity thrombin recep-
tor PAR4, another GPCR that is closely related to PAR1, to the AYPGKF peptide was normal 
(Figure 1c). The latter experiment indicates that the conformational change of the integrin 
αIIbβ3 itself was not affected as such by PUVA. Besides, membrane expression levels of key 
platelet receptors GPVI, PAR1, FcγR and αIIb on the platelet surface were normal in PUVA 
treated platelets, both in resting and activated conditions (Data not shown). 
Figure 1 : Effect of PUVA on inside-out signaling of integrin αIIbβ3 . Paired platelet samples were treated 
with PUVA (◆) or not (CTR, �) and then incubated with the indicated agonists and labeled with PAC1 for flow 
cytometry. The percentage of platelets exposing the PAC1 epitope following dose-response activation by 
(a) SFLLRN, (b) CRP-XL and (c) AYPGKF peptides are shown. The data were fitted by non-linear regression. 
Effective half-maximal concentrations (EC50) were calculated from these fits and are depicted in the inset 
tables. Data are shown as means with standard deviations, the number of repeats is indicated in the inset 
tables. 
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PUVA SELECTIVELY INHIBITS AKT AND BTK PHOSPHORYLATION
The normal integrin activation in response to specific PAR4 stimulation indicated that 
the PUVA dependent defects were restricted to selected signal transduction pathways. 
Therefore, key effector phosphorylations upstream of integrin αIIbβ3 activation were interro-
gated. Following GPCR and RTK signal transduction PI(4,5)P2 can be phosphorylated by PI 
3-kinase to yield PI(3,4,5)P3 which in his turn regulates the phosphorylation of Akt and Btk. 
Furthermore, PI(4,5)P2 can also be hydrolyzed by PLC enzymes into IP3 and DAG. 
While investigating the PI 3-kinase pathway, we found a significanty decreased phospho-
rylation of Akt and Btk in response to both CRP-XL and SFLLRN (Figure 2). The experiment 
with SFLLRN included methyl-thio-adenosine diphosphate (MeSADP) to stimulate the 
purinergic P2Y12 GPCR because phosphorylation of Akt is not efficient without co-stimula-
tion37. Specificity of the PI 3-kinase-Akt pathway was confirmed by use of Wortmannin (Wm) 
which inhibits all PI 3-kinase isoforms. Because GPVI-FcγR activation by CRP-XL causes 
amplificatory feedforward signals through remote GPCRs by thrombin, thromboxane A2 
generation and adenosinediphosphate (ADP) release, the experiment was repeated in the 
presence of respective secondary signaling inhibitors D-phenylalanyl-L-prolyl-L-arginyl 
chloromethyl ketone, indomethacine and ticagrelor, yielding similar results (data not 
shown). In addition, phosphorylation of Akt via the differential JAK signaling pathway in 
response to thrombopoietin (TPO) was also decreased (Figure 3a, c). The TPO receptor 
(alternative name, CD110) does not cause platelet activation38, confirming that the signal 
transduction defect is not a consequence of simultaneously activated remote pathways. Akt 
phosphorylation through combined activation of PAR4 and P2Y12 by AYPGKF and MeSADP 
respectively was normal (Figure 3b, c). 
To investigate if the other pivotal signaling pathway was affected by PUVA, phospholipase 
C (PLC) activation was measured. Platelets use PLCβ and PLCγ2 in response to GPCRs and 
GPVI-FcγR, respectively. The PLC activation causes archetypical inositol-tris-phosphate 
and diacylglycerol second messenger responses. The former was measured by calcium 
release from internal stores in function of time and the latter by phosphorylation of the 
major phosphokinase C reporter pleckstrin. Both processes (Figure 4) were however normal, 
demonstrating that PLC pathways were unaffected by PUVA.
Figure 2: PUVA inhibits Akt and Btk phosphorylation. Platelet lysates were analyzed by western blotting 
and subsequent densitometry. Antibodies to T308 phosphorylated Akt (P-Akt) or Y551 phosphorylated Btk 
(P-Btk) were used. For control of gel loading, the membranes were reprobed for total Akt (Akt) or total Btk 
(Btk). PUVA treatment in the presence or absence of 0.5µM Wm is indicated on top of the panels. (a) Platelets 
were activated with 1µg/mL CRP-XL for 2 minutes or (b) with 30µM SFLLRN in combination with 10µM 
MeSADP for 3 minutes. (c, d) The decrease in mean protein band density of the ratio phosphorylated kinase 
to total kinase (n=6) in PUVA treated platelets relative to untreated control counterparts is given. No change 
is emphasized by the horizontal dashed line.
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Figure 3: PUVA affects phosphorylation of Akt following signal transduction through the TPO receptor,  
but not through PAR4. (a) Platelets were activated with 100ng/mL TPO for 10 minutes or (b) with 250µM AY-
PGKF and 10µM MeSADP for 5 minutes. Platelets were lysed and the samples analyzed by western blotting. 
Antibodies to T308 phosphorylated Akt (P-Akt) were used. Membranes were reprobed for total Akt (Akt) as 
a control for loading. Wortmannin (0.5µM) was used to confirm that Akt phosphorylation was PI 3-kinase 
dependent. (c) The mean decrease in Akt signal (n=6) of PUVA treated platelets relative to untreated control 
counterparts is depicted. No change is emphasized by the horizontal dashed line.
PUVA IMPEDES NORMAL RECRUITMENT OF AKT AND BTK  
TO THE PLASMA MEMBRANE 
The signaling pathways of PAR1 and GPVI-FcγR are dissimilar, yet both result in defective 
Akt and Btk phosphorylation in PUVA treated platelets. Although these effector kinases 
exert diverse functions in the cell, both rely on a pleckstrin homology domain (PH) to inter-
act with the inner membrane leaflet. This interaction is facilitated by PI(3,4,5)P3 which is 
produced from PI(4,5)P2 by activated PI 3-kinase. Therefore, we hypothesized that PI(3,4,5)
P3 formation was defective in PUVA treated cells. Lipid extracts of PUVA treated platelets 
were analyzed by reversed phase liquid chromatography (RP-LC) coupled to high-resolu-
tion quadrupole time-of-flight (Q-TOF) mass spectrometry (MS) which primarily showed 
covalent adduct formation between the psoralen amotosalen and PIP2 in UVA illuminated 
platelet samples (Figure 5a, b). In control cells incubated with amotosalen in the dark, no 
covalent adduct formation was detected. Adduct formation with amotosalen was however 
not restricted to PI because also phosphatidylserine (PS), phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) adducts were found (data not shown). Notably, the relative 
amount of PIP2 in complex with amotosalen was at most 1.2% of total (Figure 5c) and there-
fore unlikely to interfere with PI 3-kinase activity. Indeed, PI(3,4,5)P3(18:0/20:4) levels were 
normal following stimulation with CRP-XL or SFLLRN/MeSADP in PUVA treated platelets 
(Figure 5d). These data indicate that defective PI(3,4,5)P3 formation is not the cause of 
attenuated Akt and Btk phosphorylation. Therefore and because the primary role of PI(3,4,5)
P3 is to support recruitment of peripheral effector proteins to the plasma membrane com-
partment, recruitment of Akt and Btk was investigated. Hereto, the membrane fraction of 
lysed platelets was isolated by differential (ultra)centrifugation. Western blotting indicated 
significantly defective localization to this subcellular compartment of both Akt and Btk in 
response to both CRP-XL and SFLLRN/MeSADP (Figure 5e, f). Together, the data indicate 
that in the presence of normal PI(3,4,5)P3, PUVA treatment interferes with adequate plasma 
membrane recruitment of Akt and Btk in response to selected agonists. 
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PUVA INHIBITS MEMBRANE BINDING OF MODEL PEPTIDES
Because the photochemical reaction between psoralens and phospholipids is uniquely 
through unsaturated carbon bonds19,20, we hypothesized that alterations in the membrane 
bulk properties were underlying the PUVA related signal transduction defects. Half of 
platelet phospholipids is unsaturated39 and Akt phosphorylation decreases in cells that 
contain few monounsaturated phospholipids40. One of the biophysical roles of unsaturated 
acyl chains is to fine-tune lipid packing. Their “hinged” geometry renders the phospholipid 
conical rather than cylindrical (Figure 6a, b) creating imperfections in lipid packing. These 
lipid packing defects33 (LPD) facilitate protein-membrane binding41,42 by creating dynamic 
gaps in the hydrophilic sheet that tops each bilayer leaflet. To investigate if PUVA affects 
this biophysical property, we used fluorescently labeled ALPS peptide. This sequence 
is derived from the GMAP210 protein’s N-terminus and specifically partitions to curved 
liposomes of high but not low LPD content33. As expected, the ALPS probe efficiently bound 
to liposomes enriched in conical phospholipids, which is 15 mol% 1-2-dioleoyl-sn-glycerol 
and 85 mol% 1,2-dioleoyl-sn-glycero-3-PC (Figure 6c). When treated with PUVA, binding 
to these liposomes was completely abolished, down to background levels similar of ALPS 
binding to purely cylindrical 1-palmitoyl-2-oleoyl-sn-glycero-3-PC liposomes. Surface par-
tition constants were estimated by regression analysis confirming hampered partitioning of 
the ALPS peptide to the LPD enriched liposomes. Because curvature is another significant 
determinant of ALPS partitioning to liposomes, size distributions were analyzed prior to 
binding studies but were not different between controls and PUVA treated preparations 
(data not shown). Hence, differences in binding are not related to changes in curvature. To 
confirm this observation with another unrelated lipid binding protein, fluorescently labeled 
α -synuclein was used. This particular peptide recognizes LPD containing liposomes in a dif-
ferent way than ALPS and it requires the presence of PS34. However, binding to its preferred 
liposomes was similarly affected (data not shown) indicating that PUVA prevents efficient 
insertion of membrane binding proteins in model bilayers.
Figure 4: Calcium release and PKC phosphorylation in response to platelet agonists. (a and b) BAPTA- 
Oregon Green 488 loaded platelets were used to monitor kinetics of intracellular calcium release in response 
to selected agonists, indicated on top of the panels. The PAR1 activating SFLLRN peptide (30µM) and the 
GPVI-FcγR agonist convulxin (CVX, 22ng/mL) were used. Platelets treated with PUVA (red) were compared 
to paired untreated control cells (blue) in simultaneous runs. The calcium dependent fluorescent signal (ex-
citation 488nm, emission 550nm) was recorded. Values were corrected for background. The concentration of 
ionized calcium [Ca]i was estimated by extrapolation using maximal and minimal signals of known calcium 
concentrations in separate control wells. Tracings are representative of three repeats. (c and d) Platelet acti-
vation through PAR1 was with 30µM SFLLRN and 10µM MeSADP or through GPVI-FcγR with 22ng/mL CVX. 
Paired control samples for resting platelets were incubated with the respective vehicle buffers. Following 
activation for 3 and 5 minutes, respectively platelets were lysed and the lysates were analyzed by western 
blotting. anti-phospho-tyrosine antibodies (Anti-Tyr-P) and anti-pleckstrin antibodies (Anti-pleckstrin)
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Figure 5: PUVA inhibits recruitment of Akt and Btk to the PI(3,4,5)P3 activated plasma membrane. (a) 
Overlaid extracted ion LC-MS chromatograms (m/z 1418.7073±10 ppm) of PUVA treated platelets (red 
tracing) indicate de novo formation of PIP2(18:0/20:4)-amotosalen covalent adducts which are absent in 
control extracts (blue tracing) that were not UVA treated. (b) Overlaid accurate mass spectra indicating 
covalent complexes of amotosalen and PIP2(18:0/20:4) in the PUVA treated (red) spectrum and its absence 
in not UVA illuminated control (blue) spectrum. (c) This pie chart indicates the amount of PIP2(18:0/20:4) 
forming adducts with amotosalen (AS) relative to total PIP2(18:0/20:4) in PUVA treated extracts. (d) The 
amount of PI(3,4,5)P3(18:0/20:4) in platelet lipid extracts depicted as the ratio of the peak integral (AUC) 
relative to the internal standard peak integral (AUC, IS). Platelets were activated with 1µg/mL CRP-XL or 
10µM SFLLRN+10µM MeSADP. Untreated controls (open bars) and PUVA treated samples (closed bars) are 
shown. Activation times were 2 and 3 minutes, respectively. Resting platelets were incubated with vehicle. 
Mean with SD is shown (n=4). (e, f) The platelet membrane fraction was analyzed by western blotting and 
subsequent densitometry. Antibodies to total Akt (Akt) or total Btk (Btk) were used. Loading was controlled 
by reprobing the membrane with an antibody to the membrane specific integrin aIIb. PUVA treatment or not 
(CTR) is indicated on top of the panels. The decrease in mean protein band density of the ratio kinase to aIIb 
(n=3) in PUVA treated platelets relative to untreated control counterparts is given. 
PUVA DECREASES PHOSPHORYLATION OF AKT IN T LYMPHOCYTES FROM  
ECP TREATED GVHD PATIENTS 
As a model for PUVA treatment of nucleated human cells, peripheral blood mononuclear 
cells (PBMCs) were isolated from fresh blood donations of healthy consenting volunteers. 
To activate PI 3-kinase-Akt axis in this cell mixture, stimulation of T-cells was performed 
by incubation with T-cell receptor activating CD3/CD28 beads in the presence of co-stim-
ulating interleukin-2 (IL2). The effect of two psoralens 8–methoxypsoralen (8MOP) and 
amotosalen was compared in paired experiments even though only 8MOP is currently used 
as an active component for ECP. The data show that both psoralens dose-dependently in-
hibited T cell receptor mediated phosphorylation of Akt following a fixed UVA dose (Figure 
7a, b). Because DNA may coincidently be affected by PUVA in nucleated cells, immediate 
cell death was investigated by Sytox staining in flow cytometry. But for the course of the 
T-cell activating experiment and in the psoralen concentration ranges used, no increase in 
Sytox staining was observed (data not shown). These data confirm a direct link between the 
presence of photoexcited psoralens and inhibition of Akt phosphorylation independent of 
cell death. Furthermore, it shows that amotosalen is more efficient than 8MOP achieving 
half maximal inhibition at lower concentrations. To confirm if Akt activation is affected in 
clinically relevant tissue, buffy coat cells from GvhD patients enrolled in a clinical efficacy 
study were collected before and after ECP. In these samples, Akt activation in T lymphocytes 
was also significantly decreased (Figure 7c, d). Together, these data show that PI(3,4,5)
P3 dependent signaling is affected by PUVA in cells other than platelets and in the exact 
clinical setting of ECP treatment.
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DISCUSSION 
Despite its widespread clinical use, many aspects of PUVA’s mode of action have remained 
uncertain. Our data show for the first time that PUVA treatment specifically but selectively 
inhibits the PI 3-kinase-Akt pathway. This inhibition is not on the PI 3-kinase enzyme itself. 
In contrast, the binding of crucial PI(3,4,5)P3 dependent effector kinases to the activated 
cytosolic membrane compartment is prevented in response to specific stimuli. Our model 
(Figure 8) suggests that covalent modification of phospholipids by photoexcited psoralen in 
the plasma membrane prevents efficient interactions with membrane binding proteins.
Covalent binding of photoexcited psoralen to unsaturated fatty acids has indeed been 
described both in cell-free test tubes and in cell extracts19,20,43. Our mass spectra of PUVA 
treated platelet extracts have confirmed covalent reaction with unsaturated acyl side chains 
which complies with the preferred partitioning of psoralens to the inner apolar phase of lipid 
bilayers17. Of note, all investigated phospholipid classes were more or less affected, indicating 
no obvious dependence on the hydrophilic head group. Despite this unspecific chemistry, sig-
nal transduction inhibition was remarkably specific for the PI 3-kinase pathway because Akt 
and Btk phosphorylation was decreased but the concurrent PLC axis showed no defect, even 
though both PI 3-kinase and PLC utilize the same PI(4,5)P2 substrate. Therefore it seemed 
unlikely that PUVA caused substantial decreases in the functional pool of substrate. Indeed, 
even the levels of PI(3,4,5)P3 in response to agonist activation were normal meaning that the 
defect causing decreased Akt and Btk activation was downstream of PI 3-kinase. Besides, very 
little PI(4,5)P2 was in complex with amotosalen after PUVA. Collectively, these data suggest 
that psoralen modifications of PI(4,5)P2 are not directly inhibiting activation of Akt and Btk. 
Elevated PI(3,4,5)P3 levels should normally recruit cytosolic Akt and/or Btk to the plasma 
membrane where locally restricted enzymes catalyze their phosphorylation44,45. Activated Akt 
and Btk next dissociate from the confined plasma membrane environment to execute central 
tasks in the cell cytoplasm (or nucleus). Plasma membrane recruitment thus is a crucial step 
preceding successful Akt and Btk activation46,47. Our data show that this plasma membrane 
recruitment is significantly decreased following activation of certain receptors in PUVA 
treated platelets. Because of normal PI(3,4,5)P3 levels however, this suggests that efficient 
plasma membrane sublocalization of Akt and Btk is depending on auxiliary facilitators. Since 
unsaturated fatty acids are the prime target of PUVA chemistry, such additional factors must 
require normal (levels of) fatty acyl unsaturations to fulfill their role. Even though primary 
binding is assumed to be between the PH domain sequence K-Xn(K/R)XR
48 and PI(3,4,5)P3, 
these additional factors (in)directly support Akt and Btk plasma membrane recruitment. In 
that regard, some amino acids in the PH domains of PLCδ1 and GRP1 are known to penetrate 
the inner hydrophobic core of the membrane49,50. Such membrane insertion may require that 
the targeted membrane compartment contains a certain degree of LPD33,51. 
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Figure 6: PUVA interferes with ALPS-NBD binding to LPD-rich liposomes. Binding of the NBD labeled ALPS 
peptide to (a) LPD-rich liposomes (cyan) composed of conical 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(85mol% DOPC) and 1-2-dioleoyl-sn-glycerol (15mol% DOG) was compared with (b) LPD-poor liposomes 
(magenta) entirely composed of cylindrical 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine. Liposome 
preparations containing 150µM amotosalen were treated with UVA light (PUVA, right panel series, ◆) or not 
(CONTROL, left panel series, n ) (c) The corrected peak fluorescence signal (F-F0) of NBD at 535nm (emis-
sion wavelength) is plotted in function of increasing concentrations of lipid. Data for LPD-rich liposomes 
were analyzed by regression to generate surface partition constants (Kp) as indicated. Data are shown as 
means with standard deviations (n=6). 
Our data show that binding of LPD probes to model bilayers is hampered by PUVA, indi-
cating that membrane insertion as promoted by conical phospholipids is inhibited. We 
thus hypothesize that lipid packing is the additional factor that cooperatively strengthens 
binding to accomplish successful coincidence detection52 between PH domains and the 
cytosolic membrane leaflet. The data provide the first proof in live cells that the acyl side 
chain milieu of phospholipids determines binding success of major PH-domain containing 
effector kinases in the presence of normal PI(3,4,5)P3 levels.
The extent of Akt and Btk inhibition following PUVA treatment depends on the nature of 
the stimulus, i.e. the ligand-receptor couple. Inside-out communication to activate integrin 
αIIbβ3 was most affected starting from GPVI-FcγR, less when PAR1 was activated and not at 
all through PAR4. This means that the integrin αIIbβ3 activation machinery at least is able 
to respond normally if the required signals come in correctly from the upstream cue. How 
this variability then is established remains uncertain. Maybe the separate ligand-receptor 
circuits reside in plasma membrane microdomains of specific phospholipid composition53 
that is more or less susceptible to modifications by PUVA. This would follow the spatiotem-
poral dogma of PI 3-kinase dependent signaling stating that PI(3,4,5)P3 are temporary scaf-
folding molecules for locally restricted signalosomes to build upon54. Such spatiotemporal 
restriction assigns distinct signal identity, but in a physiologic environment containing 
multiple extracellular chemicals each of these will integrate to a single compound output 
per cell that thus is variably modified by PUVA (Figure 6).
Figure 7: PUVA causes decreased Akt phosphorylation in T lymphocytes. (a) Dose escalations of (a) 8MOP 
or (b) amotosalen (AS) were added to isolated PBMC from healthy donors and subsequently illuminated with 
UVA light or not, as indicated on top of each panel. Vehicle (VH) contained no psoralen and was used as a 
negative control. (c) PBMC were isolated from clinical buffy coat samples before (pre) and after (post) ECP 
treatment for GvhD. T lymphocyte activation in the presence of 0.5µM Wm was used to control for speci-
ficity of the PI 3-kinase axis. (a-c) T lymphocytes were activated by receptor ligation in the presence of IL2 
followed by western blotting of whole cell lysates. Antibodies to T308 phosphorylated Akt (P-Akt) were used 
and membranes were reprobed for total Akt (Akt) to control for loading. (d) The mean decrease in the P-Akt 
over Akt signal ratio in samples post ECP relative to pre ECP is depicted (n=3). No change is emphasized by 
the horizontal dashed line.
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In platelets, this altered output presents as delayed thrombus formation on immobilized 
collagen in vitro23. Other experimental means of PI(3,4,5)P3 dependent signaling inhibition 
in platelets confirm significant function defects in mouse models of Akt isoform deficien-
cy55, PDK1 deficiency56 or PI 3-kinase isoform deficiency57. Of note, also Btk inhibition using 
ibrutinib significantly increases the risk of bleeding in patients suffering from B cell malig-
nancies58. PUVA is currently used in blood banks to treat platelet concentrates for trans-
fusion. It efficiently reduces pathogen and white blood cell viability by damaging its DNA. 
Originally platelets were believed to be unsusceptible to PUVA because they do not contain 
a nucleus. Our findings now reveal mechanisms of functionality decreases caused by DNA 
unrelated side-effects of PUVA treatment. Of note, side-effects following transfusion of 
psoralen-modified phospholipids represent an additional major clinical unknown. 
Our findings also have consequences for other fields that commonly apply PUVA. The exact 
drivers of clinical success in skin pathologies or GvhD for instance remain not fully un-
derstood. We propose a substantial role for selective PI 3-kinase axis inhibition, given the 
results of the buffy coat samples from our GvhD patient which clearly demonstrate reduced 
Akt phosphorylation. Yet, this single readout merely demonstrates attenuation of just one 
effector kinase (Akt), in one cell type and to one ligand-receptor combination. The exact 
cellular composition of PUVA treated tissue by type and number as well as their individual 
susceptibility to PUVA will eventually determine the response in a relevant physiological 
environment. Further study will thus require a systems approach59 to unravel the depend-
ence of relevant ligand-receptor couples to PUVA and combine the findings in an integrat-
ed view, taking into account effects on DNA replication and transcription as well. 
In conclusion, our research shows that PUVA selectively inhibits recruitment of Akt and Btk 
kinases to activated plasma membranes. This suggests that unsaturations in the plasma 
membrane co-determine kinase-lipid binding. We furthermore propose that the variable 
susceptibility of ligand-receptor couples to PUVA contributes to complex rewiring of cell 
and tissue fate, explaining the complexity in output and thus clinical success. 
Figure 8: PI(3,4,5)P3 dependent processes are selectively downregulated by PUVA. Stimulation of mem-
brane receptors including GPCRs (PAR1 & PAR4) or immune receptors (like the collagen receptor complex 
GPVI-FcγR) in platelets results in recruitment of PH domain containing effector molecules like Akt and Btk to 
the spatiotemporally restricted scavenger phospholipids PI(3,4,5)P3 in the cytosolic leaflet of the membrane. 
This causes phosphorylation of such targets (pAkt/pBtk), their release from the confined plasma membrane 
space and execution of several cellular functions downstream. Following PUVA however, covalent modifi-
cation of several unsaturated acyl side chains attenuates efficient recruitment to PI(3,4,5)P3 in response to 
certain (like PAR1 and GPVI-FcγR) but not all (PAR4) ligand-receptor couples.
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DISCUSSION
1. GENERAL DISCUSSION
REDUCTION OF PARTIAL OXYGEN PRESSURE 
TO PRESERVE THE QUALITY OF BLOOD COM-
PONENTS DURING PATHOGEN INACTIVATION
Our work studied the effects of pathogen inactivation on the quality of plasma units and 
platelet concentrates. For plasma, three bench top pathogen inactivation technologies, 
using high energy light illumination in combination with chemical photosensitizers, were 
examined. According to the manufacturers, the main mechanisms of action is crosslinking 
nucleic acids after photo-activation, thereby preventing replication and (pathogen) proli-
feration. However, all photo-excited sensitizers can in principle react with multiple electro-
negative surrounding molecules and therefore not exclusively restrict their chemistry to 
nucleic acids. Adduct formation of the excited photosensitizer with biomolecules including 
proteins, carbohydrates or lipids, typically results in biologic modifications potentially 
harming normal function. Furthermore, in the presence of dissolved molecular oxygen, 
formation of reactive oxygen species (ROS) is very likely by energy transfer between the ex-
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cited photosensitizer and the electronegative oxygen molecule1. Typical reaction products 
are singlet oxygen, superoxide anion and hydrogen peroxide. All three are very oxidative 
randomly damage (bio)molecules, ranging from proteins to lipids. Our data confirmed that 
ROS are produced during the RF-PRT illumination process, damaging plasma proteins 
important for transfusion like fibrinogen, coagulation factor VIII and ADAMTS13. Our data 
show that by lowering the partial oxygen pressure in the plasma unit prior to RF-PRT, the 
observed damage to these biomolecules can successfully be mitigated. Similar to our data 
on plasma, a recent study found increased production of ROS and protein carbonylation in 
RF-PRT treated platelets confirming our pioneering work2. Minimizing the level of dissol-
ved molecular oxygen in a transfusion product to control for off-target effects of pathogen 
inactivation may seem attractive but has a number of drawbacks. Platelet concentrates are 
currently stored in specific semipermeable containers to allow exchange of gaseous oxygen 
and carbon dioxide which is considered crucial for sustained platelet quality. Lowering 
partial oxygen pressure may thus harm the cells by promoting anaerobic respiration and 
accumulation of lactic acid. In addition, it is not entirely clear to what extent the factual 
(RF-PRT) pathogen inactivation depends on the reaction of ROS with pathogens. Even 
though the suppliers claim that the major or even sole mechanism of inactivation is via 
direct toxicity on DNA/RNA, scientific evidence is lacking to prove this statement. Especially 
for RF-PRT which in recent communications the provider has added oxidative stress as a 
mechanistic explanation for its action on pathogens. In summary, oxygen removal is attrac-
tive in theory to mitigate off-target effects (especially in RF-PRT) but the level of pathogen 
inactivation and the metabolic demands of the platelet should still be met when developing 
such a technology.
MICROFLUIDIC FLOW CHAMBERS TO EVAL-
UATE PLATELET FUNCTION IN AN IN VITRO 
MODEL OF TRANSFUSION
Platelet function can be investigated with a variety of (indirect) in vitro experiments, but 
the most comprehensive is by using microfluidic flow chambers. This experiment takes into 
account the biophysical parameter of blood flow and therefore the influence of rheology 
on participating cells and biomolecules3. This challenging technique mimics hemostasis in 
vitro and was implemented and validated at the start of my research project. By reconstitu-
ting thrombocytopenic fresh blood we were able to investigate the function of exogenously 
added platelets from platelet concentrates, treated or not with pathogen inactivation. The 
clinical translation of this assay has been investigated ever since the first description of 
“parallel-plate flow chambers”4. There are many examples of its utility in clinical investigati-
on as demonstrated in multiple papers of which three are described below. 
Casari et al5 uncovered evidence in his study that besides the loss of VWF multimers and 
thrombocytopenia, a third possible mechanism for bleeding tendency in von Willebrand 
disease type 2B patients is platelet dysfunction. This impaired platelet function is due 
to inhibition of integrin αIIbβ3 and coincides with reduced thrombus growth seen in flow 
chamber experiments. Nogami et al6 used a microchip flow chamber system succesfully to 
predict the bleeding score in von Willebrand disease type 1 patients. Finally, Flamm et al7 
determined the phenotype of the platelets of individual donors by analyzing the behaviour 
of these platelets under flow. By using a combination of cell adhesion assays and multiscale 
computer simulations, they were able to predict patient-specific thrombus formation po-
tential. Moreover, their study revealed a novel thromboxane receptor mutation (TP-V241G) 
in humans that confers resistance to indomethacin.
HOW DO TRANSFUSED PLATELETS PERFORM 
IN HEMOSTASIS IN VIVO?
Two of three available pathogen inactivation technologies used for the treatment of plate-
let concentrates utilize a photosensitizer (AS-PCT & RF-PRT) and the other does not (UV-
C). In our studies we concluded that all three methods cause decreased platelet function 
following the results of thrombus growth kinetics in a microfluidic flow chamber experi-
ment. This was confirmed by additional unrelated platelet (function) tests that investigated 
the metabolic, biochemical, and biologic characteristics of platelets. It is not clear if this 
observed platelet function decrease in vitro sustains in vivo or whether platelet function can 
recover once transfused to the patient. Alternatively, even though the function of treated 
platelets may be decreased in flow chambers it might still be sufficient to control bleeding 
because transfused (treated) platelets may indirectly promote coagulation although this 
needs further research. A platelet plug is a hierarchical structure with a core of densely 
packed, irreversibly activated platelets overlaid by a shell of loosely packed, less activated 
platelets8. It is currently unclear where transfused allogeneic platelets fit in this revised 
model of hemostasis. Therefore additional basic research is required to understand the role 
of transfused platelets in light of this hemostasis model and whether pathogen inactivation 
alters the behaviour of transfused platelets during hemostasis, in vivo. 
Clinical trials of transfusion of pathogen inactivated platelets are variable in design and 
result9-11. Platelet recovery is often measured by “corrected count increment” which is a 
measure for transfusion yield and a questionable surrogate for successful cessation or 
prevention of bleeding. Clinical trials that directly measure bleeding have been performed, 
but with conflicting conclusions as discussed in a Cochrane review published in 201312. In 
addition, bleeding assessment as a clinical outcome is practically difficult and the way this 
168 169
should be done a matter of debate. Bleeding is a difficult primary endpoint, also because 
significant bleeding is relatively rare requiring a larger cohort to be included in the trial. 
Finally, the intrinsic diversity of clinical presentations in the receiving patient population 
as well as the diversity in primary characteristics of platelet concentrates prepared by a 
multitude of component preparation methods makes comparison between institutes and 
hospitals internationally a true challenge. That’s why additional clinical studies should 
focus on standardized outcomes in well-defined research questions. Only this way an 
evidence based decision for the introduction of a given pathogen inactivation method in a 
blood bank can be made13.
THE UNDERLYING MECHANISMS OF  
PLATELET FUNCTION LOSS AFTER  
PATHOGEN INACTIVATION
Our data suggest that the underlying biochemical mechanisms of platelet damage signi-
ficantly differ between the three different pathogen inactivation methods. For instance, 
RF-PRT treated platelets display increased anaerobic metabolic respiration, continuous de-
granulation and increased phosphatidylserine exposure rates collectively pointing to an ac-
celerated storage lesion. This has been reported by independent research groups studying 
RF-PRT14-16. Our data for UV-C treated platelets indicate a fixed conformational activation of 
integrin α IIbβ3 indistinguishable of physiologic receptor activation. We are unsure what the 
impact of this is, because even though PAC1 binds to these platelets and fibrinogen is sup-
posed to do so too17. However, increased storage lesion like in RF-PRT platelets is not found. 
Therefore, premature platelet activation via sustained outside-in signal transduction after 
fibrinogen binding may be possible but is not significantly affecting platelet parameters 
during further storage. Finally, AS-PCT has a more specific effect on platelet signal trans-
duction. Integrin αIIbβ3 receptor activation by inside-out signal transduction in response 
to some but not all platelet agonists is affected. Targeted analysis of signal transduction 
pathway sections demonstrated an attenuation of PI 3-kinase/Akt/Btk signalling. So each 
method has different underlying biomolecular effects on platelets which result in decreased 
thrombus formation rates in microfluidic flow chambers on collagen. 
Research to pathogen inactivation has initially focused on achieving maximal log reducti-
ons of relevant inoculated pathogens. Potential efforts to minimize the quality loss of trea-
ted products received less attention. To successfully develop next generation technologies 
that take into account the off-target effects, basic understanding is the key: what is causing 
the loss of platelet or component function? The answer to this question can then be used 
to optimize and modify the practical process weighting out pathogen inactivation success 
and component quality. For this free access to industry manufactured tools is important to 
openly tackle important questions. 
MECHANISTIC INSIGHTS OF DECREASED 
PLATELET FUNCTION IN AS-PCT, POTENTIAL 
TO IMPROVE PIT
AS-PCT treated platelets display decreased thrombus formation rates in microfluidic flow 
chamber experiments. This functional defect was narrowed down to a defect in the signal 
transduction axis of PI 3-kinase, with diminished Akt and Btk phosphorylation. Next, we 
found that amotosalen photochemically forms covalent adducts with membrane (phospho)
lipids and that the binding of ALPS-NBD to amotosalen treated liposomes (containing pac-
king defects) is impaired. Taking these findings together and knowing that lipid-lipid and 
lipid-protein interactions play crucial roles in PI 3-kinase-Akt/Btk signalling, we hypothesi-
zed that the binding of Akt and Btk to the membrane is compromised. Indeed, following AS-
PCT spatiotemporal subcellular localization of PH domain containing proteins is impaired, 
while sufficient PI(3,4,5)P3 is produced. So we suggest that the membrane acyl chains at 
least in part cooperate for successful binding18 of Akt and Btk.
Future research should study how binding of PH domains to membranes is influenced by al-
tered packing. Besides that, pathogen inactivation based on psoralens could be optimized. 
For example by the use of a psoralen that has sufficient nucleic binding and thus pathogen 
killing capacities but without any attraction for lipids. 
TRANSLATION TO PUVA 
Our results help to understand existing PUVA treatments and suggest avenues for impro-
ving them. For example, extracorporeal photopheresis (ECP) is a leukapheresis-based PUVA 
procedure used to treat cutaneous T-cell lymphoma. It is currently under investigation for 
other disorders like GvhD, transplant rejection, Crohn’s disease19, psoriasis20 and rheumatoid 
arthritis21,22. The reigning concept of ECP is that treated cells are rendered apoptotic by DNA 
damage and then opsonized by antigen-presenting (dendritic) cells and/or macrophages. 
Subsequent T and B lymphocyte presentation then promotes immune tolerance and indu-
ces antigen-specific regulatory T cells, IL-10-producing regulatory B cells and regulatory 
CD8+ T cells, rewiring the immune system23 in favour disease mitigation. Our data suggest a 
potential role for PI 3-kinase/Akt signal transduction pathway, since this axis is affected fol-
lowing ECP treatment. The well documented link between PI 3-kinase signal transduction 
and many of the above mentioned diseases is in favour of this suggestion24-27. If proven to be 
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important in the mechanism of action, PI 3-kinase functional attenuation by ECP could be 
improved by using a more efficient psoralen or illumination regimen to control the effect on 
PI 3-kinase signalling.
In conclusion, PUVA treatment specifically decreases the phosphorylation of PH-do-
main-containing effector molecules, albeit independent of PI(3,4,5)P3 formation. The 
consequences for treatment of disease and pathogen inactivation are possibly broad but 
not easily disentangled. PUVA treatment is used for skin diseases as well as systemic T-cell 
related conditions and PI 3-kinase may thus play a more central role than thus far antici-
pated in these diseases and its therapies. Thanks to PUVA’s membrane changing capacity, 
biochemical links between the cytoplasmic membrane and the actions of PH-domain 
containing effector proteins in the cell cytoplasm has been demonstrated.
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